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Abstract 
Background 
Frailty is common and is associated with important adverse health 
outcomes.  There is evidence that exercise may influence the biological 
mechanisms of frailty and improve adverse outcomes.  This thesis 
describes the development and evaluation of the Home-Based Older 
People's Exercise (HOPE) programme - a home-based exercise 
intervention for frail older people. 
 
Methods 
The MRC framework for the development and evaluation of complex 
interventions was used to develop and evaluate the HOPE programme.  
The development process synthesised information from four key 
domains: a systematic literature review; a process of intervention 
modelling work incorporating multiperspective focus group meetings; a 
review of behaviour change techniques and a review of international 
exercise guidelines.  Following development, the HOPE programme was 
evaluated in a pilot randomised controlled trial.  The primary outcome was 
mobility, measured using the Timed-Up-and-Go test (TUGT).  Secondary 
outcomes included activities of daily living (ADL), quality of life and 
depression. 
 
Results 
 4 
The systematic review identified preliminary evidence that exercise may 
improve outcomes for frail older people. A grounded theory analysis of 
the multiperspective focus group meetings identified the important 
challenges faced by frail older people, along with motivators and barriers 
to exercise. The results were synthesised into the HOPE programme, 
which is a 12 week home-based exercise intervention. 60 participants 
were recruited to the HOPE trial. Mean age was 78 years. Baseline 
characteristics were similar in the two groups. There was a non-
significant trend towards an improved outcome in the intervention group 
(mean adjusted between group difference in TUGT 16.7s, 95% CI -33.3, 
66.6s).  There were no differences in any of the secondary outcomes. 
 
Discussion 
The HOPE trial has provided valuable process, resource, management 
and scientific data to guide the development of a future definitive RCT 
and has provided important information to help inform future research 
involving frail older people. 
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1 Chapter 1.  Introduction 
1.1 Background 
Frailty - Latin, fragilita, brittleness 
 
Frailty is a common and important syndrome that is increasingly prevalent 
with advancing age. Whilst there is no internationally agreed definition of 
frailty a consensus view is emerging in which the physical phenotype of 
frailty is considered to develop as a consequence of complex biological 
interactions promoting cell senescence, leading to a cumulative decline in 
multiple physiological systems, particularly the brain, endocrine system, 
immune systems and skeletal muscle (1). This decline results in a loss of 
homeostatic reserve which can ultimately adversely affect the whole 
person, resulting in a vulnerability to a sudden health state change that 
can be triggered by relatively minor stressor events (2). The resulting 
frailty phenotype can be detected clinically, and measured by recording 
slow walking speed, muscle weakness, weight loss, low activity and 
fatigue (2, 3). 
 
1.2 Epidemiology of frailty 
A 2010 UK study investigated the prevalence of frailty amongst 638 
community-dwelling people aged 64-74 years (4). The frailty prevalence 
 26 
rate was 8.5% for women, and 4.1% for men. The Fried investigators (3) 
recorded a frailty prevalence rate of 6.9% in a cohort of 5201 men and 
women aged 65 years or more. Frailty rates of 3.2%; 9.5%; and 25.7% 
were recorded in age groups 65-70; 75-79; and 85-89 years respectively. 
 
Frailty is self-perpetuating; its development results in a spiral of decline 
that leads to greater frailty and consequent risk of development of 
disability in older age. Recently, preliminary evidence has been reported 
that social factors, including social networks and socioeconomic status 
may also have a relationship with frailty (5). However, there remains 
significant uncertainty regarding the contribution of social vulnerability to 
the frailty syndrome and further work to characterise the key elements 
that comprise social vulnerability (6) and the relationship between social 
vulnerability and frailty is required (5). 
 
Importantly, not all older people become frail as a result of the ageing 
process. A resistance to the development of frailty and a dissociation 
between chronological and biological age is often evident in older people 
(7). In a proportion of vulnerable older people, the interaction of a number 
of processes can promote the development of frailty. 
 
A schematic overview of the complex interaction between molecular, 
cellular, physiological and clinical determinants of frailty is illustrated 
schematically in figure 1.1 and will be considered in greater detail. 
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Figure 1.1.  A schematic representation of frailty. 
The figure highlights the complex relationship between genetic 
factors, molecular damage and inflammation causing cell 
senescence, leading to impaired physiology and loss of 
homeostatic reserve, which can be detected and measured using 
clinical markers of the frailty phenotype. Reproduced with 
permission from (1). 
 
1.3 Frailty taxonomy 
The utility of any system of medical taxonomy is reliant on its capacity to 
identify specific components that allow prediction of both natural history 
and response to therapeutic interventions (8). A robust system of medical 
taxonomy also requires consideration of the underlying biological 
principles of causality, without which precise unification of diagnosis and 
treatment is not possible (8). If significant progress into the management 
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of frailty is to be made, the fundamental causative biological events 
require identification. 
 
A reliable system of frailty taxonomy should therefore predict both natural 
history and response to therapeutic intervention and be underpinned by 
biological principles of causality. Multiple systems of frailty taxonomy exist 
but each demonstrates variable utility in prediction of natural history, 
response to therapeutic intervention and consideration of underlying 
biological causality mechanisms. A 2011 systematic review identified 20 
separate outcome instruments to measure frailty, with clear variation in 
clinical utility (9).  
 
A shared central notion throughout the multiple frailty taxonomy systems 
is that frailty represents increased vulnerability to adverse health 
outcomes (10). There have been considerable recent efforts to form an 
international consensus on frailty that recognises vulnerability to adverse 
outcomes as a central feature. The two principal emerging models of 
frailty are the Fried phenotype model (3) and the Canadian Study of 
Health and Aging (CSHA) Frailty Index (11). 
 
1.3.1 The Fried phenotype model 
In order to investigate frailty, Fried et al (3) operationalised five core 
biological components to provide evidence for a frailty phenotype that is 
clinically recognisable and demonstrates predictive validity. When present 
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in combination the five core components have the potential to interact and 
cause a 'critical mass' that identifies the frailty syndrome. The core 
components (and their operationalised indicators) are presented in table 
1.1. 
 
Core component Operationalised indicator 
Weight Loss Self-reported weight loss of more than 10 pounds or 
recorded weight loss of > 5% per annum 
Exhaustion Self-reported exhaustion on CES-D depression score 
(3-4 days per week or most of the time) 
Low Energy 
Expenditure 
Energy expenditure <383 KCal/week (males) or <270 
KCal/week (females) 
Slowness Standardised cut-off times to walk 15 feet, stratified 
for sex and height 
Weakness Grip strength, stratified by sex and BMI 
 
Table 1.1.  The five core components of frailty and their 
operationalised indicators. 
CES-D, Centre for Epidemiological Studies depression scale; BMI, 
body mass index 
 
Those individuals with none of the above indicators are characterised as 
robust older people. Those with one or two indicators are considered to 
represent an 'intermediate' or pre-frail group. Those with three or more 
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indicators are considered to represent a frail older population. 
 
In a number of large prospective cohort studies, the Fried model of frailty 
has demonstrated utility in predicting the natural history and associated 
adverse health outcomes of frailty (3, 12, 13). The Fried model also 
identifies components of frailty, such as weight loss, slow walking speed 
and muscle weakness that are potential targets for therapeutic 
intervention. The model also considers the potential biological frailty 
causality mechanisms. The Fried model of frailty is supported in the frailty 
consensus statement from the American Geriatrics Society (1).  However, 
the Fried model, which was developed retrospectively using data from the 
United States (US) Cardiovascular Health Study, does not consider the 
potential contribution of cognitive and socio-economic factors, which have 
an association with adverse health outcomes including disability (14, 15) 
and mortality (16). 
 
1.3.2 The CSHA Frailty Index & Clinical Frailty Scale 
The Frailty Index (FI) and Clinical Frailty Scale (CFS) were developed as 
part of the CSHA, a five-year prospective cohort study involving 10263 
people aged 65 and older (11). The FI defines frailty as the cumulative 
effect of individual impairments - 'the more individuals have wrong with 
them, the more likely they are to be frail' (17). The FI is calculated by 
recording the presence or absence of 70 individual variables, which are a 
series of clinical deficits identified using signs, symptoms and abnormal 
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test results. These include limitations in activities of daily living, presence 
of cardiorespiratory problems, history of cognitive impairment and mood 
disorders. The FI demonstrates utility for prediction of natural history of 
disease and is highly reproducible but it is less practical for routine clinical 
use.   
 
In order to develop a more practical FI that has greater utility for clinical 
use, the CSHA investigators constructed and validated a model based on 
specialist Comprehensive Geriatric Assessment (FI-CGA) (18). The FI-
CGA is a valid and reliable method of frailty assessment that facilitates 
risk stratification and identification of future adverse health outcomes.   
 
The CFS, validated against the FI, is a further model of frailty that is 
based on clinical judgment.  Following a detailed clinical assessment the 
subject is categorised into one of seven domains, ranging from very fit to 
severely frail. The categories provide predictive information on the natural 
history of frailty, including five year risk of death and nursing home 
admission. 
 
1.3.3 A comparison of frailty models 
The phenotype model and FI have been compared in an analysis of data 
from 2305 participants in the CSHA (19). There was a moderate overall 
correlation between the two different measures (correlation coefficient, R 
= 0.65). There was a strong correlation with functional ability in both 
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models, but a weaker correlation with cognition in the phenotype model 
(R = -0.35) compared to the FI (R = -0.58). Furthermore, the continuous 
FI demonstrated greater discriminatory ability for those with moderate 
and severe frailty when compared to the categorical phenotype model. 
 
The prediction of adverse health and social care outcomes by the FI and 
CFS is of great potential utility to both clinical decision makers and health 
policy planners. However, although the mathematical properties of the FI 
provide some insight into mechanisms of frailty, the prediction of 
response to therapeutic interventions is less clear. Furthermore, the FI 
provides limited insight into the fundamental biological causative 
mechanisms of frailty. 
 
Although there are potential limitations regarding discriminatory function, 
the Fried phenotype model predicts natural history of frailty and potential 
response to therapeutic intervention. It also provides insight into the 
underlying biological causative mechanisms of frailty. As unification of 
diagnosis and treatment will be facilitated through greater understanding 
of biological causation, the insight into underlying biology provided by the 
Fried model is of particular value. 
 
1.4 Understanding mechanisms of frailty 
As with any clinical phenotype, identification of the frailty phenotype using 
the Fried criteria provides a framework around which understanding can 
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be structured, but precision can only come through a deeper 
understanding of the underlying frailty causality mechanisms (8). To 
understand causality, the fundamental principles of disease mechanism 
and pathophysiology must be considered. Disease mechanisms are 
based on the complex interplay between genes, epigenetics1 and 
environmental exposures and it is through consideration of these factors 
that greater understanding of frailty will be gained (8). 
 
Frailty and ageing are inexorably linked, but chronological and biological 
age are not synonymous. The genetic, epigenetic and environmental 
factors that underlie different vulnerabilities of people who are of the 
same chronological age will provide insight into the biological 
mechanisms of frailty.  
 
Deeper understanding of frailty will be gained through consideration of 
ageing theory and genetic determinants of longevity, exploration of the 
biological mechanisms of molecular, cellular and tissue ageing and 
investigation of the relationship between organismal ageing and 
development of the frailty phenotype. These will be explored in greater 
detail below. The epigenetic factors that moderate genetic determinants 
and the influence of social vulnerability and the environment will also be 
                                            
1 Epigenetics are the mechanisms that regulate the differential expression 
of genes in different cells.  Epigenetic mechanisms are discussed further 
in section 1.8. 
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explored. Finally, the relationship between frailty, disability and future 
population projections will be considered. 
 
1.5 Ageing theory 
1.5.1 The disposable soma theory of ageing 
The disposable soma theory of ageing predicts that ageing results from 
the lifelong accumulation of unrepaired molecular and cellular damage.  
The theory predicts that the accumulation of damage is inherently 
stochastic (i.e. strongly influenced by chance) and is caused by multiple 
mechanisms that are regulated by a complex maintenance and repair 
network that exhibits plasticity in order to allocate finite energy resources 
to a number of competing processes. The theory predicts that the genes 
controlling this maintenance and repair network are the principal 
determinants of longevity (20, 21). 
 
A schematic model of the interaction between multiple mechanisms of 
molecular and cellular damage leading to biological ageing is illustrated in 
figure 1.2. These mechanisms of molecular and cellular frailty will be 
considered in greater detail.  
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Figure 1.2.  A model of interaction illustrating the accumulation of 
DNA damage through multiple interacting molecular and cellular 
mechanisms. 
These interacting mechanisms cause metabolic and cellular 
senescence that ultimately leads to impaired tissue function and 
biological ageing.  UV, ultraviolet radiation; IR, ionising radiation; 
BMI1, polycomb group gene BMI1; p16/ARF, p16 protein/alternate 
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open reading frame; p53, p53 protein; CR, caloric restriction; 
SIRT1/SIRT6, sirtuin 1/6; PGC 1", prostaglandin C1"; ROS, reactive 
oxygen species.  Reproduced with permission from (22). 
 
1.6 Molecular frailty 
1.6.1 DNA damage - a critical contributor to ageing 
There is a growing consensus that loss of genetic information through 
accumulation of damage to the DNA molecule is a critical contributor to 
ageing (23, 24). DNA is present in both the cell nucleus and mitochondria 
and genetic mutations in both nuclear and mitochondrial DNA can give 
rise to a variety of inherited degenerative conditions that are 
characterised by accelerated ageing (24-26).   
 
DNA damage can occur as a result of cell-intrinsic factors, including 
oxidative damage, defective DNA repair mechanisms and telomere 
dysfunction (23). DNA damage can also occur as a result of external 
factors, including ionising radiation and genotoxic drugs. The contribution 
of the important cell-intrinsic factors to the accumulation of DNA damage 
and how this leads to biological ageing will be explored in greater detail. 
 
1.6.1.1 Free radical mediated oxidative DNA damage 
Oxidative DNA damage is considered to be a central component in the 
biology of ageing, and is hypothesised to occur as a direct result of free 
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radical generation, as described in the Free Radical Theory of Ageing 
(27). The Free Radical Theory of Ageing was first postulated over 50 
years ago and a large body of evidence has since accumulated to support 
the theory. The theory suggests that ageing results from the deleterious 
effects of intracellular free radicals (27). Free radicals are atoms, 
molecules and ions that contain an unpaired electron and are therefore 
chemically unstable. The instability of free radicals leads to high reactivity 
and potential to cause damage. 
 
1.6.1.2 Reactive Oxygen Species (ROS) 
Intracellular free radicals exist in the form of Reactive Oxygen Species 
(ROS) (27) which are generated in multiple cellular compartments and by 
multiple intracellular enzymes (28). Cellular ROS include superoxide, 
hydrogen peroxide and hydroxyl radicals (29). The large majority (around 
90%) of ROS are generated in the mitochondria (28) and as the 
mitochondria contribute the principal ROS burden they are considered to 
be of key importance in oxidative DNA damage and biological ageing.  
Along with the mitochondria, the cell membrane, peroxisomes and 
cytoplasm also contain important enzymes that generate ROS (29). 
 
1.6.1.3 Mitochondrial generation & metabolism of ROS 
Mitochondria produce the majority of energy in animal cells through the 
release of energy generated during the passage of electrons along a 
series of respiratory enzymes in a process called oxidative 
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phosphorylation that results in the production of Adenosine Triphosphate 
(ATP) (30). This also results in the generation of mitochondrial ROS, and 
it is the process of oxidative phosphorylation that is therefore considered 
to provide the large majority of cellular ROS (28).   
 
Following generation, rapid metabolism of mitochondrial ROS is facilitated 
by a number of intracellular scavenger enzymes, including Superoxide 
Dismutase (SOD), catalase, peroxiredoxin (Prx) and Glutathione 
Peroxidase (GP) (28). These scavenger enzymes exist in the 
mitochondria but can also be found in the cytoplasm and extracellular 
space. The mitochondrial production of ROS through oxidative 
phosphorylation and degradation via enzymatic scavenger reactions is 
illustrated schematically in figure 1.3. 
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Figure 1.3.  A schematic representation of mitochondrial production 
and degradation of Reactive Oxygen Species (ROS). 
ROS, illustrated by O2!-, are produced by oxidative phosphorylation 
complexes I - IV.  ROS are then degraded by scavenger enzymes 
present in the mitochondria, cytoplasm and extracellular matrix.  
NADH, reduced nicotinic acid dinucleotide; NADHDH, reduced 
nicotinic acid dinucleotide dehydrogenase; CoQ, Coenzyme Q; 
FADH2, reduced flavin acid dinucleotide; UP, uncoupling protein; 
SOD, Superoxide Dismutase; Prx, Peroxiredoxin; GP, Glutathione 
Peroxidase.  Reproduced with permission from (28). 
 
 40 
1.6.1.4 Cell membrane and cytoplasmic generation of ROS 
NADPH Oxidase (NOX) enzymes contained within the cell membrane 
and cyclooxygenase (COX) enzymes contained within the cytoplasm also 
contribute to the cellular ROS (28).  
 
1.6.1.5 Phagocyte generation of ROS 
When generated by NOX in phagocyte cells, ROS have an important 
immunological function. ROS are catalysed by SOD to form H2O2, which 
in turn serves as a substrate for peroxidases, for example neutrophil 
myeloperoxidase (MPO). Peroxidases drive the generation of 
antimicrobial hypohalous acids, which are converted to cytotoxic 
chloramines (31). This series of reactions is the basis for the powerful 
phagocyte respiratory burst, an essential component of the immune 
response. 
 
1.6.1.6 Deleterious effects of ROS 
A situation of oxidative stress exists when cellular ROS generation 
exceeds the metabolic capacity of scavenger enzymes such as SOD, Prx 
and GP (32). Cellular ROS, derived principally from mitochondria, but 
also from cell membrane, cytoplasmic, peroxisomal and phagocytic 
sources, have the potential to react rapidly with important biomolecules, 
including DNA, to cause oxidative damage that can accumulate in a 
stochastic manner. 
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Oxidative DNA damage in the form of single strand base damage, single 
strand nicks and double strand breaks can lead to irreplaceable 
information loss (24). This progressive, irreversible oxidative DNA 
damage is considered to be a powerful contributor to biological ageing. 
 
Oxidative damage to proteins, lipids and carbohydrates can also occur as 
a result of cellular ROS (29). Although oxidative damage to proteins and 
lipids can accumulate gradually over time without immediate damage to 
the cell, evidence exists that the accumulation of damaged proteins can 
contribute to the development of a number of important disorders whose 
incidence increases with age, including cataract, Alzheimer's disease and 
Parkinson's disease (20). 
 
1.6.1.7 Other effects of ROS 
Although the effects of ROS have generally been considered to be 
deleterious, more recent evidence has begun to emerge regarding the 
potential role of ROS in other important cellular functions. ROS 
generating enzymes appear to be distributed throughout many cell types 
and a low-level formation of ROS may also play an important role in cell 
proliferation, cell apoptosis, receptor signalling and modification of the 
extracellular matrix (29) 
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1.6.2 Nuclear and mitochondrial DNA damage 
Nuclear DNA (nDNA) is an important target for ROS induced damage and 
consequent ageing related changes. As there are only two to four copies 
of the nuclear genome per cell, compared to many thousands of copies of 
the mitochondrial genome, and as nDNA must last the lifetime of the 
organism it is considered particularly vulnerable to damage (24).  
However, mitochondrial DNA (mDNA) damage may also play an 
important role in ageing and age-dependent increases in damaged mDNA 
have been observed, particularly in post-mitotic tissues (e.g. brain) where 
the levels of mDNA damage are greater than nDNA damage (33). The 
proximity of mDNA to the main source of cellular ROS increases the 
vulnerability to oxidative damage, and the potential for a vicious cycle of 
damage has been proposed, whereby oxidative mitochondrial damage 
causes impaired mitochondrial function, increased ROS production and 
accelerated mDNA damage (28). 
 
1.6.2.1 DNA damage and frailty 
The association between oxidative DNA damage and frailty is beginning 
to be explored. Using the Fried criteria as the operational definition, a 
2009 study of 90 elderly Chinese participants reported a significant 
association between oxidative stress and frailty, measured using the main 
oxidised DNA nucleoside, 8-hydroxy-2-deoxyguanosine (34). The study 
analysis incorporated a multivariate analysis that controlled for important 
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potential confounding variables including age, comorbidity, and smoking 
status. 
 
In order to investigate the association between mitochondrial genetic 
variation and frailty susceptibility, a 2010 study compared the presence of 
mitochondrial DNA polymorphisms in 5275 frail and non-frail older 
people, diagnosed using the Fried criteria (35). Three mitochondrial DNA 
single nucleotide polymorphisms were significantly associated with frailty 
and independently associated with grip strength, supporting a role for 
mitochondrial variation in frailty and muscle strength in older age. 
 
1.6.3 Defective DNA repair 
Defective DNA repair is considered to be another important mechanism 
contributing to cellular and molecular damage associated with ageing. As 
DNA is critical to cellular function, a number of DNA repair mechanisms 
exist to maintain functional DNA in response to extrinsic and intrinsic 
damage. Beginning with initial detection of DNA damage by the ataxia-
telangiectasia mutated (ATM) kinase, a collection of kinase enzymes and 
cellular proteins interact to facilitate DNA repair (23). DNA double-strand 
breaks are repaired by nonhomologous end-joining (NHEJ) and 
homologous recombination (HR) pathways, whereas single-strand lesions 
are repaired by base excision repair (BER) and nucleotide excision repair 
(NER) (23). Defective DNA repair capacity can predispose to premature 
ageing in a number of animal models (22) and most premature ageing 
 44 
syndromes are caused by gene mutations in proteins involved in DNA 
repair (24). Conversely, increased levels of enzymes involved in the DNA 
repair pathway have been associated with increased life expectancy (36). 
 
1.6.4 Telomere dysfunction 
Telomeres are specialised structures situated at the ends of human 
chromosomes consisting of tandem nucleotide repeats (37). Telomeres 
help protect the ends of chromosomes from enzymatic damage to avoid 
loss of genetic information, help maintain chromosomal integrity and 
facilitate cell division (22, 38).  
 
Repeated cell division results in replication-associated telomere 
shortening which can eventually compromise the protective function of 
telomeres. This shortening is detected by the DNA damage-repair 
machinery, which can buffer telomere shortening until a critical limit is 
reached, whereupon the cell can enter a state of proliferative arrest 
(cellular senescence), undergo apoptosis (programmed cell death) or give 
rise to neoplastic division (38). If cell proliferation progresses beyond this 
critical limit, often termed the Hayflick limit (39), further telomere erosion 
is precipitated, causing profound chromosomal instability (22). As part of 
the DNA molecule, telomeres are themselves subject to extrinsic and 
intrinsic damage and must undergo maintenance and repair. The enzyme 
telomerase maintains telomeres, but is only present in germ cells (testis 
and ovarian cells) and in certain adult stem cells.   
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Supported by the absence of telomerase in adult somatic cells, replication 
associated telomere shortening has previously been considered to 
function as a biological 'time-clock' that, following a pre-determined 
number of cell divisions, leads to natural cell senescence and protection 
against malignancy (40). However, there is evidence to suggest that 
telomere shortening may be a more complex process driven primarily by 
ROS mediated DNA damage (20). Increasing cellular ROS generation 
leads to increased telomere shortening and single strand DNA breaks 
accumulate at a rate dependent on applied oxidative stress (41). It is 
therefore plausible that telomere shortening, and its associated 
contribution to cell senescence, is driven principally by the level of cellular 
oxidative stress and can be accelerated (or reduced) under conditions of 
increased (or decreased) stress (20, 42). 
 
Previous cohort studies have demonstrated positive correlations between 
telomere length, overall health profile and life expectancy (43, 44).  
Introduction of the catalytic subunit of telomerase into normal human cells 
has been demonstrated to stabilise telomere length and allow unlimited 
cell division without neoplastic transformation (45). Conversely, inherited 
mutations that affect the structure of telomerase can lead to accelerated 
ageing syndromes (46). Telomeres and telomerase are therefore 
considered to play a key role in the biology of ageing. 
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1.6.4.1 Telomeres and frailty 
Although an association is biologically plausible, one study that 
investigated the association between telomere length and frailty in 2006 
participants living in Hong Kong reported no association between frailty 
and telomere length (47). 
 
1.6.5 Control of protein turnover 
All cellular proteins are continually being degraded and replaced.  
Regulation of protein turnover is essential to control enzymes and 
proteins required for growth and metabolism, permit adaptation to new 
physiological conditions, facilitate immune system recognition of foreign 
peptides and selectively remove damaged proteins (48). Tight regulation 
is required, as destruction of an essential protein can deleteriously alter 
cell function. Similarly, failure to degrade and clear damaged proteins can 
lead to accumulation and alteration of cell function.   
 
Precise regulation is important in certain physiological states, including 
fasting and inflammation, to increase protein breakdown in order to 
provide amino acids as both a muscle energy source and for hepatic 
gluconeogenesis (48).   
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1.6.5.1 Proteolytic systems 
Proteins are degraded by a series of cellular proteolytic systems and 
different systems process different proteins.  An overview of the 
proteolytic systems is provided in figure 1.4. 
 
 
Figure 1.4.  Roles of cellular proteolytic systems in the degradation 
of various classes of cell proteins. 
Reproduced with permission from (48). 
 
The ubiquitin-proteasome pathway is involved in the breakdown of most 
cellular proteins. Ubiquitin is a small protein cofactor that is enzymatically 
activated before covalent attachment to mark proteins for degradation.  
Once marked, proteins are identified by a large proteolytic complex, the 
proteasome, and undergo rapid degradation (49). Although it is potentially 
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capable of degrading multiple proteins, features of the ubiquitin-
proteasome pathway allow remarkable selectivity and control of protein 
degradation (48). 
 
Lysosomes are involved in the degradation of extracellular proteins, cell 
membrane proteins and bacteria. They are an important component of 
the immune response, but do not play an important role in the turnover of 
most cellular proteins, including muscle protein (48). 
 
ROS can directly activate proteolytic pathways during periods of oxidative 
stress (50). However, ROS can also impair the efficiency of these 
proteolytic systems through oxidative structural changes and oxidation of 
regulatory enzymes (51). These changes to proteolytic systems may 
contribute to the development of cell senescence. 
 
1.7 Cellular frailty 
1.7.1 The cellular response to cumulative DNA damage 
Multicellular organisms are composed of two fundamentally different cell 
types - mitotic cells that can divide (and can give rise to cancer), and 
postmitotic cells that are unable to divide (52). In mammals, mitotic cells 
include epithelial and stromal skin cells, vascular endothelial cells, 
intestine, liver, kidney and glial cells. Mitotic cells also comprise major 
components of the haematopoeitic system and include the 
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undifferentiated stem cells that provide differentiated tissue cells (53).  
Postmitotic cells include mature neurons, skeletal muscle cells, cardiac 
muscle cells and adipocytes (54).   
 
A consequence of the finite energy resource allocation prediction of the 
disposable soma theory is that the multiple mechanisms of molecular 
damage that have been outlined can act in parallel to cause cumulative 
damage to the cell. This encourages the synthesis of a network theory of 
ageing which, rather than viewing these individual mechanisms in 
isolation, predicts the interaction of all of these mechanisms to cause 
biological ageing. An interactive network theory incorporates the 
possibility that multiple mechanisms of cellular and molecular damage 
may cause different outcomes in mitotic and postmitotic cells. Mitotic 
cells, which are actively proliferating, are more vulnerable to DNA 
mutations and telomere erosion. Non-proliferating post-mitotic cells are 
more vulnerable to the accumulation of abnormal proteins and waste 
products because, in contrast to mitotic cells, they are unable to 
synthesise new cellular components through cell division (20). 
 
1.7.2 Cell senescence 
Mitotic cells can undergo cell senescence, which is a fundamentally 
protective stress response characterised by irreversible inhibition of cell 
proliferation to prevent uncontrolled proliferation and malignant 
transformation. Cumulative DNA damage, oxidative damage and 
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oncogene activation are important triggers for cell senescence. To 
provide ongoing protection, maintenance of senescence can continue in 
the absence of the initial stress trigger (55). Importantly, although cell 
senescence is a fundamentally protective response, the cumulative effect 
of a growing number of senescent cells has the deleterious consequence 
of impaired tissue structure and organ function that can ultimately 
manifest in recognisable disease and organismal ageing (53). 
 
Cellular senescence is restricted to mitotic cell types as these cells have 
the potential to divide, and hence undergo malignant transformation.  
Post-mitotic cells, which have lost the ability to divide, do not undergo 
senescence as it is currently defined but instead demonstrate important 
features that may represent a senescence equivalent (53). For example, 
post-mitotic neurons accumulate age-related oxidative DNA damage that 
can adversely influence synaptic function, protein transport and 
mitochondrial function, which can potentially contribute to impaired 
neuronal function. 
 
1.7.3 Pathways to cell senescence 
Cumulative DNA damage has the potential to compromise critical genetic 
information and appears to precipitate a protective cascade that begins 
with initial detection of damage by ATM kinase. Following detection, ATM 
kinase activates multiple subsequent downstream factors that can 
ultimately induce cell senescence (23, 55).  
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Although multiple different stimuli can induce cell senescence, activation 
appears to converge on one or both of two downstream pathways (52).  
One critical downstream pathway is governed by the p53 tumour 
suppressor protein. A second important downstream pathway mediating 
cellular senescence is the p16/pRb pathway. 
 
1.7.3.1 The p53 pathway 
The p53 protein is a key regulator of the cell cycle and is activated by 
DNA damage to induce cell cycle arrest, senescence, or apoptosis 
through alteration of target gene transcription (56, 57). Although 
experimental inactivation of p53 in senescent cells can completely 
reverse growth arrest (58), this arrest cannot be reversed by physiological 
signalling (52). 
 
Animal models which have been induced to express activated p53 
demonstrate early ageing phenotypes, with reduced physical activity, 
osteoporosis, organ atrophy and diminished stress tolerance, whilst at the 
same time exhibiting resistance to spontaneous tumour development 
(57). It is considered likely that p53 induces cellular senescence in an 
attempt to protect the organism against tumour development but this 
protective mechanism may ultimately accelerate organismal ageing. 
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1.7.3.2 The p16/pRB pathway 
Oncogenes and other types of stress can induce the activation of the 
tumour suppressor p16, which in turn activates pRB, leading to 
irreversible cell senescence that cannot be overcome by inactivation of 
p53, pRB or both (59). The p16/pRB pathway causes cell senescence by 
reorganisation of cellular chromatin, the tightly bound DNA/protein 
complex that constitutes chromosomes (37). 
 
1.7.3.3 Relationship between p53 and p16/pRB pathways 
There is a growing consensus that the p53 pathway mediates cell 
senescence due to DNA damage and telomere dysfunction, whilst the 
p16/pRB pathway mediates senescence due to oncogene activation, 
chromatin disruption and cell stresses (59).   
 
The roles of p53 and p16/pRB in the senescence response are illustrated 
in figure 1.5. 
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Figure 1.5.  Roles of the p53 and p16/pRB pathways in the 
senescence response. 
A)  The p53 pathway to senescence.  Detection of DNA damage 
activates the p53 damage response.  The transcription of p53-
dependent genes induces a senescent-like growth arrest that 
cannot be reversed by physiological mechanisms but is reversible 
upon inactivation of p53.  B)  The p16/pRB pathway to senescence.  
Oncogenes and other types of stress induce p16, which activates 
pRB causing cell senescence through reorganisation of chromatin 
that cannot be reversed by inactivation of p53, pRB or both.  
Reproduced with permission from (59). 
 
Although cell senescence is associated with organismal ageing there is 
an absence of evidence regarding the relationship between cumulative 
cell senescence and phenotypic frailty. 
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1.8 Epigenetic factors 
Human cells contain identical genetic information. Certain genes that 
regulate essential cellular functions are expressed in all cells. However, 
some genes are required in particular cells to provide different proteins 
that enable specialised physiological function (60). Epigenetic 
mechanisms regulate the differential expression of genes in certain cells 
but do not result in a change to gene sequence or structure (61). DNA 
methylation and histone modification are considered to be the key 
mechanisms involved in the epigenetic regulation of gene expression 
(61). These mechanisms, which are responsive to physiological and 
environmental cues and demonstrate reversibility, may have particular 
importance in the determination of physical phenotype and ageing (61, 
62). As epigenetic mechanisms are responsive to environmental cues, 
they provide an attractive potential link between environmental factors, 
ageing and disease (63). 
 
Epigenetic mechanisms have been investigated in the post-mitotic cells of 
the brain and have been associated with the development of synaptic 
plasticity and memory (64). A growing body of literature supports the 
presence of an association between epigenetics, brain ageing and 
cognitive impairment (65). Although there is evidence to support a 
potential link between epigenetics and ageing, the role of epigenetics in 
frailty is currently unclear and represents an area for future research.  
Importantly, as DNA methylation and histone modification are potentially 
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reversible, epigenetic mechanisms may represent a potential target for 
future pharmacological therapeutic intervention. 
 
1.9 Summary of molecular and cellular frailty 
Multiple, interacting molecular mechanisms have the potential to cause 
cumulative DNA damage that is regulated by a complex maintenance and 
repair network. Cumulative damage is detected by a series of intracellular 
proteins that can initiate one or both of two pathways that ultimately 
induce cell senescence when a critical level of DNA damage is 
accumulated or oncogenes are expressed. 
 
Senescent cells remain metabolically active and influence the 
surrounding microenvironment leading to extracellular remodelling, 
inflammation and a potential increase in risk of malignant transformation 
of surrounding cells. The stochastic aspect of cell senescence means that 
senescent cells accumulate alongside relatively undamaged cells. This 
cell senescence is irreversible under normal physiological circumstances 
and protects the cell from undergoing malignant change but has the 
potential consequence of compromised tissue function, which is detected 
as phenotypic ageing. The cumulative volume of senescent cells that is 
required to cause impaired organ physiology is currently unknown and is 
an important area of ongoing research. 
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1.10 Frail tissues 
1.10.1 Alteration of tissue structure and function by 
senescent cells 
As the total number of tissue cells is relatively constant, the accumulation 
of senescent cells may alter tissue architectural structure and 
compromise essential renewal and repair mechanisms (59). This 
alteration of tissue structure may impact directly on physiological function. 
 
Although senescent cells are unable to progress through the cell cycle, 
they remain metabolically active (53). Induction of cell senescence by p53 
and p16/pRB pathways leads to the upregulation of a number of genes 
encoding enzymes, growth factors and cytokines that can alter tissue 
structure and function through alteration of the surrounding 
microenvironment (59). For example, senescent fibroblasts increase the 
secretion of proteins that remodel the extracellular matrix and mediate 
local inflammation (53, 66). 
 
The upregulation of local regulatory proteins is considered to be the more 
likely mechanism underlying alteration of tissue structure and function by 
senescent cells (59). This alteration of the tissue microenvironment by 
senescent cells may also promote the development of malignancy by 
stimulating growth and angiogenesis in nearby pre-malignant cells (53, 
59). 
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A further potentially important consequence of senescence may be the 
impact on stem cells, which are found in adult tissues and promote repair 
and renewal. Both direct stem cell senescence and indirect effects on 
stem cells from surrounding senescent cells may affect the proliferation 
and differentiation of tissue stem cells, ultimately compromising tissue 
regeneration (59). 
 
A schematic overview of the potential alteration of tissue structure and 
function by senescent cells is provided in figure 1.6. 
 
 
Figure 1.6.  The contribution of senescent cells to ageing and age-
related pathology, including cancer. 
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A)  Senescent cells may disrupt normal tissue structure and 
function by producing degradative enzymes and inflammatory 
cytokines that can disrupt tissue structure and function. 
B)  Senescent cells may promote cancer progression.  Both 
senescent  cells and cells with preneoplastic mutations accumulate 
with age, as does the probability of both occurring in close 
proximity.  When this occurs, molecules secreted by senescent 
cells may create a permissive microenvironment that allows the 
proliferation of preneoplastic cells.  Reproduced with permission 
from (59). 
 
Cumulative cell senescence can ultimately cause impaired organ 
physiology. The relationship between cell senescence and physiological 
impairment, and the relationship between physiological impairment and 
frailty will be considered. 
 
1.10.2 Cell senescence and physiological impairment 
The stochastic element of DNA damage and associated cell senescence 
implies that damaged senescent cells must exist alongside relatively 
undamaged actively dividing cells (20). Although senescent cells can 
disrupt the normal structure and function of tissues, the cumulative 
volume of senescent cells that is required to cause impaired organ 
physiology is currently unknown. There is only limited experimental data 
regarding loss of skin physiological function due to cell senescence in 
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accelerated ageing syndromes, and the cumulative contribution of cell 
senescence to impaired organ physiology is an area of ongoing research 
(67). 
 
1.11 Frail organ systems 
The brain, endocrine system, immune system and skeletal muscle are 
considered to be the organ systems that play a central role in the 
development of frailty. The relationship between cell senescence and 
physiological impairment in these interacting organ systems and the 
effects of cumulative physiological impairment to promote frailty will be 
explored. 
 
1.12 The frail brain 
Human ageing is accompanied by structural and neurophysiological 
changes in the brain. These changes are associated with varying degrees 
of cognitive decline and dementia in a significant proportion of the 
population (68).   
 
Although age is the dominant risk factor for the development of 
Alzheimer's disease (AD), cognitive decline is frequently observed in 
advanced age even in the absence of detectable pathology such as AD 
and a fundamental question is whether the cognitive decline of ageing is 
clearly distinct from the pathological processes associated with such 
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diseases (69, 70). Loss of hippocampal neurons is observed in both 
normal ageing and AD, but neuronal loss predominates in certain areas 
of the hippocampus in AD when compared to normal ageing, suggesting 
a pathological distinction between the two (71). However, other 
parameters including synapse loss, amyloid plaques and neurofibrillary 
tangles can be extensive in AD, but are also present in variable densities 
in normal brain ageing (68). 
 
The mechanisms that underlie brain ageing and the associated 
pathophysiological consequences will be explored in greater detail. 
 
1.12.1 Neuronal cell cycle 
Central nervous system (CNS) neurons are classically described as 
postmitotic cells, i.e. that they are in a state of permanent cell cycle 
arrest. However, maintenance of cell cycle arrest is an active process and 
highly differentiated neurons must constantly keep their cell cycle in 
check, otherwise re-entry into the cell cycle can be initiated, resulting in 
vulnerability to neuronal cell death (72). It has been postulated that 
neuronal cell cycle re-entry may be the cause of a number of 
neurodegenerative disorders, including Alzheimer's disease (AD), 
Parkinson's disease (PD) and motor neuron disease (MND) (72).   
 
Interestingly, although there is global loss of higher cortical function with 
ageing, the loss of individual neurons in the majority of cortical regions in 
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the ageing brain is minimal (68). Given that neuronal loss is minimal, 
altered synaptic function, protein transport and mitochondrial function are 
potentially important mechanisms underlying the global loss of higher 
order neuronal function that is observed with ageing (68). In line with 
ageing theory, cumulative DNA damage and mitochondrial damage are 
considered to be important mediators of neuronal and brain ageing, in 
association with impaired cellular autophagy and abnormal microglial cell 
function (69, 73, 74). 
 
1.12.1.1 ROS mediated neuronal DNA damage 
Inherited deficiencies in components of the DNA damage-repair cascade 
are frequently associated with accelerated neuropathology, implying that 
DNA damage is important in neuronal ageing (69). Although ROS 
mediated DNA damage is inherently stochastic, certain DNA regions that 
are involved in synaptic function, protein transport and mitochondrial 
function appear to be particularly vulnerable to oxidative damage (75). 
 
The neuron responds to detection of oxidative damage by upregulating 
DNA damage and repair genes, but if areas of neuronal DNA remain 
unrepaired they are silenced, leading to a state of transcriptional 
repression (68, 75, 76). As non-dividing post-mitotic cells do not undergo 
neoplastic transformation it may be advantageous for neurons to remain 
in this state, avoiding apoptosis even if DNA damage has accumulated 
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(69). This maintenance of neurons in a repressed state may also explain 
the observation that neuronal volume loss with ageing is minimal. 
 
In the ageing human pre-frontal cortex, there is disproportionate down-
regulation of genes encoding the inhibitory neurotransmitter #-
aminobutyric acid (GABA) (76). Although this alteration in the balance 
between excitatory and inhibitory neurotransmission could initially be 
compensatory, increased excitatory neurotransmission could eventually 
lead to excitotoxic neurodegeneration. 
 
1.12.1.2 Reduced neuronal mitochondrial function 
Brain (and muscle) cells are particularly dependent on mitochondrial 
function, being adversely affected in a number of inherited mitochondrial 
disorders (68). A progressive age-related reduction in neuronal 
mitochondrial gene expression causing impaired mitochondrial function 
through reduced expression of important oxidative phosphorylation 
proteins has been recorded in humans (75). Neurons with high metabolic 
demands, for example the large hippocampal pyramidal neurons, may be 
disproportionally affected by declining mitochondrial function and be 
rendered vulnerable to damage (68). The hippocampus is an area of the 
brain that coordinates the storage and retrieval of information and has 
been identified as an important mediator in the pathophysiology of 
cognitive decline and Alzheimer's dementia (77). In addition, the 
hippocampus is a key component of the stress response, sensing 
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increased glucocorticoid levels and relaying information to the 
hypothalamus in a negative feedback loop (78). Therefore, damage to 
hippocampal neurons has the potential to affect both cognition and the 
organismal response to stress. 
 
However, the relationship between neuronal mitochondrial function and 
ageing is complex. Modestly reduced mitochondrial function can, in 
certain cases, increase overall longevity but a more severe reduction in 
mitochondrial function can shorten lifespan (79). It has been proposed 
that the initial decline in neuronal mitochondrial gene expression may be 
a protective mechanism to increase stress resistance, but further 
oxidative stress may reduce neuronal mitochondrial function to a level at 
which there is critical DNA damage that results in gene silencing and 
transcriptional regression (68). 
 
1.12.1.3 Impaired cellular autophagy 
Autophagy is a process of continuous cellular 'housekeeping' to dispose 
of unwanted or damaged cellular proteins (74). Under inhibitory regulation 
by the energy-sensing Target of Rapamycin (TOR) kinase system, 
damaged monomeric cellular proteins can be tagged by proteins such as 
ubiquitin and are then disposed of by a series of enzymatic degradation 
systems including the proteasome system (74). However, this system of 
degradation cannot handle more complex cellular protein 
microaggregates, which require intact autophagy systems. The 
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accumulation of protein microaggregates as inclusion bodies can be toxic 
to the cell and hence the autophagy system is an important protective 
mechanism, particularly in neurons, which are unable to grow and divide 
to eliminate waste products (74). 
 
Autophagy involves the initial sequestration of protein aggregates in a 
double membrane vesicle and the subsequent delivery of the vesicle to 
an organelle termed the lysosome, which breaks down the sequestered 
protein. This occurs at a continuous low-level rate in a process termed 
basal autophagy. There is evidence that reduced basal autophagy in 
mice can lead to the formation of inclusion bodies similar to those seen in 
neurodegenerative diseases such as AD, and there is evidence that 
suppression of the regulatory TOR kinase system can extend lifespan 
(80, 81).   
 
Whilst it has traditionally been considered that the inclusion bodies and 
protein aggregates such as amyloid are intrinsically toxic to neurons, it 
has more recently been proposed that they represent a relatively terminal 
phase of neurodegeneration as opposed to an important intermediate 
phase during which targeted interventions to prevent further decline may 
be successful (74). An overview of autophagy is provided in figure 1.7. 
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Figure 1.7.  The role of autophagy in protecting against neuronal 
cell death. 
Misfolded proteins are tagged with ubiquitin and degraded by the 
proteasome system.  However, proteasome is unable to degrade 
certain proteins, which accumulate in the cytoplasm creating 
microaggregates and potentially causing cell death.  Basal 
autophagy acts to keep levels of these microaggregates down to 
prevent toxic effects by sequestration for delivery to lysosomes.  
The folded proteins can also form large aggregates or inclusion 
bodies that can induce autophagy.  These large aggregates may be 
more protective than harmful.  Reproduced with permission from 
(74). 
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1.12.1.4 Abnormal microglial cell function 
Microglia are the resident immune cell population of the CNS and are the 
CNS equivalent of macrophages. Microglia, in contrast to neurons, are 
cells that have the potential to divide (82, 83). In the healthy adult brain, 
microglia are found in a 'resting' state as a small cell body with fine 
projections and low expression of antigens (82). This resting microglial 
state is controlled by neuron-microglia contact, neuronal electrical activity 
and neurotransmitter actions (73). In response to brain injury and local 
inflammation, microglia migrate to the site of inflammation and proliferate 
to phagocytose dying cells and/or release cytokines to maintain the 
microenvironment and support injured neurons (73). In addition to local 
inflammation, microglia can be activated by systemic inflammation, with 
the result of an overall increase in brain inflammation (84). 
 
In younger people the microglia response is protective. However, 
dystrophic microglial structural changes are observed in the ageing brain, 
including abnormal cytoplasm characterised by distorted projections, 
along with altered immune expression and inflammatory profile. These 
dystrophic changes are accompanied by alterations in microglial function, 
and microglia become primed to be over-responsive to small stimuli, 
which can potentially cause damage and neuronal death (73, 84, 85).  
These dystrophic changes and abnormal response to stimuli are believed 
to represent the microglial equivalent to cell senescence, and primed 
microglia are postulated to play an important role in the pathophysiology 
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of delirium, which is associated with important adverse consequences 
including increased morbidity and mortality (84, 86). 
 
Increased numbers of dystrophic microglia have been observed in older 
people, and impaired microglial function has been reported in 
neuropathological conditions including AD (87). Microglial senescence, 
with its accompanying structural and functional changes, may 
compromise the immune function of the brain and contribute to the 
development of neurodegenerative disease through diminished 
neuroprotection (85). The exact mechanisms underlying microglial 
senescence are yet to be elucidated but are likely to include common 
mechanisms of DNA damage, telomere shortening and mitochondrial 
dysfunction. Indeed, significant microglial telomere shortening and 
reduced telomerase activity have been recorded in animal models of 
normal ageing, and these changes are accelerated by the presence of 
amyloid, suggesting that microglial cells may have an important role to 
play in the pathophysiology of age-related cognitive decline and AD (88). 
 
A schematic representation of microglial overactivity leading to 
progressive neurotoxicity is provided in figure 1.8. 
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Figure 1.8.  Reactive microgliosis drives progressive neurotoxicity. 
Microglia can become overactivated and cause neurotoxicity 
through two mechanisms.  First, microglia can initiate neuron 
damage by recognising pro-inflammatory stimuli, such as 
lipopolysaccharide (LPS), becoming activated and producing 
neurotoxic pro-inflammatory factors.  Second, microglia can 
become overactivated in response to neuronal damage, which is 
then toxic to neighbouring neurons, resulting in a perpetuating 
cycle of neuronal death. A!, amyloid beta; H2O2, hydrogen 
peroxide; IL-1!, interleukin-1 beta; MMP3, matrix mettaloproteinase 
3; MPP, 1-methyl-4-phenylpyridinium ion; MPTP, 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine; NO, nitric oxide; NOO, peroxynitrite; O2-, 
superoxide; PGE2, prostglandin E2; TNF", tumour necrosis factor-
".  Reproduced with permission from (89). 
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1.12.2 Frailty, delirium and dementia 
There is indirect evidence to support a biologically plausible association 
between frailty and delirium. Proxy markers of frailty, including age, 
cognitive reserve, cognitive impairment, comorbidity, disability and long-
term care residence have all been identified as independent risk factors 
for delirium (90-92). The hippocampus is activated early in delirium and 
metabolically vulnerable hippocampal neurons may characterise the frail 
brain at risk of delirium (93). 
 
There is accumulating evidence from observational studies to support a 
temporal association between frailty, cognitive impairment and dementia.  
A 2010 prospective cohort study including 750 older people without 
cognitive impairment at baseline reported that physical frailty was 
associated with increased risk of developing mild cognitive impairment 
(MCI) over 12 years of follow-up, controlling for depression, disability, 
vascular risk factors and vascular disease (94). MCI is a condition that is 
increasingly recognised as a precursor to dementia, and each one-unit 
increase in frailty (measured using grip strength, timed walk, body 
composition and fatigue) was associated with a 63% increase in MCI risk 
(hazard ratio, HR, 1.63, 95% confidence interval, CI, 1.27 - 2.08). A 
higher level of physical frailty was also associated with a faster rate of 
cognitive decline.. 
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A 2007 cohort including 823 participants reported that frailty was 
associated with increased risk of AD during three years of follow-up (95).  
Using an operationalised frailty index, both baseline frailty and annual 
rate of change were associated with increased risk of AD. Each 1/10 of a 
unit increase in baseline frailty was associated with an approximately 
twofold increase in AD risk (HR 1.94, 95% CI 1.31 - 2.87) and each 1/10 
of a unit increase in rate of change of frailty was associated with an 
approximately threefold increase in AD risk (HR 3.30, 95% CI 1.52 - 
7.13). 
 
1.13 The frail endocrine system 
There is accumulating evidence that the endocrine system has a crucial 
role in the regulation of organismal ageing and frailty. The brain and 
endocrine system are intrinsically linked through the hypothalamo-
pituitary (HP) axis, which controls the metabolism and energy use of the 
organism via the signalling action of a series of homeostatic hormones 
(68). Regulation of glucocorticoid (GC) secretion and insulin-like growth 
factor (IGF) signalling are considered to be of key importance, as deficits 
in these hormonal systems have been associated with adverse ageing 
profiles and frailty.  
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1.13.1 Glucocorticoid secretion and frailty 
The hypothalamus receives and integrates multiple afferent inputs from 
diverse regions of the brain to coordinate the organismal response to 
stress and inflammation, partly through the control of GC secretion (96).  
Basal GC secretion is necessary for the normal function of many cells 
and levels are increased in response to virtually any stress, including 
physical and psychological stress, or the presence of inflammation, to 
provide the altered physiological requirements that promote survival (97). 
Peripheral cytokines such as IL-1 and IL-6 that are released in response 
to stress and inflammation have both direct and indirect effects on the 
hypothalamus to promote GC secretion (97). Circulating GC are 
subsequently sensed by the hippocampus, which suppresses 
hypothalamic stimulation of GC production in a negative feedback loop.   
 
Uncontrolled inflammation has the potential to cause cellular damage, 
and a functional GC system is an important component of the 
homeostatic regulation of local and systemic inflammation. The loss of 
hippocampal neurons that is observed in both normal ageing and AD may 
impair the homeostatic control of the GC system, with the consequence of 
uncontrolled inflammation and increased cellular damage, promoting 
organismal ageing. Loss of homeostatic control of the GC system may 
itself promote further neurodegeneration, as chronically elevated levels of 
GC have been hypothesised to increase hippocampal neuronal damage 
(98). The loss of hippocampal neurons that is observed in both normal 
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ageing and AD may therefore promote a spiral of accelerated neuronal 
damage through impairment of the GC negative feedback loop, 
uncontrolled inflammation and neurotoxic effects of chronically elevated 
GC levels (68). 
 
A recent cross sectional study involving 214 female participants reported 
that frailty, measured using the Fried criteria, was independently 
associated with chronically elevated diurnal cortisol levels, even after 
adjustment for depressive symptoms, which are themselves associated 
with increased cortisol (99). A link between chronically elevated cortisol 
and frailty is biologically plausible, as persistently high levels of cortisol 
have been associated with increased catabolism, leading to loss of 
muscle mass, anorexia, weight loss and reduced energy expenditure - the 
cardinal clinical features of frailty (50). 
 
1.13.2 Insulin-like growth factor signalling and frailty 
Insulin-like growth factors (IGFs) are a family of small peptides that 
increase anabolic activity in many cells. Promotion of neuronal plasticity 
and increased skeletal muscle strength are considered to be particularly 
important effects (100). The principal IGFs are IGF-1, IGF-2 and insulin. 
IGF-1 is synthesised in the liver in response to circulating Growth 
Hormone (GH) in a process that is regulated by the HP axis. A range of 
growth factors and hormones also stimulate local synthesis of IGF-1 by 
neurons, muscle cells and white blood cells (WBCs). 
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The local autocrine and paracrine actions of IGF-1 are considered to be 
important for the promotion of neuronal plasticity and increased skeletal 
muscle strength (100, 101). Age-related impairments in autocrine, 
paracrine and endocrine activity of IGF-1 are considered to be important 
in the development of neuronal senescence and sarcopenia (100, 101). 
 
IGF-1 regulates the production of a number of transcription factors that 
influence the expression of multiple genes that are implicated in oxidative 
stress, inflammatory regulation and cellular autophagy (102). One 
important downstream transcription factor is DAF-16 and recent evidence 
suggests that this may play a key role in influencing organismal lifespan 
(103). Indeed, genetic variations in the IGF signalling pathway have been 
associated with increased life expectancy in humans (104). 
 
Evidence is beginning to accumulate to support the hypothesis that IGFs 
play an important role in frailty. A 2004 cross-sectional study including 51 
older participants reported significantly lower levels of IGF-1 in those who 
were identified as frail by the Fried criteria when compared to age-
matched controls (105). An inverse correlation between IGF-1 and IL-6 
levels was observed, identifying a potential relationship between IGF-1 
and the frail immune system. 
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A 2009 cross-sectional study involving 696 older women from the US 
Women's Health and Aging Study identified a significant correlation 
between white blood cell counts and IGF-1. A complex U-shaped 
association between IGF-1, WBC count and frailty was also reported.  
Compared to a reference of high IGF-1 and low WBC counts, when IGF-1 
levels were low, both low and high WBC counts were associated with 
increased risk of frailty. Conversely, when WBC counts were high, both 
low and high levels of IGF-1 were associated with frailty (106). 
 
1.13.2.1 IGFs and the brain 
IGFs promote neuronal survival by inhibiting apoptosis and can increase 
learning and memory in humans (68, 107). Primary neuronal changes in 
the hippocampus and hypothalamus may affect the IGF pathway, 
resulting in a predisposition for accelerated neuronal death and a 
consequent deterioration in physiological function (68). 
 
1.13.2.2 IGFs and muscle 
IGFs stimulate myogenic differentiation and induce skeletal muscle 
hypertrophy, with IGF-1 exhibiting greatest potency (100, 108).  Amino 
acid uptake, protein production, glucose uptake and muscle cell 
proliferation are all stimulated by IGFs, which act principally via the IGF-1 
receptor located on myocytes and skeletal muscle stem cells (100). 
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A schematic representation of the brain and endocrine system as a 
potential regulator of organismal ageing and frailty is provided in figure 
1.9. 
 
 
Figure 1.9.  The brain and endocrine system as a potential regulator 
of organismal ageing. 
The ageing of the brain may be coordinated with the ageing of 
organ systems through hormonal feedback circuits.  Stressors 
induce hypothalamic production of corticotrophin-releasing 
hormone (CRH), leading to glucocorticoid release from the adrenal 
glands.  The hippocampus senses glucocorticoid concentration 
through the glucocorticoid receptor (GR) resulting in feedback 
inhibition of release.  Chronically elevated glucocorticoid levels 
during ageing may be detrimental to hippocampal function, 
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potentially setting up a spiral of hormonally mediated hippocampal 
decline.  The right hand side of the diagram shows a general 
mechanism contributing to the decline of other functional systems 
in the brain, for example the IGF system.  Reproduced with 
permission from (68). 
 
1.14 Summary of brain and endocrine frailty 
Cumulative ROS mediated DNA damage in post-mitotic neuronal cells 
may reduce the expression of selectively vulnerable genes leading to 
impaired synaptic plasticity, protein transport, mitochondrial function and 
neuronal survival that manifests as the cognitive decline of ageing (75).  
Cumulative age-related microglial damage leading to microglial priming 
may cause an abnormal response to local and systemic inflammation, 
with microglial overactivity following relatively minor stressor events 
causing accelerated neurotoxicity. Brain ageing in the hypothalamus and 
hippocampus may be a potential regulator of organismal ageing, through 
abnormal neuroendocrine homeostasis and impaired organ physiology.  
Impairments in glucocorticoid and IGF-1 homeostasis can potentiate 
neurotoxicity and may precipitate a spiral of progressive neurological and 
organismal decline. This progressive decline may manifest clinically as an 
increased risk of developing delirium in response to minor stressor 
events, worsening cognitive impairment and dementia. 
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1.15 The frail immune system 
The competence of the immune system is reduced with age and is 
characterised by an age-related decline in immune stem cell lineages and 
an abnormal inflammatory response (22). Oxidative DNA damage to stem 
cells, mitochondrial dysfunction and telomere shortening are all 
considered to contribute to age-related immune senescence (22, 109).  
Significant changes in haematopoetic stem cells (HSCs) are observed, 
with a functional reduction in regenerative capacity and reduced output of 
B and T lymphocytes. In contrast, stem-cell derived neutrophil and 
macrophage numbers are increased, but the phagocytic ability of 
neutrophils and macrophages is reduced (22). 
 
There is accumulating evidence to support the hypothesis that the 
senescent immune system has an important role in the pathophysiology 
of frailty. This appears to be principally through an abnormal inflammatory 
response that is constitutively active at a low-grade level, inappropriately 
hyper-responsive to inflammatory stimuli and persistently active for a 
prolonged period following removal of the initial inflammatory stimulus.   
 
1.15.1 Inflammation 
Inflammation is a protective immune response that is triggered by 
conditions such as infection and tissue injury, including ischaemia, 
hypoxia, trauma and physical/chemical injury (110-112). Inflammation is 
 78 
designed to rid the organism of noxious stimuli and pathogens and hence 
restore physiological homeostasis; the absence of an adequate 
inflammatory response would lead to multiple deleterious outcomes, 
including unchecked infections and absence of wound healing (111).  
However, if the inflammatory response is not tightly regulated, chronic 
ROS mediated molecular and cellular damage may occur, accelerating 
cellular senescence and organismal ageing. A brief review of the 
inflammatory pathway will help identify the important mechanisms that 
are associated with frailty. 
 
1.15.2 The inflammatory pathway 
When considering the inflammatory pathway, it is helpful to distinguish 
between inducers, sensors, mediators and effectors of inflammation 
(110).   
 
1.15.2.1 Inducers of inflammation 
Inducers of inflammation are the exogenous and endogenous signals that 
initiate the inflammatory response. Exogenous signals can induce an 
acute inflammatory response either directly, in the case of some microbial 
pathogens, or through the effects of microbial virulence factors on host 
tissue cells, for example Gram-positive bacterial exotoxins (110). Non-
microbial exogenous inducers include allergens, foreign bodies and 
toxins. 
 79 
 
Endogenous inducers of acute inflammation are signals produced by 
stressed, damaged and malfunctioning tissues that are, under normal 
circumstances, confined to the cell. Cellular damage can result in the 
transmembrane release of a large number of inflammatory inducers 
including ATP, potassium ions and calcium binding proteins (110). These 
inducers can both directly induce the inflammatory response and activate 
pain receptors (nociceptors) which relay information to the central 
nervous system; a key regulator of the inflammatory response (113, 114).  
Furthermore, damage to vascular endothelium allows plasma proteins to 
access the extracellular space and facilitates direct activation of the 
inflammatory response (115). 
 
A further series of endogenous inducers include monosodium urate and 
calcium pyrophosphate crystals, which precipitate in joints and 
periarticular tissues to cause gout and pseudogout. These crystals are 
detected by macrophages and treated in the same manner as foreign 
bodies to precipitate an inflammatory response (110).   
 
High-density and low-density lipoprotein molecules can induce an 
inflammatory response following oxidation by macrophage-generated 
ROS, and ROS dependent oxidation of extracellular matrix components 
can also induce inflammation (110).  
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1.15.2.2 Sensors of inflammation 
Exogenous and endogenous inducers of inflammation are detected by a 
series of sensors, which include receptors such as IgE and the Toll-like 
receptors that are present on the surface of immune cells, including 
macrophages, B lymphocytes and mast cells (110). 
 
1.15.2.3 Mediators of inflammation 
Once detected by sensors, inflammatory inducers trigger the generation 
of multiple mediators of inflammation, which can ultimately alter the 
function of tissues and organs. Derived from plasma proteins or produced 
by specialised leukocytes and tissue cells, the inflammatory mediators 
can be classified into seven groups; vasoactive amines (e.g. histamine 
and serotonin), vasoactive peptides (e.g. substance P), complement 
components (e.g. C3a, C4a, C5a), lipid mediators (e.g. eicosanoids and 
platelet activating factor), cytokines (e.g. TNF ", interleukin-1 (IL-1), 
interleukin-6 (IL-6)), chemokines and proteolytic enzymes (e.g. elastin, 
proteinases) (110, 111).  Inflammatory mediators can also alter the 
production of other mediators, for example TNF activates cells to increase 
expression cytokines (e.g. IL-1) and eicosanoids. 
 
1.15.2.4 Effectors of inflammation 
The effectors of inflammation are the cells and tissues that are affected 
by the inflammatory mediators. Some mediators (e.g. TNF, IL-1) exert 
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their effects on virtually all cells, but the effects may be different 
depending on cell type (110). Although outcomes such as exudate 
formation through changes to endothelial cells and promotion of leukocyte 
migration are perhaps more obvious effects of inflammatory mediators, 
many mediators have equally important effects on the neuroendocrine 
system and metabolism (97, 110). 
 
Acute inflammation is classically associated with infection and tissue 
injury. Localised chronic inflammation can occur as a result of, for 
example, chronic infection and autoimmune disease. Systemic chronic 
inflammation occurs in a variety of diseases, including type 2 diabetes 
and cardiovascular disease (110). Although the physiological purpose of 
the acute inflammatory response following an infective trigger has been 
well characterised (i.e. to remove infection), the physiological purpose of 
systemic chronic inflammation is less well understood but appears to be 
associated with a more generalised physiological homeostatic imbalance 
(110). 
 
1.15.3 Regulation of the inflammatory response 
Adequate regulation of the magnitude of the inflammatory response is 
essential; an insufficient inflammatory response can lead to 
immunodeficiency and overwhelming infection, an excessive response 
can lead to chronic inflammatory damage and autoimmune disease. In 
certain situations, such as septic shock, the inflammatory response can 
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initiate a more detrimental outcome than the initial stimulus (116). 
Through a critical homeostatic inflammatory feedback reflex, a number of 
checkpoints exist to precisely regulate the targeted destruction and 
assisted repair that characterise the inflammatory response (117). This 
precise regulation involves a complex interaction between multiple local 
and circulating pro- and anti-inflammatory mediators that are reflexively 
monitored and adjusted by the nervous system (116). 
 
1.15.3.1 Pro-inflammatory mediators 
An acute inflammatory response that is triggered by infection or tissue 
injury results in the delivery of plasma proteins (e.g. antibodies) and 
leukocytes to the site of infection or injury.  The response is initiated by 
tissue macrophages and mast cells, which produce a wide range of 
inflammatory mediators that promote increased tissue blood flow, 
increased vascular permeability to plasma proteins and neutrophil 
migration (110, 111).   
 
Tumour-necrosis factor (TNF) is an important pro-inflammatory mediator 
that is required for both local and systemic inflammation (111).  Produced 
by activated macrophages, local increases in TNF lead to detectable 
signs of inflammation (redness, heat, swelling) whereas systemic 
increases in TNF can mediate tissue injury by depressing cardiac output, 
inducing microvascular thrombosis and causing increased capillary 
permeability (116).   
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Neutrophils that are activated by direct contact with pathogens or 
inflammatory cytokines release ROS and potent enzymes in an attempt to 
kill the invading agent.  As these ROS and enzymes do not discriminate 
between invading agents and host tissues, some damage to host cells is 
inevitable (117). 
 
1.15.3.2 Anti-inflammatory mediators 
Although the inflammatory response functions as a defense mechanism, 
the unregulated generation of pro-inflammatory mediators can cause 
injury to healthy cells (118). To regulate inflammation, cell-cell 
interactions between activated leukocytes and tissue cells promote the 
generation of a series of anti-inflammatory mediators that limit the 
inflammatory response and prevent the dissemination of pro-inflammatory 
mediators into the systemic circulation (116). Anti-inflammatory cytokines, 
including interleukin-10 (IL-10) and transforming growth factor-! (TGF-!), 
inhibit the release of pro-inflammatory mediators such as TNF-" (119).  
Anti-inflammatory hormones including adrenal glucocorticoids, adrenaline 
and "-melanocyte stimulating hormone ("-MSH) also inhibit inflammatory 
cytokine synthesis. Local anti-inflammatory agents including spermine, 
prostaglandin E2 and acute phase proteins inhibit macrophage activation 
and cytokine synthesis (116, 118). These anti-inflammatory mediators are 
generated hours to days after the initial inflammatory stimulus. 
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Experimental impairment of these anti-inflammatory responses in animals 
can cause significant detriment. Loss of adequate glucocorticoid 
response via hypophysectomy or adrenalectomy causes an amplified 
response to endotoxin and overexpression of TNF; IL-10 deficiency leads 
to development of chronic inflammatory bowel disease; pharmacological 
spermine antagonism increases local TNF activity and amplifies the 
inflammatory response (116, 118, 120, 121). Loss of these anti-
inflammatory mechanisms converts a protective, self-limiting 
inflammatory response into an unregulated, excessive, potentially 
damaging systemic response (116). 
 
Although fundamentally protective, inadequate regulation of inflammation 
can lead to persistent molecular and cellular damage. A diagrammatic 
overview of inflammatory response triggers and their associated potential 
physiological and pathological outcomes is provided in figure 1.10. 
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Figure 1.10.  Triggers, physiological purposes and pathological 
outcomes of inflammation. 
Depending on the trigger, the inflammatory response has a different 
physiological purpose and pathological consequence. Reproduced 
with permission from (110). 
 
The senescent immune system may function adequately in the quiescent 
state but fail to respond appropriately to the stress of acute inflammation, 
including the common precipitants of infection and tissue injury (22). A 
low grade inflammatory state is common in older people and activated 
lymphocytes and monocytes of healthy older people produce greater 
levels of the pro-inflammatory cytokine IL-6 (122-124). Inflammation has 
been implicated as having an important pathogenic role in many age-
related diseases, including Alzheimer's disease, atherosclerosis, heart 
failure, osteoporosis and osteoarthritis (117, 125-127). Inflammation has 
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also been implicated in the pathophysiology of sarcopenia, an important 
component of the frailty phenotype (128, 129). 
 
1.15.4 Inflammation and frailty 
There is substantial evidence to indicate that inflammation has a key 
pathophysiological role in frailty. A large prospective cohort study 
involving 5201 participants reported an association between C-reactive 
protein (CRP) and incident frailty as defined by the Fried criteria (130). In 
a multivariate analysis adjusted for important covariates, every standard 
deviation increment in baseline CRP increased the five year incidence of 
frailty by 18% (Hazard Ratio, HR 1.18, 95% confidence interval, CI, 1.04 - 
1.34).   
 
A recent UK case-control study that included 101 participants reported 
results from a multivariate analysis demonstrating that TNF-", IL-6 and 
CRP were independently associated with increasing frailty, defined using 
Fried criteria, Frailty Index and functional status. Increasing frailty was 
negatively associated with albumin using all three definitions of frailty 
(131). 
 
A further cross-sectional study reported an independent association 
between increased white blood cell (WBC) counts, IL-6 and frailty in 558 
older women (132). Those in the top tertile for WBC measurements had 
an odds ratio (OR) of 3.15 (95% CI 1.34 - 7.41) for frailty. The 
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corresponding OR for IL-6 was 2.81 (95% CI 1.19 - 6.64). Two additional 
studies that pre-dated current definitions of frailty reported that increased 
IL-6 and CRP were associated with increased risk of functional disability 
and death in community dwelling older people (133, 134). 
 
The molecular mechanisms underlying increased levels of inflammatory 
cytokines in frailty are beginning to be elucidated. CXC chemokine ligand-
10 (CXCL-10) is a potent pro-inflammatory mediator that is produced by 
many types of immune cells in response to stimuli including 
lipopolysaccharide (LPS) and interferon-# (IFN-#) to stimulate neutrophil 
and lymphocyte activation (135). CXCL-10 levels increase with age, but in 
two recent cross-sectional studies older people identified as frail using the 
Fried criteria had higher levels of unstimulated and LPS-stimulated 
monocyte CXCL-10 expression when compared to age matched controls 
(136, 137). There was also a strong association between CXCL-10 and 
IL-6 in the frail older participants (136). 
 
1.15.5 The frail brain and impaired endocrine 
regulation of the inflammatory response 
The brain and nervous system play a central role in regulation of the 
inflammatory response by both sensing and responding to inflammation 
through circulating humoral and direct neural mechanisms.  Circulating 
inflammatory cytokines including TNF gain nervous system access 
through areas of the brain in which a blood-brain barrier is absent, and 
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stimulate hypothalamic-pituitary (HP) responses to inflammation, 
including fever and anorexia (116). Afferent sensory and pain fibres 
transmitted from peripheral tissues via the vagus and other nerves can 
also activate HP inflammatory responses, notably at levels of 
inflammation below that required for circulating cytokine activation. 
Furthermore, cells of the immune system can produce neuropeptides 
such as endorphins and neurotransmitters including acetylcholine to 
provide additional input to the nervous system (116). 
 
Detection of inflammation by the nervous system leads to activation of the 
hypothalamic-pituitary-adrenal (HPA) axis and stimulation of anti-
inflammatory glucocorticoid release, leading to suppression of further 
inflammatory cytokine release (138). In addition to regulation of the HPA 
axis, the nervous system modulates the inflammatory response directly 
via efferent sympathetic and parasympathetic nerve activity. Adrenaline 
and noradrenaline mediated afferent sympathetic activity can induce 
macrophage inhibition, suppression of inflammatory cytokine synthesis 
and increases in the anti-inflammatory cytokine IL-10 (139, 140).  
Acetylcholine mediated vagal afferent parasympathetic innervation 
induces similar macrophage inhibition and suppression of TNF and other 
cytokine production (116). Vagus nerve activity is also relayed to other 
areas of the brain, including the hypothalamus, to increase activation of 
the HPA axis. 
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The wiring of this complex reflex mechanism is illustrated 
diagrammatically in figure 1.11. 
 
 
Figure 1.11.  The inflammatory reflex. 
Inflammatory products produced in damaged tissues activate 
afferent signals that are relayed to the nucleus tractus solitarius.  
Subsequent activation of vagus efferent activity inhibits cytokine 
synthesis through the cholinergic anti-inflammatory pathway (the 
inflammatory reflex). Information can also be relayed to the 
hypothalamus and the dorsal vagal complex to stimulate the release 
of ACTH, thereby activating the humoral anti-inflammatory pathway.  
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Activation of the sympathetic outflow can increase local 
concentrations of catecholamines, which can suppress 
inflammation further.  ACTH, adrenocorticotrophic hormone; TNF, 
tumour necrosis factor; IL-1, interleukin-1. Reproduced with 
permission from (116). 
 
1.15.6 The hypothalamic-pituitary-adrenal (HPA) axis, 
cortisol and frailty 
Inflammatory mediators activate the HPA axis to produce cortisol, which 
has multiple downstream effects including feedback inhibition of the 
inflammatory response, increased metabolism and altered brain function 
characterised by increased hippocampal activity (141). Supported by a 
large meta-analysis, there is a growing consensus that reactivity of the 
HPA to inflammatory stimuli is significantly increased with age (142). 
 
Demonstration of persistence of elevated cortisol levels in frail older 
people following inflammatory and adrenal challenge would provide 
further evidence to support the biologically plausible potential role of an 
abnormal inflammatory reflex in the development of frailty. 
 
1.15.7 Ageing and anaemia 
Anaemia is common in older people, becoming increasingly prevalent 
with advancing age, and is associated with vulnerability to adverse 
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outcomes, including an independent increase in mortality risk (143, 144).  
Anaemia has been independently associated with increased risk of frailty 
in one cross-sectional analysis that included 670 older participants, but 
the possibility of residual confounding despite adjustment for important 
covariables was reported (145). 
 
1.16 Frail skeletal muscle - sarcopenia 
Sarcopenia is characterised by progressive loss of skeletal muscle mass, 
strength and power and is considered to be a key component of frailty 
(146, 147). Under normal circumstances, muscle homeostasis is 
maintained in a delicate balance between new muscle cell formation, 
muscle cell hypertrophy and muscle cell protein loss. This delicate 
balance is coordinated by the brain, endocrine system and immune 
system and is influenced by nutritional factors and senescent physical 
activity. The adverse molecular, neural, endocrine and immune 
components of frailty have the potential to upset this delicate homeostatic 
balance and accelerate the development of sarcopenia.  
 
Muscle strength and power are required for the critical basic mobility skills 
of getting out of bed, standing up from a chair, walking a short distance 
and getting off the toilet (148). When the ability to perform these critical 
skills is impaired, an older person is at risk of immobility, causing further 
loss of muscle mass, risk of falls and activity limitation. Indeed, 
sarcopenia has been independently associated with increased falls risk 
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(OR 2.6, 95% CI 1.42 - 4.73) and development of disability (OR 3.7, 95% 
CI 1.4 - 10.0). 
 
Muscle power, the product of muscle torque and movement, appears to 
be more closely associated with functional physical performance than 
static muscle strength and declines more rapidly with age (149). Muscle 
power may therefore have greater utility as a measure of physiological 
impairment and functional deficit. As muscle strength and power do not 
depend entirely on muscle mass, and the relationship is non-linear, 
recent consensus criteria recommend using the presence of low muscle 
mass and either low muscle strength or low physical performance to 
diagnose sarcopenia (147). Observational studies have reported losses 
of muscle strength and power of between 1-3% per annum in older 
people, with even greater losses observed in the oldest old (150). 
 
A schematic representation of the interaction of these multiple 
mechanisms is provided in figure 1.12. The complex interaction between 
these multiple contributory factors will be considered in greater detail. 
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Figure 1.12.  Mechanisms of sarcopenia. 
Reproduced with permission from (147) 
 
1.16.1 Skeletal muscle stem cells 
Skeletal muscle fibres (myocytes) are syncytia derived from the fusion of 
multiple individual embryonic cells and therefore contain multiple nuclei 
(111). These post-mitotic cells are supported by a stem cell population 
located beneath the myocyte cell membrane that are responsible for 
generating new muscle fibres in response to injury (151). Muscle stem 
cells, or satellite cells (SCs), are activated by stimuli that alter the 
microenvironment, including exercise and injury. Interstitial cells, immune 
cells and vascular cells are activated to secrete multiple factors that 
promote SC growth, including endothelial derived growth factors such as 
Vascular Endothelial Growth Factor (VEGF) and IGF-1 (151). SCs are 
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also influenced by neural factors and are also activated in response to 
neuromuscular denervation (152). 
 
Ageing SCs demonstrate an impaired capacity for differentiation and 
regeneration and are more susceptible to apoptosis (153, 154).  
Diminished regeneration is most apparent after muscle injury (22).  
Although absolute numbers of satellite cells are reduced in animal models 
of ageing, human skeletal muscle does not reliably demonstrate a similar 
reduction, and changes to the SC microenvironment are considered to be 
more important (155). This is supported by the observation that an 
adequate surrounding microenvironment can restore the function of aged 
SCs (22, 151).  These age-related changes to the microenvironment are 
illustrated schematically in figure 1.13. 
 
 
Figure 1.13.  Schematic illustration of the satellite cell (SC) niche in 
aged skeletal muscle. 
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Age-related changes to endothelial cells, interstitial cells, and 
immune cells, a thickened basal lamina and remodelling of the 
neuromuscular junction all contribute to reduced activation and 
proliferation of SCs.  Reproduced with permission from (151). 
 
1.16.2 Oxidative damage and sarcopenia 
There is accumulating evidence to support a central role of increased 
oxidative stress and mitochondrial DNA damage in the development of 
sarcopenia. Increased muscle protein carbonyl levels, indicators of 
oxidative stress, along with evidence of increased mitochondrial DNA 
damage in muscle samples from older people have been reported (156, 
157). Furthermore, a 2007 cross-sectional study involving 672 women 
aged 65 and older identified that higher levels of carbonylated proteins 
were associated with reduced grip strength, an indicator of sarcopenia 
(146). 
 
1.16.3 Reduced muscle mitochondrial function 
Muscle is a tissue with high metabolic activity and is adversely affected in 
a number of inherited mitochondrial disorders (68). Mitochondrial DNA 
mutations accumulate with age and have been associated with 
mitochondrial dysfunction, apoptosis and sarcopenia in animal models 
(158). Mitochondrial DNA polymorphisms have also been independently 
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associated with grip strength, a measure of sarcopenia, in older adults 
(35). 
 
1.16.4 Muscle protein breakdown and sarcopenia 
All cellular proteins are continually being degraded and replaced. The rate 
of turnover is dependent on cell type and in muscle cells the majority of 
proteins are replaced every one to two weeks (48). The homeostatic 
balance between protein synthesis and breakdown is critical and tight 
regulation of this process is necessary as even a small change to protein 
synthesis or breakdown can result in a significant loss of body mass (48).  
Muscle protein breakdown pathways are influenced by components of the 
inflammatory reflex and endocrine factors. 
 
1.16.4.1 The ubiquitin-proteasome pathway 
The ubiquitin-proteasome (UP) pathway is of key importance in the 
breakdown of muscle protein leading to the muscle wasting that is 
observed in many catabolic states, including malnutrition, chronic 
inflammation and malignancy. Levels of ubiquitin conjugates in muscle 
cells and ubiquitin mRNA increase during these conditions, indicating a 
coordinated response that promotes muscle wasting during periods of 
stress to provide amino acids as both a direct muscle energy source and 
a substrate for hepatic gluconeogenesis (159). A similar ubiquitin 
mediated response occurs following muscle denervation, leading to 
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muscle wasting (159). The activity of the UP pathway is influenced by 
both inflammatory and endocrine factors. 
 
1.16.4.2 Lysosomal pathways 
Skeletal muscle cells contain few lysosomes and they are not considered 
to contribute significantly to overall proteolysis (160). 
 
1.16.5 Inflammation and sarcopenia 
There is evidence that inflammation is associated with the development 
of sarcopenia. A cross-sectional sample of 680 people participating in a 
prospective cohort study identified that IL-6 was independently 
associated with sarcopenia following a multivariate analysis that adjusted 
for important confounding variables (128). 
 
1.16.5.1 Inflammation and increased proteolysis 
Inflammatory cytokines such as IL-6 and TNF can activate the UP 
pathway leading to muscle proteolysis. In addition to the generation of 
amino acids for energy, activation of UP by IFN appears to facilitate the 
cleavage of small antigenic peptides that have the potential to enhance 
the specificity of the immune response (161). This response, which under 
normal circumstances serves a fundamentally protective physiological 
purpose, may become pathological in the presence of an overactive, 
insufficiently regulated inflammatory response that characterises frailty.  
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Functionally debilitating loss of muscle mass and strength may therefore 
be the consequence of an overactive inflammatory response in the 
presence of frail skeletal muscle. This may be detected clinically as a 
significant deterioration in the basic mobility skills of standing from a 
chair, getting out of bed, walking to the toilet, and climbing stairs, which 
may manifest as measurable functional impairment. 
 
1.16.6 Endocrine components of sarcopenia 
1.16.6.1 IGF-1 
IGF-1 is considered to play a key role in the maintenance of muscle 
strength. Although systemic GH dependent IGF synthesis by the liver 
may have a role, the autocrine and paracrine effects of GH-independent 
local IGF-1 production by muscle cells in response to changes in the 
microenvironment are believed to be of particular importance (101). 
 
IGF-1 acts to increase muscle strength by promoting increased myocyte 
number, activating muscle cell hypertrophy and inhibiting muscle protein 
breakdown. Increased myocyte number is considered to be through 
promotion of SC proliferation and differentiation (151). Activation of 
muscle cell hypertrophy is through an IGF-mediated direct and indirect 
cascade of kinase enzymes and the TOR signalling pathway (162).  
Inhibition of muscle protein breakdown is facilitated through 
downregulation of components of the UP pathway (163). 
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Evidence to support an association between IGF-1 and sarcopenia has 
been provided by a prospective cohort study involving 558 participants, 
which reported results from a multivariate analysis that identified a 
statistically significant association between IGF-1 levels and sarcopenia 
(128). 
 
1.16.6.2 Glucocorticoids 
Glucocorticoids (GCs) stimulate muscle protein breakdown by 
upregulating expression of mRNA encoding for UP subunits leading to 
increased proteolysis (50, 164). GCs also act to inhibit protein synthesis.  
The chronic elevation and inadequate feedback regulation of GCs in 
frailty has the potential to promote the accelerated, sustained 
development of sarcopenia. 
 
1.16.6.3 Testosterone 
Testosterone supplementation can increase skeletal muscle mass in both 
young and older males, principally through promotion of myofibre 
hypertrophy and increased SC number (165). However, a recent 
randomised controlled trial of testosterone supplementation involving 209 
older participants with limitations in mobility and low serum testosterone 
was terminated early due to safety concerns. Although the intervention 
group demonstrated significant improvements in arm and leg strength 
compared to the placebo group, a higher rate of adverse cardiovascular 
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and respiratory events in the intervention group led to a recommendation 
from the data and safety monitoring board that the trial be discontinued 
(166). 
 
1.16.7 Neuromuscular components of sarcopenia 
Ageing skeletal muscle demonstrates impaired neuronal innervation 
characterised by alterations in spinal cord motor neurons and reduced 
neuromuscular junction synapse formation. These changes are 
considered to contribute to the development of sarcopenia via reduced 
action potential generation leading to reduced force of muscle contraction 
and changes to stimulation of neurotropic factors, including nerve growth 
factor (NGF) and insulin-like growth factor-1 (IGF-1). 
 
Recent evidence indicates that impaired neuromuscular activation may be 
more pronounced in older people who are mobility limited compared to 
those who are not limited (149).  Changes to the nervous system, 
including loss of cortical projections to spinal motor neurons, reduced 
inhibition between cerebral hemispheres and reduced corticospinal 
pathway excitability may underlie this impaired neuromuscular activity 
(167-169). 
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1.17 Nutrition and frailty 
Weight loss is considered to be one of the core components of frailty and 
has been associated with adverse outcomes including increased risk of 
infection, admission to long-term care and mortality (3, 170-172).  
However, the multiple potential confounding variables that require 
consideration in observational studies of nutrition and frailty mean that 
there is ongoing uncertainty regarding whether nutrition is a true 
independent risk factor for adverse outcomes.  
 
A complex interaction between inflammatory mediators and the 
hypothalamus, along with changes in leptin and neuropeptide Y are likely 
to be important factors in the pathophysiology of weight loss in older age 
(173, 174). 
 
1.17.1 Inflammation and nutrition 
Inflammation is associated with anorexia and catabolism of skeletal 
muscle and adipose tissue (173). This can be detected clinically as 
weight loss, and may be of particular functional importance in the 
presence of pre-existing sarcopenia. Inflammatory cytokines including IL-
1, IL-6 and TNF are considered to be key pathophysiological mediators of 
anorexia and tissue catabolism in acute and chronic inflammation (173, 
175). 
 
 102 
Inflammation associated anorexia is a fundamentally protective 
mechanism to divert resources away from food seeking behaviour and 
digestion so that energy can be directed towards generating a vigorous 
immune response. The brainstem, hippocampus, amygdala and 
hypothalamus are key components of a complex neuronal network that 
regulates the feeding response. Although peripheral sensory nerves and 
inflammatory cytokines provide direct and indirect input into these brain 
areas, and are considered to be important moderators of the feeding 
response, the precise neuronal mechanism for induction of inflammation 
associated anorexia is currently unknown (176). 
 
1.17.2 Leptin and frailty 
Leptin is a circulating peptide hormone with a number of important roles 
including regulation of energy homeostasis and metabolism (177). It is 
manufactured by adipose tissue and, under certain conditions, skeletal 
muscle and gastric parietal cells (178). Leptin signals the nutritional 
status of the body to the brain through stimulation of receptors located in 
the hypothalamus and limbic system. Hypothalamic stimulation 
moderates the production of a series of neuropeptides that regulate 
appetite, including neuropeptide Y, resulting in reduced food intake.  
Stimulation of the limbic system moderates motivation and reward 
pathways associated with feeding (177). 
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A 2008 cross-sectional study involving 140 participants investigated the 
association between inflammation, leptin and frailty (174). The frailest 
participants displayed features of cachexia, with significantly lower BMI 
when compared to those who were less frail. Leptin levels were 
correspondingly lower in the most frail and inflammatory markers were 
significantly increased. Pressure ulcers were more common in those who 
were most frail. Although participant numbers were relatively small, this 
study provides support for a biological mechanism of weight loss in frailty.   
The combination of a frail brain, frail immune system and frail endocrine 
system may lead to weight loss and cachexia through an inability to 
regulate an overactive inflammatory response in association with 
impaired hypothalamic endocrine control. 
 
1.17.3 Nutritional intervention in frailty 
There is a paucity of high quality randomised controlled trials (RCTs) 
investigating nutritional intervention in frailty. One RCT that investigated 
the effects of exercise and nutritional supplementation in 100 frail older 
people living in long-term care reported that nutritional supplementation 
had no effect on muscle strength, gait velocity, stair climbing activity or 
physical activity (179). A 2003 Cochrane review of nutritional 
interventions for preventing and treating pressure ulcers in older hospital 
patients, an at risk group who are more likely to be frail, reported that it 
was not possible to draw any firm conclusions due to a general absence 
of trials of high methodological quality (180). Furthermore, calorific 
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restriction has been observed to extend lifespan in a number of 
organisms and appears to reduce organ injury following inflammation in 
animal models (181). It is possible that the weight loss and cachexia that 
are observed in frailty result from a hyperactive, inadequately regulated 
inflammatory response and interventions to target these adverse 
biological mechanisms may have potential to improve the adverse 
nutritional profile of frailty. 
 
1.18 Social vulnerability and frailty 
Multiple social vulnerability factors including neigbourhood deprivation, 
social isolation and poor socioeconomic status have been associated with 
important adverse health outcomes including depression, cognitive 
impairment, admission to long-term care and death (182-184). More 
recently, evidence to support an association between social vulnerability 
and frailty has been reported in two large observational studies (5, 185). 
 
In order to operationalise social vulnerability according to a deficit 
accumulation approach, investigators from the Canadian Study of Health 
and Ageing (CSHA) analysed data from 10,263 study participants aged 
65 and over. The social vulnerability index included items such as 
communication, social support, social engagement and socioeconomic 
status. Social vulnerability increased with age and was greater in women. 
A moderate correlation between frailty and social vulnerability was 
reported. Both frailty, identified using the FI, and social vulnerability 
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independently contributed to increased risk of mortality suggesting that, 
although related, frailty and social vulnerability are likely to be distinct (5). 
 
A 2009 cross-sectional analysis of data from 4818 participants in the 
English Longitudinal Study of Ageing (ELSA) identified an independent 
association between individual socioeconomic status, neighbourhood 
deprivation and frailty. In a multivariate analysis adjusted for important 
potential confounding variables, lower individual wealth and greater 
neighbourhood deprivation were independently associated with frailty, 
identified using the FI (185). 
 
1.18.1 Potential biological effects of social 
vulnerability 
The relationship between frailty and social vulnerability is complex, but 
there is evidence to support a potential association between psychosocial 
stress and accelerated cell ageing through molecular, epigenetic and 
neuroendocrine mechanisms (186). Environmental stressors trigger a 
series of neurological and endocrine responses designed to preserve 
homeostasis (187). The most common responses involve activation of the 
autonomic nervous system and HPA axis, and the frail brain and 
endocrine system may be increasingly vulnerable to an overactive, 
sustained GC response following environmental stress (188). Although no 
causative relationship can be inferred, a 2008 analysis of cross-sectional 
data from a cohort of 8,643 older people in the UK reported a 
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socioeconomic gradient in IGF-1 levels and markers of inflammation in 
older people (186). 
 
Recent studies have demonstrated an association between chronic 
psychosocial stress, levels of cellular oxidative stress and shorter 
telomere length (189, 190). The activation of autonomic and 
neuroendocrine systems, with an associated glucocorticoid driven 
increase in ROS, may accelerate telomere damage, p53 activation and 
cell senescence (22, 190). 
 
1.18.2 Epigenetic factors 
It has been hypothesised that epigenetic programming early in life may 
influence the late-life stress response (61). There is preliminary evidence 
that social adversity in early life is associated with increased levels of 
DNA methylation in hippocampal neurons (61). There is ongoing 
uncertainty regarding the persistence and importance of early epigenetic 
changes throughout life, the reversibility of these changes and the role of 
late-life epigenetic mechanisms that result from social adversity in older 
age. Investigation of the relationship between epigenetic mechanisms, 
social vulnerability and frailty will potentially provide insight into how 
social adversity and biological health are intrinsically related. Greater 
insight into these mechanisms will further understanding and inform the 
future development of interventions to improve the adverse health 
outcomes of social vulnerability in frail older people. 
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1.19 Consequences of frailty 
Bernard Isaacs contended that, if you look closely enough, all common 
problems in older age can be traced back to one or more of the four 
'geriatric giants', namely intellectual impairment, instability, immobility and 
incontinence (191).  Frailty, and markers of frailty, have been 
independently associated with all four of these giants (3, 94, 95, 192). 
Frailty is also independently associated with increased risk of 
hospitalisation, admission to long-term care and death (3, 11).  
Understanding the biological causative mechanisms of frailty provides 
deeper insight into these adverse consequences.   
 
Characterised by vulnerable hippocampal neurons and primed microglia, 
a frail brain that is unable to maintain homeostatic control of an 
inappropriate inflammatory response originating from a frail immune 
system may be at risk of rapid intellectual impairment in the form of 
delirium. Accelerated neuronal damage may subsequently increase the 
risk of further cognitive decline and dementia. The combination of a frail 
brain and frail muscles may result in a cumulative impairment of 
coordination and strength, jeopardising successful completion of the 
complex task of walking, resulting in instability and falls. Frail skeletal 
muscle, with reduced regenerative capacity, is at risk of a temporary or 
permanent loss of strength leading to immobility and disability, particularly 
following the persistent catabolic endocrine state that characterises the 
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frail inflammatory reflex. Impaired neuronal control and reduced ability to 
walk to the toilet resulting from the combination of a frail brain and frail 
muscles may cause or exacerbate incontinence.   
 
Delirium and falls are common precipitants for hospital admission.  
Behavioural problems associated with dementia and the onset of 
incontinence are common reasons for admission to long-term care. A 
deeper understanding of the biological mechanisms of frailty provides 
clearer insight into the contribution of frailty to the common problems and 
adverse health outcomes that are frequently observed in older age. 
 
1.20 Frailty, disability and comorbidity 
The relationship between frailty, disability and comorbidity (defined as the 
presence of two or more chronic diseases) is complex. There is emerging 
agreement that, whilst frailty, disability and comorbidity are closely related 
and exhibit significant overlap (193), they are not synonymous. Therefore, 
as frailty develops with multisystem physiological decline, it is possible 
that an individual may be phenotypically and measurably frail in the 
absence of comorbidity. However, the effects of a single disease that is 
severe, the presence of subclinical disease or the presence of 
undiagnosed disease adds further complexity. 
 
Disability in older age can be measured using standardised instruments 
that assess activities of daily living (ADL), for example the Barthel Index 
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(194). Disability in older age can develop progressively (e.g. as a result of 
frailty) or catastrophically (e.g. as a result of stroke or hip fracture).  
Results from a cohort of 6640 older people suggest that approximately 
50% of disability in older age develops progressively and 50% develops 
catastrophically (195). The contribution of physiological frailty to the 
development of disability in older age is likely to be considerable. 
 
1.21 Frailty, disability and future population 
projections 
1.21.1 The ageing population 
A gain in life expectancy (LE) of approximately 30 years was recorded 
over the course of the 20th century and a linear increase in LE looks set 
to continue throughout the 21st century (196). LE is an estimate of mean 
expected life span (197). Period life expectancy (PLE) provides an 
estimate of the mean LE at a given age (see table 1.2). Although 
important measures, LE and PLE provide no estimate of the proportion of 
life an individual can expect to remain in good health and free of disability. 
 
Health expectancies measure both quality and quantity of life and divide 
LE into years of good health and years of ill health. Disability free life 
expectancy (DFLE) is one measure of health expectancy that provides an 
estimate of the number of years of life an individual can expect to be free 
of either a limiting long-term condition or disability (198). 
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 Period Life Expectancy (Years) 
Age (Years) Male Female 
70 13.4 15.8 
75 10.2 12.2 
80 7.6 9.0 
85 5.5 6.5 
90 3.9 4.4 
95 2.8 3.1 
100 2.1 2.1 
Table 1.2.  2005-2007 UK period life expectancy. 
Source: National Statistics Website: www.statistics.gov.uk.  Crown 
copyright material is reproduced with the permission of the 
Controller Office of Public Sector Information (OPSI) 
 
1.21.2 Ageing and disability 
The Measuring Health and Disability in Europe (MHADIE) consortium 
propose a definition of disability based on the World Health 
Organisation's (WHO) International Classification of functioning, disability 
and health (ICF).  The MHADIE definition describes disability as "...a 
difficulty in functioning at the body, person, or societal levels, in one or 
more life domains, as experienced by an individual with a health condition 
in interaction with contextual factors" (199). 
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Older people can expect to remain independent and free of disability for 
the majority of the duration of their life expectancy (200, 201). Between 
the ages of 70-79, 73% of older people are estimated to be free from any 
disability and 93% are estimated to be independent for ADLs (201).  
Above the age of 80 the corresponding figures are 63% and 81%. Males 
aged over 80 can expect to remain in a disability free health state for 72% 
of their remaining life expectancy, with a corresponding figure for females 
of 64% (201). 
 
1.21.3 Future projections 
The above data suggest that the latter stages of life are likely to be 
associated with a period of disability. For accurate health and 
socioeconomic planning, it is of critical importance to determine whether 
gains in LE will be associated with improvements in HLE and DFLE. As 
frailty has a negative impact on health and well-being and is an 
independent risk factor for disability, prediction of the future prevalence of 
frailty is important. The development of interventions that improve the 
adverse health outcomes of frailty would have potential to improve HLE 
and DFLE. Although currently uncertain, it is plausible that any future 
changes in disability prevalence will be preceded by similar changes in 
frailty prevalence. 
 
Three potential scenarios are projected for the future of HLE (202). 
1. Compression of morbidity 
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 LE and HLE gains are mirrored and the period of healthy life 
 prior to death is increased. Health and social care costs 
 (primarily in the form of long-term care) will potentially be 
 reduced, although pension costs will continue to increase. 
2. Expansion of morbidity 
 Increase in overall LE is not mirrored in HLE gains. The 
 period of ill health prior to death is extended. Substantial 
 increases in health and social care expenditure are to be 
 anticipated. 
3. Dynamic equilibrium 
 Modifications to disease progression resulting in a lower 
 burden of severe levels of disability create a consequent 
 reduction in severe disability and overall equilibrium in 
 health and social care costs. 
 
Current UK projections suggest that the increase in overall LE may not be 
mirrored by an increase in HLE. Between 1981 and 2004, LE increased 
at a faster rate than HLE (see figure 1.14). However, there is scope for 
optimism; between 2001 and 2004 there was a decrease in the time 
spent with a limiting illness or disability in both men and women in the 
UK. A decrease of 1 year was noted in men; a decrease of 0.5 years in 
women (203). 
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Figure 1.14.  Life expectancy, healthy life expectancy and disability 
free life-expectancy, UK, 1981-2004. 
Source: National Statistics Website: www.statistics.gov.uk.  Crown 
copyright material is reproduced with the permission of the 
Controller Office of Public Sector Information (OPSI) 
 
It is reassuring to note that there is also increasing international evidence 
to suggest that prevalence rates of disability in older age in Western 
populations are falling (196), with the caveat that this apparent fall may 
be due in part to an increase in the prevalence denominator. Data from 
the European Union (EU) for the period 1995-2003 show a degree of 
variation in trends in LE and DFLE across EU member states (figure 
1.15) (204). 
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Figure 1.15 - Estimated life expectancy and disability-free life 
expectancy by gender, in 14 EU member states, 1995-2003. 
Reproduced with permission from (204). 
 
Encouragingly, the majority of older people in the UK continue to live in 
their own home. Data from the 2001 Census of England and Wales reveal 
that 95.5 per cent of people aged 65 years and over, and 79.6 per cent of 
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people aged 85 years and over, reside in their own home (205). 
 
Nonetheless, it remains clear that an ageing population presents 
significant health and social care implications. Private expenditure by 
older people on social care in the UK is projected to rise from £5.9 billion 
in 2006 to £13.4 billion in 2026 and a parallel shortfall in public funding of 
social care for older people is projected over this time period (206). 
Health and social care interventions that halt the development and 
progression of frailty, and hence prevent disability in older age, would 
have the potential to improve the general health and well-being of the 
population. Successful interventions would also provide a clear and 
powerful opportunity to impact positively on future health and social care 
expenditure. 
 
1.22 Future research directions 
Future translational research to investigate molecular, cellular, tissue and 
organ frailty will help determine the underlying biological causative 
mechanisms and, ultimately, aid the unification of diagnosis and 
treatment.  Efforts to unify diagnosis and treatment of frailty should be 
complemented by a steady evolution of frailty taxonomy models. 
 
Research into epigenetic mechanisms associated with frailty and social 
vulnerability in early and later life will identify potential targets for future 
medical and social intervention.  Future applied health and social science 
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research will facilitate the development of complex interventions to halt 
the development and progression of frailty, and improve the general 
health and well-being of frail older people. 
 
1.23 Summary 
Frailty can be considered to be the result of a complex interaction 
between genetic, environmental and epigenetic factors. Multiple systems 
of frailty taxonomy exist but each demonstrates variable utility in 
prediction of natural history, response to therapeutic intervention and 
consideration of underlying biological causality mechanisms. 
 
Cumulative ROS mediated nuclear and mitochondrial DNA damage, 
defective DNA repair mechanisms, telomere shortening and abnormal 
protein turnover promote cell senescence. These molecular mechanisms 
are of variable importance in mitotic and post-mitotic cells but the overall 
effect of cumulative cell senescence is impaired organ physiology.  
Impairments in brain, endocrine, immune and muscle physiology are 
considered to be of particular importance in frailty. The complex 
interaction between the frail brain, frail endocrine system, frail immune 
system and frail muscles results in a potential vulnerability to adverse 
outcomes through an inability to maintain homeostasis following physical 
stress, commonly in the form of an overzealous inflammatory response 
resulting from infection and physical injury. This prolonged inflammatory 
response initiates a persistent catabolic state that, although 
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fundamentally protective in origin, becomes pathological in nature, 
leading to loss of muscle mass and strength, with attendant decline in 
functional ability. 
 
Influenced by social vulnerability factors, these adverse outcomes include 
the 'geriatric giants' of intellectual impairment, instability, immobility and 
incontinence, along with the associated risks of hospitalisation, admission 
to long-term care and death. All these adverse outcomes of frailty affect 
health and wellbeing, and have substantial health and socioeconomic 
costs. Successful health and social care interventions to halt the 
development and progression of frailty would have the potential to 
improve health and well-being in older age, and have substantial health 
and socioeconomic impact. 
 
Future basic science and translational research will provide greater 
insight into the underlying causative biological mechanisms of frailty, and 
identify potential therapeutic targets. Greater understanding of causation 
will facilitate the unification of diagnosis and treatment. Future applied 
health and social science research will drive the development of health 
and social care interventions to halt the development and progression of 
frailty. 
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2  Chapter 2.  Do home-based exercise 
interventions improve outcomes for frail 
older people? 
 
2.1 Introduction 
Any attenuation of the prevalence or severity of frailty is likely to have 
large benefits for the individual, their families and for society. There is 
accumulating evidence from basic science and applied health research 
that exercise has the potential to influence the biological mechanisms of 
frailty and improve associated adverse outcomes through effects on the 
brain, endocrine system, immune system and skeletal muscle. The role of 
exercise in the prevention and treatment of frailty will be considered in 
greater detail and a systematic review to identify whether home-based 
exercise interventions improve outcomes for frail older people is 
presented. 
 
2.2 Exercise to prevent and treat frailty 
2.2.1 Regulation of DNA damage 
Basic science research has begun to identify potential mechanisms of 
molecular protection through exercise. A 2010 study demonstrated that 
exercise increases levels of silent information regulators (SIRTs) in 
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skeletal muscle of ageing rats (207). SIRTs are NAD-dependent protein 
deacetylases that have been demonstrated to influence DNA damage-
repair mechanisms, gene expression and muscle differentiation. An 
increase in SIRT levels through exercise has the potential to reduce the 
deleterious effects of biological ageing by moderating the accumulation of 
DNA damage (207). 
 
2.2.2 Increased neuroprotection 
Exercise has also been shown to increase the levels of several other 
neurotrophic and vascular growth factors, including brain-derived 
neurotrophic factor (BDNF) and vascular endothelial growth factor 
(VEGF) (208). Increased neuroprotection through exercise may have the 
potential to improve the adverse cognitive outcomes that have been 
associated with frailty. 
 
2.2.3 Increased muscle mass and strength 
There is accumulating evidence to indicate that muscle growth is 
increased through physical activity (PA) in older age, principally through 
hormonal factors (209). IGF-1 is generated locally in response to physical 
activity in animal studies, and is believed to have an important role in the 
development of increased muscle strength and mass through exercise 
(101, 210). Interestingly, the muscles of frail, nonactive older people 
appear to retain the capability to respond to IGF-1, suggesting that the 
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mechanisms triggering muscle growth are likely to remain active during 
frailty (211). This provides important biological evidence for the potential 
effects of exercise to improve muscle mass and strength in frail older 
people. 
 
2.2.4 Reduced inflammation 
Recent research has begun to identify potential mechanisms of reduced 
inflammation through exercise. Regular, moderate exercise increases the 
release of a number of hormones that exert influence over the immune 
system, including adrenaline, cortisol and growth hormone (212).  
Exercise also appears to reduce immune cell expression of Toll-like 
receptors (TLRs) (213). TLRs are immune cell surface receptors that play 
an important role in the production of inflammatory cytokines. A long-term 
reduction in TLR expression may reduce chronic inflammation through a 
decrease in the inflammatory capacity of leukocytes. A reduction in 
inflammation through exercise may have particular relevance for the 
inadequately regulated inflammatory response in frailty. 
 
2.2.5 Improved response to psychosocial stress 
Exercise appears to buffer telomere shortening in people who experience 
chronic stress, potentially via upregulation of telomerase activity. A 2010 
prospective cohort study identified an independent association between 
increased exercise and telomere length in 63 older women (214).  
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Furthermore, exercise may improve the adverse response to 
psychosocial stress through effects on the autonomic nervous system 
and neuroendocrine pathways, including glucocorticoid responses to 
stress (215) 
 
2.3 Home-based exercise interventions for frail 
older people 
Sarcopenia, one of the key components of frailty, is a potential target for 
frailty prevention interventions that incorporate exercise to increase 
muscle mass and strength. Physical activity interventions, particularly 
those involving strength and balance training, have been successful at 
improving muscle strength and functional abilities in frail people. Falls 
prevention and pulmonary rehabilitation interventions, which include 
exercise components, have previously been demonstrated to be effective 
at improving important outcomes and are part of routine care (216, 217). 
A proportion of older people who receive these interventions are likely to 
be frail, but improved outcomes related specifically to frailty are unclear. 
 
A 2010 systematic review concluded that exercise interventions, 
particularly those involving strength and balance training, can be 
successful at improving muscle strength and functional abilities in long-
term care residents; a group of older people who are very likely to be frail 
(218). However, the large majority of older people in the UK live at home 
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(205). Exercise interventions for older people living at home can be 
delivered either individually in their homes, or elsewhere as a group 
activity. A 2005 Cochrane review concluded that both home-based and 
group-based exercise interventions are associated with improved 
outcomes for patients receiving cardiac rehabilitation, but that home-
based interventions may be associated with improved adherence (219). 
Furthermore, the 2006 UK Department of Health (DH) white paper ʻOur 
health, our care, our say: a new direction for community servicesʼ argued 
for a different, more community-based approach to people with long term 
conditions with the provision of more and better quality services 
summarized as “care closer to home” (220).   
 
A successful home-based exercise intervention for frail older people 
would have the potential to improve the health and well-being in this 
vulnerable group at high risk of important adverse health outcomes that 
have substantial health and socioeconomic costs. To explore the 
available evidence for frail older people, a systematic review was 
undertaken on the effectiveness of home-based exercise interventions. 
 
2.4 Methods 
2.4.1 Search strategy 
A systematic search was undertaken to identify all randomised controlled 
trials (RCTs) and cluster RCTs that evaluated home-based exercise 
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interventions for frail older people. A search strategy was developed for 
Medline, with appropriate amendments for AMED, CINAHL, Cochrane 
Library, EMBASE, PsychINFO and PedRO, with literature searching to 
February 2010.  A full copy of the search strategy is available in Appendix 
1.   
 
2.4.2 Eligibility criteria 
The initial search criteria were deliberately broad and all studies that 
recruited a cohort of older people (defined for this review as a mean age 
of 70 years or older in the study cohort) were initially considered for 
inclusion. The individual study description, selection criteria and reported 
cohort baseline characteristics were then carefully examined by two 
independent assessors with expertise in both the assessment of frail 
older people and frailty indices to determine whether the study 
populations were frail. Studies were considered as frail only if they 
selected participants or stratified results using an operationalised 
definition of frailty or if one or more of the five frailty criteria (weight loss, 
exhaustion, low energy expenditure, slow gait speed or muscle 
weakness) were identified. 
 
Studies in which the target population were selected on the basis of the 
presence of a specific medical condition (e.g. chronic obstructive 
pulmonary disease, heart failure, cognitive impairment, etc), and studies 
conducted in care home facilities, were excluded. 
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2.4.3 Types of outcomes 
The primary outcomes for this review were measures of mobility (e.g. the 
Timed Up and Go Test (221)), health-related quality of life indices (e.g. 
EuroQol Group 5-Dimension Self-Report Questionnaire (EQ5D) (222)) 
and measures of activities of daily living (ADL, e.g. Barthel index (194)). 
Secondary outcomes measures were muscle strength, balance, 
depression, bone strength and adverse outcomes including falls and 
admission to hospital or long-term care. 
 
2.4.4 Types of interventions 
For this review, exercise is defined as an activity requiring physical effort 
that is intended to improve or maintain fitness. Studies in which the 
intervention included a mix of home-based and group based exercise 
were only included if the home-based component formed the greater 
proportion of the intervention. Entirely group-based exercise interventions 
were not considered for this review.   
 
The evidence base for falls prevention interventions is already well 
established and a recent systematic review concluded that the Otago 
Exercise Programme (OEP), a home-based falls prevention intervention, 
was effective at reducing falls and mortality (216, 223). However, the 
evidence base from the falls prevention literature is not necessarily 
 125 
generalisable to frail older people. Falls prevention interventions are 
usually targeted at older people who are living independently or with few 
restrictions in ADL. Strengthening exercises in falls prevention 
interventions are often of moderate-to-high intensity and are usually 
performed standing with weights or thera-bands to provide resistance.  
Balance exercises incorporate dynamic movement and may be of greater 
risk for frail older people. Additionally the majority of falls prevention 
interventions include a substantial aerobic component that usually 
comprises moderate intensity walking/cycling/aerobics for 20-30 minutes, 
2-3 days a week. Furthermore, the duration of falls prevention exercise 
sessions are frequently for between 30 minutes and 90 minutes and this 
is not necessarily appropriate for frail older people considering the low 
energy expenditure and fatiguability that characterize frailty. For these 
reasons, trials in which the intervention had been delivered as the main 
component of a falls prevention package were also excluded from this 
systematic review.   
 
2.4.5 Study selection 
All titles and abstracts were screened for eligibility by two independent 
reviewers and any disagreements settled by a third reviewer. Full texts of 
eligible studies were obtained and reference lists were reviewed for 
further eligible studies. Two reviewers extracted data using Revman 5.0 
software. One reviewer evaluated each study for risk of methodological 
bias as outlined in the Cochrane Handbook for Systematic Reviews of 
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Interventions (224). Studies were assessed for allocation sequence 
generation, allocation concealment, blinding, completeness of outcome 
data, selective outcome reporting and other potential sources of bias. For 
each of these domains a judgement of adequate, partially adequate or 
inadequate was recorded to determine the risk of methodological bias for 
individual studies. The assessment of bias risk was to inform a sensitivity 
analysis whereby greatest emphasis was given to the studies that were at 
lowest risk of methodological bias. Only studies considered to be at low 
risk of methodological bias would be considered for meta-analysis. If data 
available precluded meta-analysis then a narrative synthesis was 
planned. 
 
2.5 Results 
The review process is summarized in figure 2.1 using the PRISMA 
guidelines (225).   
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Figure 2.1.  PRISMA flow diagram. 
 
2.5.1 Study characteristics 
Six RCTs involving 987 participants met the review inclusion criteria (226-
231) and are summarised in table 2.1 
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Table 2.1. Summary table of study characteristics, intervention 
details, main findings and risk of methodological bias. 
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Key: SD, Standard Deviation; ADL, Activities of Daily Living; NA, not 
available 
 
The median age was 83 years (range 78 - 88) and the majority of 
participants were female (median 79% female, range 50 - 88%). Three 
trials were conducted in Western Europe (228, 229, 231), two in the USA 
(226, 227) and one in New Zealand (230). A median of 71% (range 8 - 
88%) of older people living at home were eligible for trial inclusion and, of 
those who were eligible, a median of 75% (range 17 - 87%) were 
recruited. The wide range of values reflects the use of different eligibility 
criteria and different methods of recruitment in the studies. 
 
Two trials used an operationalised, non-validated frailty model to select 
and stratify participants (226, 227). Four trials did not use an 
operationalised frailty model to select participants but reported inclusion 
criteria or baseline characteristics that identified slow walking speed (228, 
229, 231) or physical exhaustion (230) and were therefore considered by 
consensus to be frail. 
 
All trials assessed participants at the end of the intervention. Median 
duration of follow-up was six months (range six weeks - 18 months). Two 
studies included follow-up of 12 months or more (227, 228). 
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2.5.1.1 Methodological quality & study power 
Four trials were assessed as low risk of methodological bias (227-230), 
one at moderate risk (231) and one at high risk of bias (226). Although 
the majority of trials were single (assessor) blind, one was unblinded 
(231). Methods of randomisation were generally well described but an 
adequate description of the method of allocation concealment was 
provided in only two studies (229, 230). Only three trials performed an a 
priori power calculation (228-230). Three of the trails recruited less than 
100 subjects; only two recruited more than 200 subjects. 
 
2.5.1.2 Exercise interventions, completion & adherence 
One intervention included a single component of progressive resistance 
exercise (226). Two combined progressive resistance exercises with one 
or more additional components of balance, walking or range of motion 
exercises (229, 231). Two interventions were complex interventions 
combining multiple exercise components with an occupational 
intervention (227, 228). One study used an electronic device that counted 
the number of sit-to-stands (GrandStandTM system) (230). 
 
Modal treatment frequency was three times per week (range 3 - 21 
sessions per week). Modal treatment duration was 6 months (mean 28 
weeks, range 6 weeks - 18 months). 
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Information regarding the percentage of participants who completed the 
exercise intervention through to follow-up was available in all six studies.  
Completion rates were generally high (median 83%, range 65 - 88%); 
interventions of shorter duration generally recorded higher completion 
rates. Rates of adherence to the exercise intervention, measured as the 
number of individual exercise sessions undertaken as a proportion of the 
total possible, were recorded in three studies (227, 230, 231). Various 
methods were used to define acceptable adherence and rates were 
generally high (median 78%, range 66 - 89%). 
 
2.5.2 Analysis of primary outcome data 
Meta-analysis of primary outcome data from the studies at low risk of 
methodological bias was precluded by the absence of consistent 
reporting of data required for calculation and pooling of standardised 
mean differences (SMDs) for these continuous outcomes. Therefore, a 
narrative synthesis of the available evidence from all studies is provided 
that describes the direction and size of effect, its consistency across 
studies and the overall strength of the evidence. A narrative description of 
the evidence from the studies at low risk of methodological bias is also 
provided. 
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2.5.3 Analysis of secondary outcome data 
Meta-analysis of long-term care admission data was possible, using 
dichotomous data from two trials at low risk of methodological bias (227, 
228). These data were pooled for meta-analysis using random effects 
modeling (Revman 5.0 software) and are presented as risk ratios in a 
forest plot (figure 2.2). It was not possible to pool continuous outcome 
data for the other secondary outcomes due to the data limitations 
described above and a narrative synthesis is presented. 
 
2.5.4 Primary outcomes 
2.5.4.1 Effects on mobility 
Four trials reported an outcome measure relating to mobility, using 
various measures of gait speed (228-231). Improved gait speed was 
reported in one trial (228), a trend towards improved gait speed was 
reported in one further trial (229) and gait speed did not improve in two 
(230, 231). 
 
2.5.4.2 Effects of health-related quality of life 
One trial reported an improvement in quality of life, measured using the 
EQ5D (231). The other trials did not record quality of life measurements. 
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2.5.4.3 Effects on activities of daily living 
Measures of Activities of Daily Living (ADL) were reported in four trials 
(227-230). Improvements in ADL were reported in one trial (227), no 
improvements in ADL were reported in the other three trials (228-230).   
 
2.5.5 Secondary outcomes 
The meta-analysis of long-term care admission data is presented in figure 
2.2. A non-significant trend towards reduced long-term care admission is 
observed (pooled risk ratio 0.89, 95% confidence interval 0.55-1.45). 
 
 
Figure 2.2.  Forest plot presenting individual and pooled risk of 
long-term care admission from two trials at low risk of 
methodological bias. 
 
Three trials measured muscle strength using upper and lower body 
strength (226, 231) or grip strength (229). One trial reported improved 
lower body strength (226). There was no improvement in either upper or 
lower body strength in one trial (231). No improvement in grip strength 
was recorded in the one trial that measured this outcome (229). No 
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improvement in general physical performance was reported in one trial 
(231). 
 
Improved balance was reported in one trial (228) but there was no effect 
on balance in three trials (229-231). There was no effect on depression 
(228), bone density or flexibility (229). Hospitalisation rates were not 
reported in any trials. 
 
2.5.6 Adverse outcomes 
Between group differences in adverse outcomes were reported in only 
two trials (227, 228). Increased angina diagnoses were recorded in one 
trial (227) but no differences in fractures, musculoskeletal pain or death 
were reported (227, 228).  
 
2.5.7 Trials at low risk of methodological bias 
There were four high quality trials at low risk of methodological bias (227-
230). One trial selected and stratified participants using an 
operationalised, but non-validated, measure of frailty (227). Participants 
were considered for inclusion and defined as being frail if they took >10 
seconds to walk three metres, or if they were unable to stand from seated 
with both arms folded. Participants with one of the two criteria were 
defined as moderately frail; participants with both criteria were defined as 
severely frail. This relatively large trial (n=188) investigated the effects of 
a six month complex individualised exercise and occupational 
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intervention and reported an improvement in disability score at seven 
months for people with moderate frailty (227). This improvement was 
maintained at 12 months follow-up. There was no effect for people with 
severe frailty.   
 
Although the other three trials at low risk of methodological bias recruited 
frail older people they did not use an operationalised measure of frailty to 
stratify results. One large trial (n=486) that investigated a complex 
individualized exercise intervention reported improved mobility and 
balance but no effect on ADL (228). One smaller trial (n=86) of a six 
month intervention in a cohort living in sheltered housing reported a trend 
towards improved mobility but no effect on ADL, grip strength or balance 
(229). One small trial (n=66) of a six week intervention reported no effects 
on mobility, ADL, grip strength or balance (230). 
 
None of the four high quality trials reported overall effects on the quality of 
life of participants. 
 
2.6 Discussion 
This systematic review summarizes the evidence from research trials that 
recruited 987 participants. Strengths of the review include a robust search 
strategy and rigorous review procedures that included a detailed 
assessment of risk of methodological bias using well recognised 
methods. A potential weakness of the review is that, although a 
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consensus decision was reached regarding whether individual trials 
included frail older people on the basis of the frailty phenotype, only one 
high quality trial both selected participants and stratified results using an 
operationalized measure of frailty. 
 
Included trials were generally of high methodological quality. However, 
individual sample sizes were frequently small and a priori power 
calculations were not routinely completed, giving rise to the possibility of 
Type II statistical error due to small sample size. Limitations of data 
analysis and reporting precluded meta-analysis of primary outcome data, 
which could otherwise have pooled statistical power. Guidelines for 
developing RCTs aimed at preventing functional decline and disability in 
frail older people are available (232) and reference to these guidelines will 
help in the development of future RCTs. Standardisation of outcome 
measures and reporting will further aid the future synthesis of evidence 
for meta-analysis. 
 
One high quality trial used an operationalised, non-validated measure of 
frailty to both select and stratify participants. This trial reported an 
improved disability score in people with moderate frailty and this was 
maintained at 12 months. No improvement was reported for people with 
severe frailty. Other higher quality trials reported inconsistent effects on 
mobility and disability. None of the four high quality trials reported effects 
on quality of life. 
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Meta-analysis of data from two trials at low risk of methodological bias 
demonstrated a non-significant trend towards reduced long-term care 
admission. The relatively low rates of long-term care admission in these 
two trials and wide confidence intervals identify a requirement for future 
long-term trials that are adequately powered to detect a significant 
difference in this important outcome. 
 
Generally high rates of completion and exercise adherence suggest that 
home-based exercise interventions are acceptable and feasible for frail 
older people. This supports the similar finding from the earlier systematic 
review of exercise interventions for older people living in care homes 
which also identified high rates of intervention completion and adherence 
(218). 
 
2.7 Conclusion 
There is preliminary evidence from one high quality trial that selected and 
stratified participants using an operationalised measure of frailty to 
suggest that home-based exercise interventions may be effective at 
improving disability in community-dwelling older people with moderate, 
but not severe, frailty. Operationalised measures of frailty were not used 
to stratify participants in the other high quality trials and inconsistent 
effects of exercise interventions on outcomes including mobility and 
disability were reported. There is significant uncertainty regarding the 
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effects of home-based exercise interventions on important outcomes 
including quality of life and long-term care admission for the frail elderly. 
 
Home-based exercises are a potentially simple, safe and widely 
applicable intervention to prevent dependency decline for frail older 
people. Adequately powered RCTs that use validated measures to select 
and stratify frail older people, and that incorporate long-term follow-up of 
important outcome measures including mobility, disability, quality of life 
and long-term care admission, will help address the uncertainties that 
have been identified in this review. 
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3 Chapter 3.  Development of the Home-
Based Older People's Exercise (HOPE) 
programme 
 
3.1 Introduction 
A home-based exercise intervention for frail older people is an example of 
a complex health intervention. The Medical Research Council (MRC) 
framework for the development and evaluation of complex health 
interventions identifies the key elements of the design and evaluation 
process (233). The MRC framework has therefore been adopted to 
develop and evaluate the Home-Based Older People's Exercise (HOPE) 
programme, an exercise programme to improve the mobility and daily 
living activities of frail older people living at home. This chapter describes 
the development of the HOPE programme with reference to the MRC 
framework.  
 
3.2 Development of the HOPE programme 
The HOPE programme has been developed by synthesising information 
from four key domains: a systematic literature review to identify the 
evidence base for home-based exercise interventions for frail older 
people (Chapter 2); a process of intervention modelling work 
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incorporating a series of multiperspective focus group meetings, an 
information provision needs assessment exercise and a Delphi 
consensus approach; a review of the relevant behaviour change literature 
and a review of international consensus guidelines on the development of 
exercise interventions for older people. This process is illustrated 
schematically in figure 3.1 and an initial brief description of the four key 
domains is provided in 3.2.1 - 3.2.4. 
 
Following the initial brief description, this chapter (Chapter 3) focuses on 
the intervention modelling work, consensus process and behaviour 
change literature and is presented in four sections. Section 1 (3.3 - 3.9) 
discusses the series of multiperspective focus group meetings; section 2 
(3.10 - 3.14) presents the information provision needs assessment 
exercise; section 3 (3.15 - 3.19) presents the Delphi consensus process 
and section 4 (3.20 - 3.22) discusses the relevant behaviour change 
literature. The following chapter (Chapter 4) describes how the 
information obtained through the development process was synthesised 
into the HOPE programme and includes a complete description of the 
intervention. 
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Figure 3.1.  Schematic representation of the development of the 
HOPE programme by synthesising information from four key 
domains. 
 
3.2.1 Systematic literature review 
The systematic review of the literature (Chapter 2) was conducted to 
identify RCTs of high methodological quality that investigated home-
based exercise interventions for frail older people. This review was 
complimented by an earlier systematic review of exercise interventions 
for frail older people in long-term care (218). The key components of the 
exercise interventions in the RCTs of high methodological quality were 
used to inform the frequency, intensity and duration of the intervention. 
 
3.2.2 Modelling work and consensus process 
Briefly, a series of multiperspective focus group meetings with frail older 
people and experienced healthcare professionals were conducted to 
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model the HOPE programme. Views were first sought from frail older 
people living at home who had recently received therapy-based 
interventions at Westbourne Green Community Hospital, a residential 
NHS intermediate care site in Bradford. The multiperspective focus group 
meetings with frail older people incorporated an information provision 
needs assessment exercise to inform the design of the HOPE manual. 
Views were also sought from experienced healthcare professionals to 
facilitate the development of the HOPE programme by gaining valuable 
insights.  
 
Following the series of focus group meetings a Delphi consensus process  
(234) was conducted to seek agreement on the key principles to be 
incorporated into the HOPE programme. 
 
3.2.3 Behaviour change literature 
It is recognised that people can contribute to their overall health and well-
being by adopting or avoiding certain health behaviours (235). Choice of 
health behaviour is influenced by multiple factors, including personality, 
cognitive and socioeconomic factors. To facilitate health behaviour 
change, a series of theoretical frameworks have been developed that 
consider these important factors (235). These theoretical frameworks 
were reviewed to incorporate appropriate behaviour change techniques 
into the HOPE programme and are considered in greater detail in 3.20 - 
3.22. 
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3.2.4 International consensus guidelines 
International consensus guidelines on the development of exercise 
interventions for older people from the American College of Sports 
Medicine (ACSM) and the American Heart Association (AHA) were 
reviewed (236). These guidelines recommend that exercise interventions 
for older people should be multi-dimensional and include exercises to 
improve whole body muscle strength, mobility, balance and aerobic 
capacity.
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3.3 Section 1:  Modelling of the HOPE programme 
 
3.4 Background 
The MRC framework for developing and evaluating complex interventions 
has identified that intervention modelling is a critical phase of 
development during which it is advantageous to involve service users in a 
co-design process (233). Focus groups are considered to be a 
particularly useful method of exploring people's knowledge and 
experiences; the group process is considered to help participants explore 
and clarify their views (237). Multiperspective interviews with patients, 
families and professionals can provide insight into individual needs and 
facilitate the integration of suggestions for developing services (238). A 
series of multiperspective focus group meetings with frail older people 
and healthcare professionals were therefore conducted to develop 
greater understanding about the nature and scope of a home-based 
exercise intervention for frail older people. Practical difficulties and time 
constraints precluded involving families in the series of focus group 
meetings. 
 
3.5 Methodology 
Views were sought from frail older people living at home who had recently 
received therapy-based interventions, to learn from their experiences and 
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consider coping strategies to draw on these for motivational purposes.  
Intermediate care facilities provide a range of therapy-based services to 
frail older people to promote recovery from illness, prevent unnecessary 
hospital admission, support discharge and maximise independent living 
(239). Two focus group meetings were therefore chosen to take place at 
Westbourne Green Community Hospital, a residential NHS intermediate 
care site in Bradford where therapy-based rehabilitation typically follows 
an acute illness prior to return home. The meetings were semi-structured 
interviews with a small number (3-5) of older people who were considered 
to be frail by the nursing and therapy staff. The semi-structured interview 
schedules were informed by a series of key questions that are presented 
in figure 3.1. The meetings were audio-recorded and contemporaneous 
field notes were taken. Written, informed consent was taken from all 
participants. Full ethics approval was given by Bradford Research Ethics 
Committee (REC reference 09/H1302/55). 
 
 
Focus Groups 1 & 2 
1)  What factors contribute to daily functional limitations for frail 
older people living at home? 
2)  How is the concept of exercise in old age understood by frail 
older people? 
3)  What are frail older peopleʼs perceived barriers to involvement in 
a targeted exercise programme? 
4)  What would motivate frail older people living at home to 
complete a targeted exercise programme lasting 12 weeks? 
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Figure 3.1.  Key questions that informed the semi-structured 
interview schedules for focus group meetings 1 & 2. 
 
3.5.1 Sampling frame 
As residence in intermediate care is for a relatively short period of time, 
convenience sampling methods were used to select participants for the 
focus group meetings. Although convenience sampling was used, 
purposive sampling methods were also employed to guide individual 
participant selection. This ensured that both sexes were represented in 
the sample and that the sample included frail older people with a range of 
living circumstances in different types of housing. To gain insight into 
perceived barriers to successful exercise participation, frail older people 
who expressed difficulties in engaging with rehabilitation in intermediate 
care were sought alongside those who engaged with greater ease. 
 
Experienced community based healthcare professionals were invited to a 
third focus group meeting at the Bradford Institute for Heath Research.  
The views of community physiotherapists, who have considerable 
experience in providing therapy services to frail older people in the 
community, and community matrons, who are experienced nurses with 
advanced practitioner skills working with frail older people, were also 
sought to facilitate the development of the HOPE programme. The 
meeting schedule for healthcare professionals was informed by key 
questions that are presented in figure 3.2. 
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Figure 3.2.  Key questions that informed the semi-structured 
interview schedules for focus group meeting 3. 
 
The phenotype model of frailty (3), and the associated adverse health 
consequences, were introduced to participants in a short presentation at 
the beginning of the meeting to stimulate initial discussion. The meeting 
was audio-recorded and contemporaneous field notes were taken.  
Written, informed consent was taken from all participants. 
 
3.5.2 Data analysis 
The data analysis was conducted by myself, with expert guidance from 
Mary Godfrey, reader in Health and Social Care, Academic Unit of Elderly 
Care & Rehabilitation, University of Leeds. 
 
Focus group 3 
1) What limitations in the functional ability of frail older people living 
at home are commonly seen by community physiotherapists? 
2) What types of exercises are likely to be effective at improving 
functional abilities of frail older people living at home? 
3) What would motivate/aid frail older people to adhere to a home-
based exercise training programme? 
4) What are potential barriers to exercising in the home for frail older 
people? 
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Interview transcripts and field notes were analysed using grounded theory 
methods (240). Following initial data familiarisation, key emerging issues, 
concepts and themes were identified and coded to aid data interpretation. 
All generated data were analysed alongside new data collection using 
constant comparison methods (241) to allow refinement of research 
questions and identification of new avenues of inquiry throughout the 
research process. Data from the meetings with frail older people and 
healthcare professionals were initially analysed separately and emerging 
themes were compared to identify areas of commonality or disagreement. 
 
3.6 Results 
A total of nine participants took part in the two focus group meetings with 
frail older people. The median age of the nine participants was 87 years 
(range 80 - 97 years). Five participants were female and four were male.  
A range of living circumstances were represented; four participants lived 
alone, three lived with a spouse, one lived with her daughter and one 
lived with a friend. Different home dwellings were identified including 
houses with/without stairlifts and bungalow accommodation. 
 
Seven experienced healthcare professionals (one head of therapy 
services, one physiotherapy clinical coordinator for older people, three 
community physiotherapists and two community matrons) took part in the 
meeting with healthcare professionals. The results from the focus group 
meetings with frail older people and healthcare professionals are 
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presented separately. Two case studies are presented to help illustrate 
the challenges experienced by frail older people living at home. 
 
3.6.1 Frail older people 
3.6.1.1 Wanting to keep on going 
The overarching theme identified from the focus group meetings with frail 
older people was 'wanting to keep on going'. Participants identified a 
range of constraints that prevent frail older people from keeping going, 
including physical and environmental constraints and examples of these 
are presented below. A range of coping strategies and mechanisms to 
overcome these constraints were discussed by participants. It became 
clear that some constraints were more surmountable than others, and the 
social support network of family and friends was identified as a 
particularly important modifying factor. 
 
3.6.1.2 Trying to cope with physical constraints 
Frail older participants identified that muscle weakness, joint 
pain/stiffness and physical fatigue are important physical constraints that 
can make keeping going more difficult. A particular constraint was muscle 
weakness in the important muscle groups that are required to complete 
the basic mobility task of standing from a chair. Illustrative comments 
describing important physical constraints experienced by frail older 
people are provided below. 
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"Thatʼs what it is with me, itʼs legs, itʼs legs with me, thatʼs why I 
had to go to live with my daughter because I couldnʼt manage my 
own house at the finish, it was getting too much for me with having 
my own house. Cleaning the house, washing and that, it got too 
much for me because I couldnʼt move about when my legs were 
really bad, so I had to keep going in hospital and coming out."  
(Participant 2, focus group 1.  90 year old lady living with her 
daughter in a house with stairs) 
 
"Yes, thatʼs what does me, pushing up from a chair." (Participant 2, 
focus group 2. 89 year old gentleman living with his wife and 
daughter in a house with a stairlift) 
 
"(Getting up out of a chair is) one of the hardest parts, yes." 
(Participant 3, focus group 2. 80 year old gentleman who lives with 
his wife in a semi-detached house with stairs) 
 
"Itʼs the same in the morning when I get off of bed, Iʼve got to stand 
for nearly five minutes before Iʼve got my balance enough to move 
my legs." (Participant 2, focus group 2. 89 year old gentleman 
living with his wife and daughter in a house with a stairlift) 
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 "I think really, the outstanding fact I think comes in front of steps, 
 and that is the pain factor." (Participant 1, focus group 1. 86 year 
 old gentleman, widowed two years previously, living alone in a 
 bungalow). 
 
"Yeah, well I just used to go… my daughter used to take me 
shopping a bit, thatʼs about all we did, and I used to go out for my 
tea one day. I didnʼt do a lot because I didnʼt have much energy."  
(Participant 3, focus group 1. 87 year old lady living alone in a 
bungalow). 
 
3.6.1.3 Trying to cope with environmental constraints 
Stairs were identified as an important environmental constraint that 
present a significant challenge to frail older people. Struggling with stairs 
inside the home can make it difficult for older people to manage activities 
of daily living. Struggling with stairs to the front door and stairs at the 
homes of family and friends restrict frail older people to the immediate 
home environment and can limit both social participation and social 
support networks. However, coping strategies employed by frail older 
people can make it easier to overcome the challenges posed by 
environmental constraints. 
 
"I find (steps) difficult, really difficult. Itʼs okay if you havenʼt got 
your steps, but if you have, youʼve got to struggle with them. I (live 
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at) my daughter's and I have to go upstairs to the toilet and I 
struggle going up you see, I manage to only go once usually, 
because I canʼt manage any more. Theyʼre very steep, her steps."  
(Participant 2, focus group 1. 90 year old female living with her 
daughter in a house with stairs) 
 
"I thinks steps are difficult for everybody, I would say that, would 
you?" (Participant 5, focus group 1. 87 year old lady who lives with 
a friend in a house with a stair lift). 
 
3.6.1.4 Managing to cope despite physical and environmental 
constraints 
Although a range of physical and environmental constraints were 
identified, it became clear that older people in the two focus groups had 
the capability to overcome these potential constraints. Personal 
determination to keep going appeared to help overcome many of the 
physical constraints. Environmental constraints could frequently be 
overcome through environmental modification, such as grab-rails and 
stairlifts that make it easier to keep going. Methods to make it easier to 
cope with environmental constraints based on practical experience were 
identified by frail older people, such as raising the level of the bed to 
make it easier to get out of bed in the morning. Furthermore, the home 
environment itself could be used to make it easier, for example by using 
furniture for support when walking. 
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"So we bought two reclining chairs and they lift you forward and lift 
you at the same time."  (Participant 2, focus group 2. 89 year old 
gentleman living with his wife and daughter in a house) 
 
"Itʼs four steps going from the road outside and a handrail at each 
side. And inside weʼve got the bedroom steps that are just inside 
the front door, thereʼs a chairlift, a walk-in shower - sit-down."  
(Participant 4, focus group 1. 83 year old gentleman who lives with 
his wife and grandson in a house.) 
 
"Well, itʼs a terrace house, the front door is only one step and there 
is rails that have been put up both sides, so you can pull yourself 
up with that one step. And inside, weʼve got a chairlift." (Participant 
5, focus group 1. 87 year old lady who lives with a friend in a 
house) 
 
"Now theyʼve stopped me going home three times, the welfare 
people...first they grade my bed is too low...and they canʼt fathom 
out how to raise our bed five inches. So if they canʼt do it in the 
end, Iʼm going to scrap the bed - itʼs a new bed - and weʼll buy two 
single beds. And if theyʼve got wooden legs, within an hour, Iʼll 
have legs made for it and everything." (Participant 2, focus group 
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2. 89 year old gentleman living with his wife and daughter in a 
house with a stairlift) 
 
"Well you try to arrange… well, we do, try to arrange the house so 
that when youʼre walking round...thereʼs a settee that you can hold 
onto and the chair and then by that time, you get into the kitchen. 
When you get to the kitchen, youʼve got your units and then we 
have a trolley what we put our meals on and push it in. And you 
work round which you think is best for yourself and easy and 
easiest for yourself."  (Participant 5, focus group 1. 87 year old 
lady who lives with a friend in a house.) 
 
3.6.1.5 Managing to cope through the help of family and friends 
The social support networks of family and friends were identified as being 
particularly important in helping frail older people to cope and manage to 
keep going. Social support networks were important both for people living 
alone and people living with family and friends. Illustrative comments are 
provided below. 
 
"Iʼve got a good daughter twenty minute away in Guiseley...so if I 
need anything, Iʼve got all I need." (Participant 1, focus group 1. 86 
year old gentleman, widowed two years previously, living alone in 
a bungalow) 
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"But I would be able to manage at home because my daughter 
comes you see, comes most days and sees to me." (Participant 3, 
focus group 1. 87 year old lady living alone in a bungalow) 
 
"Yeah, well I just used to go… my daughter used to take me 
shopping a bit, thatʼs about all we did, and I used to go out for my 
tea one day." (Participant 3, focus group 1. 87 year old lady living 
alone in a bungalow) 
 
"Iʼm lucky, Iʼve got the wife and grandson to look after me, Iʼm 
getting a carer coming in to wash and dress me in the mornings, 
so thatʼll make it a bit better." (Participant 4, focus group 1.  83 
year old gentleman living with his wife and grandson in a house 
with a stairlift) 
 
"Weʼre lucky because weʼve got a fairly big family, thereʼs always 
somebody pops in to see weʼre alright and do things for us, so 
weʼre lucky that way." (Participant 4, focus group 1. 83 year old 
gentleman living with his wife and grandson in a house with a 
stairlift) 
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3.6.2 Healthcare professionals 
3.6.2.1 Managing to keep moving 
The overarching theme identified from the focus group meeting with 
healthcare professionals was that frail older people need to manage to 
keep moving in order to remain independent. Healthcare professionals 
talked more about individual movements that they considered crucial to 
remaining independent when compared to frail older people. A particularly 
crucial movement was considered to be the sit-to-stand, as this enables 
frail older people to undertake basic needs, such as going from the bed or 
chair to the toilet. Climbing the stairs was considered to be another crucial 
movement to enable frail older people to remain independent at home.   
 
A further important theme identified by healthcare professionals was that, 
although exercise has the potential to help frail older people keep going, 
there are a range of personal and health constraints that are important 
potential barriers to successful exercise participation. Furthermore, it was 
identified that frail older people may be constrained by a fear of falling 
and associated loss of confidence, which can overwhelm even those with 
the physical abilities to keep going. 
 
3.6.2.2 Personal constraints 
Limited personal life experience with exercise was considered to be an 
important potential barrier to successful participation. Similarly, it was 
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considered that cultural expectations could influence the uptake of 
exercise interventions by frail older people. Explaining that exercise 
interventions can potentially help frail older people to do simple, yet 
crucial tasks and giving a purpose to the exercises to make them more 
meaningful were considered to be particularly important methods of 
increasing motivation and participation. 
 
"And a lot depends on their life up to that point as well, doesnʼt it, if 
theyʼve never exercised in their life up to that point, itʼs not been 
part of their daily routine, to suddenly be faced with this person 
telling them theyʼve now got to exercise, itʼs a huge cultural shock, 
isnʼt it? And they canʼt understand why itʼs going to make any 
difference now at this point in their life." (Community 
physiotherapist 3) 
 
"Yeah, you said about explaining to people, itʼs like this exercise 
might seem pointless, bridging is one I can think of, lying on a bed 
and lifting your bottom off the bed, people say ʻItʼs a strange 
exercise, Iʼd never need to do thatʼ yeah, but thatʼs the same 
muscles that are going to lift you out of the chair, itʼs the muscles in 
your backside. And once youʼve explained that to them, as long as 
they can understand that ʻoh yeah, I can see thatʼ and then they 
relate to it and will practice it." (Physiotherapy clinical coordinator 
for older people) 
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"Iʼve also found from my experience, that if you take the time at the 
beginning to explain why the exercise is actually going to help 
them...in ways that they understand, they can actually start to think 
ʻwell actually, I need to do thisʼ rather than ʻIʼm just doing this 
because this medical person has told me I have to do itʼ."  
(Community physiotherapist 3) 
 
"Once they get used to doing that then if they move on to getting 
out of a chair theyʼll really feel theyʼve achieved something. They 
know theyʼre starting with this because itʼs a way of building their 
muscle so theyʼll be able to get out of a chair.  When they do move 
on to getting out of a chair theyʼll really feel theyʼve actually 
achieved something." (Community Matron 2) 
 
3.6.2.3 Health constraints 
Important health constraints were identified, including pain, low mood and 
cognitive impairment. Day-to-day variability in these health constraints 
means that frail older people often report having 'good days' and 'bad 
daysʼ, which can influence their motivation to participate in exercise.  
 
"One thing weʼve not mentioned is pain and pain is a big barrier to 
exercise and particularly with this group of people and theyʼre 
frightened to exercise because it hurts when theyʼre beginning to 
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move and a big part of our education is actually if you move more 
frequently, you might experience less pain. Thatʼs quite a difficult 
thing to accept really." (Physiotherapy clinical coordinator for older 
people) 
 
"Iʼve just thought that a big barrier for my particular group of 
patients, is their mood, if theyʼre depressed, theyʼre less likely to 
engage with anything." (Community Matron 1) 
 
"But itʼs how they feel theyʼre doing themselves, if theyʼre not 
feeling very well, they lack the motivation because they canʼt be 
bothered for that day and you hear older people say theyʼve had a 
good day or a bad day." (Community Matron 2) 
 
"What Iʼve found is thereʼs a huge variability in that somebody one 
day will be really good and really seem to be progressing and then 
youʼll go the next week and theyʼll be ʻI really have had a bad 
week, Iʼm not so goodʼ. You obviously need to catch them on a 
good day to get anywhere and they have a lot of bad days and itʼs 
almost one step forward, two steps back sometimes and that can 
be quite difficult." (Community physiotherapist 1) 
 
"Or theyʼll even contact us and cancel and say “Iʼm not well” and 
donʼt want us to call and then to try to get back in there, if you 
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phone, they say “oh, Iʼm still not well” and then thatʼs it, they just 
donʼt want you to come anymore sometimes." (Community 
physiotherapist 2) 
 
3.6.2.4 Constrained by fear of falling 
Being constrained by fear of falling and loss of confidence, particularly 
following a recent medical illness, were identified by healthcare 
professionals as important factors influencing the ability to keep going.  
These were considered to be particularly important because even if frail 
older people have the physical capability to manage the simple 
movements to keep going, a fear of falling and associated lack of 
confidence can be overwhelmingly constraining. 
 
"One of the big issues as well is confidence issues, if they have 
just come out of hospital and returned home, they tend to just want 
to sit in their favourite chair and any movement from there, it fills 
them with fear sometimes. So they don’t want to move because 
they don't feel safe to move, so that’s another issue sometimes." 
(Community physiotherapist 4). 
 
"I think (confidence) is probably the biggest thing, a lot of patients 
we see and weʼve worked with, we might think they have the 
physical capability to do something but if they havenʼt got the 
confidence, it doesnʼt actually make a difference at the end of the 
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day. And a lot of that confidence is around them having their 
postural stability to be able to do something and not be frightened 
that theyʼre going to fall over or theyʼre frightened to let go of the 
support of the walking aid or the back of the chair to do things; 
functional activities." (Physiotherapy clinical coordinator for older 
people) 
 
3.6.3 Case studies 
A case study is a detailed examination of a single example (242). 
Description and explanation of individual cases are part of the steps 
towards generalisation and the closeness of case studies to real-life 
situations is considered to facilitate the development of a richer 
understanding of reality (243, 244). Two case studies are therefore 
provided to illustrate the real-life constraints that are experienced by frail 
older people who want to keep going (figures 3.2 and 3.3). 
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Figure 3.2.  Case study 1. 
Case study 1 
LL, a 90 year old lady who was widowed many years earlier.  She lives with her daughter 
in a three bedroom semi-detached house with stairs and is usually mobile with a walking 
stick.  The district nurses attend twice a week to dress her leg ulcers. 
 
After the death of her husband at the age of 52 she lived alone for many years but, being 
a very house-proud lady, eventually found that it got too much to clean the house due to 
increasing weakness in her legs and pain in her feet.  She felt that the house was getting 
neglected and, following a number of hospital admissions, has recently decided to move 
in with her daughter, where she is now very happy.  She currently spends much of the 
day in her upstairs bedroom but tries to come downstairs to have a meal with her 
daughter.  When she is downstairs, she occasionally walks around with her stick and 
holds on to the furniture a bit for support. 
 
She finds the stairs especially difficult.  She struggles up the stairs, which are very steep, 
and usually only manages this once a day.  The toilet is upstairs, so if she comes down 
for a meal she has to go back up again for the toilet.  She maintains a spirit of 
determination and perseverance, which she feels she gained during the war, when she 
had to look after herself and her daughter while her husband was away. 
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Figure 3.3.  Case study 2. 
 
3.6.4 Triangulation of data by exploration of the research 
literature 
A 2009 UK Department of Work and Pensions report (245) presented the 
results from five UK national surveys: the British Household Panel Survey 
(BHPS); English Longitudinal Survey of Ageing (ELSA); Family 
Resources Survey (FRS); General Household Survey (GHS) and Medical 
Research Council Cognitive Function and Ageing Study (MRC CFAS). 
The four surveys recorded disability in a total of 45,340 older people 
Case study 2 
SH, an 89 year old gentleman who lives with his wife in a house with stairs.  He is 
usually mobile at home with a Zimmer frame and his house has a number of aids 
and adaptations that both he and his wife use, including a wheelchair, two recliner 
chairs, grab rails, a stairlift and a bath winch.  He had to buy some of these himself 
and has been frustrated by the amount of time that it has taken social services to 
provide and fit the aids and adaptations. 
 
He finds it very difficult to get up out of a chair, due to generalised weakness in both 
arms and legs. He also finds it particularly difficult to get up out of bed in the morning 
and needs around 10 minutes to do this.  He has had a number of recent trip falls, 
which have resulted in rib injury and, more recently, a hip fracture. 
 
His wife has been wheelchair-bound for the last 18 months and has required 
increasing amounts of care from himself and his daughter.  He feels that his 
daughter does a great deal for both himself and his wife and he is worried that he will 
have to rely on his daughter more following his recent hip fracture.  His daughter has 
a job of her own but comes over early every morning to get his wife out of bed and 
make the breakfast.  She also comes over every night, regularly takes his wife to the 
doctor for appointments and does all of their washing and shopping.   
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using a variety of instruments that measure different domains of 
instrumental activities of daily living. 
 
The results from the five surveys indicate that difficulty with stairs is 
particularly common in older people, with a median prevalence of 26.3% 
(range 20.7-27.4%). Difficulty getting in and out of bed is less common, 
with a median prevalence of 8.6% (range 7.3-9.8%). Other areas of 
difficulty in instrumental activities of daily living are shopping (median 
prevalence 25.5%, range 12.2-38.7%), bathing (median prevalence 
16.7%, range 14.1-16.9%) and, less commonly, toileting (median 
prevalence 4.5%, range 4.4-4.6%). 
 
Interestingly, although these results from national surveys support a 
proportion of the key findings from the focus group meetings, one key 
theme emerging from the focus group meetings with frail older people and 
healthcare professionals is not reported in the surveys. Both frail older 
people and healthcare professionals identified difficulty in standing up 
from a chair as a key limitation that adversely affects the ability to keep 
going. However, standing from a chair is not included in any of the activity 
of daily living instruments that were used to gather data for the five 
national UK surveys. 
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3.7 Reflexive account 
A vibrant discussion throughout the series of multiperspective focus group 
meetings has provided a rich dataset giving deep insight into the 
experiences and constraints of frail older people who are trying to keep 
going. The focus group meetings have provided an opportunity to learn 
from the rich narrative presented by frail older people and healthcare 
professionals. Although it is possible that the meetings may have been 
influenced by the thoughts of the main facilitator (AC) it was notable that 
the majority of discussion during the focus group meetings was 
undertaken by frail older people and healthcare professionals, with a 
relatively low requirement for facilitator steering and prompting. 
 
An important theme emerging from the focus group meetings was that 
frail older people can be constrained by difficulty in standing up from a 
chair. Standing up from a chair is a critical movement that is necessary 
for older people to ambulate around the home and get up and go to the 
toilet. Reduced ability to stand up from a chair has been associated with 
increased risk of disability and falls (246). This constraint would not have 
been identified by a review of national survey data alone as standing up 
from a chair is not included in any of the instrumental activity of daily 
living measures that have been used in five UK national surveys. 
 
In addition, it is difficult to get an impression of the weighted importance 
of IADLs from surveys and a greater sense of the importance of IADL 
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difficulties can be gained from the rich narrative that has been provided in 
this series of multiperspective focus group meetings with frail older people 
and healthcare professionals. 
 
3.8 Discussion 
It is clear that the frail older people in our focus group meetings want to 
keep going and will often struggle through difficult circumstances to 
remain living independently at home. Both frail older people and 
healthcare professionals identified that loss of muscle strength in the legs 
and arms can make keeping going more difficult. This loss of muscle 
strength makes it harder for frail older people to manage to keep doing 
the important basic mobility tasks of standing from a chair, climbing stairs 
and getting out of bed in the morning.  
 
Loss of muscle strength can be compounded by other constraints 
including pain, fatigue and acute exacerbations of chronic medical 
conditions. However, frail older people are able to keep going and 
overcome many of these often considerable physical constraints. These 
physical and health constraints are potential barriers to successful 
participation in exercise interventions and participants emphasised the 
importance of considering these constraints when developing exercise 
interventions for frail older people. Some constraints appear to be more 
difficult to overcome than others; physical fatigue and fear of falling are 
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particularly problematic for a frail older person who is struggling to keep 
going.   
 
Environmental constraints were also identified as making it more difficult 
to keep going. However, these environmental constraints appear to be 
more easily overcome than some physical and health constraints through 
the use of simple aids and adaptations. The importance of support from 
family and friends was highlighted and, where possible, the involvement 
of family and friends is likely to be important for the successful 
engagement of frail older people in exercise interventions. 
 
3.9 Conclusions 
A home-based exercise intervention for frail older people should consider 
including exercises to improve leg and arm muscle strength to help with 
the important movements of standing from a chair, getting out of bed and 
climbing stairs. To help engage frail older people, the functional purpose 
of each exercise should be explained clearly to participants. 
Consideration should be given to potential barriers to participation, 
particularly fatigue, fear of falling and joint pain/stiffness. Furthermore, the 
likelihood of frail older people having good days and bad days, which may 
impact on intervention adherence, should be considered. Some barriers 
to participation, such as loss of confidence and physical fatigue, are likely 
to be more constraining than others and factors to accommodate this 
should be incorporated into the intervention. Family and friends are a 
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powerful potential modifying factor and, if practical, their involvement in 
the intervention should be sought wherever possible. 
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3.10 Section 2.  Information provision needs 
assessment 
 
3.11 Background 
Visual impairment in older age has been described as a 'hidden' disability 
and a significant unmet need for provision of information to visually 
impaired older people has been identified (247). Visual impairment is 
common in older people, especially older women, and the prevalence 
increases from 6% in those aged 75-79 years to 37% in those aged 90 
and older (248). Around half of visually impaired older people have a mild 
impairment, the other half have a moderate to severe impairment (249).  
An independent association between frailty and visual impairment has 
previously been reported (250). 
 
The United Kingdom (UK) Royal National Institute of Blind People (RNIB) 
Clear Print Guidelines are available to support the development of 
documents for visually impaired people (251). We conducted a needs 
assessment exercise to help design an exercise manual to meet the 
needs of visually impaired frail older people. 
 
3.12 Methodology 
We conducted a focus group meeting with frail older people at 
Westbourne Green Community Hospital, a residential intermediate care 
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site in Bradford where therapy-based rehabilitation typically follows an 
acute illness prior to return home. To develop greater insight we 
attempted to identify a range of participants with and without visual 
impairment to provide a range of views on appropriate provision of 
information. Written, informed consent was taken from all participants. 
Full ethics approval was given by Bradford Research Ethics Committee 
(REC reference 09/H1302/55). 
 
Sample pages from four example exercise manuals were presented to 
the group and are available in appendix 4. The four exercise manuals 
were deliberately chosen as they had all been designed for use by older 
people but incorporated different page layouts, font types, text sizes, 
illustrations and photographs. Different types and amounts of colour and 
contrast were also used in the example exercise manuals. All four 
manuals were freely available and downloaded from the internet. 
Although the design of the exercise manuals was the main focus of the 
meeting, the clarity of the language used throughout the text was also 
discussed. 
 
Example 1 was a patient handout from the American Geriatrics 
Foundation for Health in Aging (252). The example used size 14 Times 
New Roman font with no illustrations.  The example was orientated in 
portrait layout. 
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Example 2 was a patient handout from horizonmedtech (253).  The 
example used size 10 Arial font with small diagrams. The example was 
orientated in portrait layout. 
 
Example 3 was a falls prevention manual from AgeUK (254). The 
example used size 25 Helvetica font with large 
black and white diagrams. The example was orientated in landscape 
layout. 
 
Example 4 was an exercise manual from the US Department of Health 
and Human Services (255). The manual used size 11.5 Helvetica font in 
colour with colour photographs. The example was orientated in landscape 
layout. 
 
The meeting was audio-recorded and contemporaneous field notes were 
taken. Written, informed consent was taken from all participants. The 
audio-recordings and transcripts were analysed using grounded theory 
methods. 
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3.13 Results 
Four frail older people took part in the focus group meeting. Two were 
male and two were female; the median age was 89 years (range 80 - 97 
years). 
 
Participant one was a 97 year old lady with relatively good vision requiring 
only the occasional use of reading glasses.  
 
Participant two was an 89 year old gentleman with an unspecified 
refractive error who wore bifocals for general purposes and had a pair of 
reading glasses that he used less frequently. 
 
Participant three was an 80 year old gentleman with relatively good vision 
who did not use glasses. However, his wife had ARMD requiring 
corrective aids for reading, providing him with important insight into the 
needs of visually impaired older people. 
 
Participant four was an 88 year old lady with age-related macular 
degeneration (ARMD) (wet in one eye and dry in the other) requiring 
treatment with anti-vascular endothelial growth factor injections. She wore 
glasses for general purposes and had a magnifying glass at home to help 
with reading.  
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3.13.1 General problems as a result of visual 
impairment 
Participants with visual impairment reported a range of general problems 
as a result of poor vision, including reading print in magazines, identifying 
numbers on the telephone and reading subtitles on the television.  
Illustrative comments describing the difficulties are provided below. 
 
"Sometimes you think (when youʼre reading text you get) a false 
impression, itʼs something different to what it is and itʼs a bit 
difficult...itʼs all disorientated, like when you look at a window and 
the straight lines are not straight, theyʼre all diddly." (participant 4. 
88 year old female with age-related macular degeneration) 
 
"She canʼt watch telly as good and things are blurry." (participant 3.  
80 year old male with relatively good vision whose wife has age-
related macular degeneration) 
 
"Yeah, the subtitles, she finds that awkward. It sort of blurs." 
(participant 3. 80 year old male with relatively good vision whose 
wife has age-related macular degeneration). "Small… I donʼt know 
if your wife experiences that, but I do, (the subtitles are) all small." 
(participant 4. 88 year old lady with age-related macular 
degeneration).  "Yes, she sometimes moans about the size of 
them, yes, as though itʼs shrunk." (participant 3). 
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"She gets very uptight about it, she canʼt thread a needle and 
things like that." (participant 3. 80 year old male with relatively 
good vision whose wife has age-related macular degeneration). 
 
"Oh, she canʼt dial the phone...(the numbers arenʼt) plain enough, 
you know." (participant 3. 80 year old male with relatively good 
vision whose wife has age-related macular degeneration). 
 
3.13.2 Black and white, plain and simple  
A key theme emerging from the discussion of the four examples was a 
preference for black text on a white background using a plain font. A size 
14 font was considered by participants to be adequate although a larger 
font was preferred. Participants expressed a strong preference for the 
use of simple language without jargon. Diagrams or photographs were 
considered to help clarify the text explanations. Participants expressed 
different views regarding use of colour text. Those with better vision 
tended to be more open to the use of colour, as long as it wasn't 
overdone, whereas those with visual impairment found colour text more 
difficult to read, and could be distracted by its use. Illustrative comments 
are provided. 
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"Simple and plain. A decent size print." (participant 2. 89 year old 
male with a refractive error who wears bifocals for general 
purposes and reading glasses).  
 
"Iʼd prefer to see everything on there for us to read in black and 
white; plain, what you can see and understand." (participant 2. 89 
year old male with a refractive error who wears bifocals for general 
purposes and reading glasses). 
 
"I think Iʼd rather have black and white." (participant 1. 97 year old 
lady with relatively good vision requiring only the occasional use of 
reading glasses). 
 
"A bit colour is nice I think...If itʼs not overdone, yes...when you get 
blue, blue printing on a red background, thatʼs no good." 
(participant 3. 80 year old male with relatively good vision whose 
wife has age-related macular degeneration). 
 
"Well, if you can see (the picture) just as plain or plainer in black 
and white, and colour tends to distract you." (participant 2. 89 year 
old male with a refractive error who wears bifocals for general 
purposes and reading glasses) 
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"I find (the diagrams) very good, theyʼre black and white, arenʼt 
they?." (participant 4. 88 year old female with age-related macular 
degeneration) 
 
Each of the four examples is discussed in turn, with illustrative comments 
provided. 
 
3.13.2.1 Example 1 
The size 14 font used in example 1 was considered to be adequate for 
participants, although the exercise instructions were felt to be unclear.  
Participants identified that the addition of diagrams would help clarify the 
text descriptions. Illustrative comments are provided below. 
 
"Oh, the writingʼs okay yeah, I can read the writing through my 
bifocals, but I could read it better with my reading glasses." 
(participant 2. 89 year old male with a refractive error who wears 
bifocals for general purposes and reading glasses) 
 
"Well, Iʼve got to go back and read it again. I follow it now, but first 
time through, I didnʼt get it." (participant 3. 80 year old male with 
relatively good vision whose wife has age-related macular 
degeneration). 
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"Little diagrams would be a big help as well." (participant 3. 80 year 
old male with relatively good vision but whose wife has age-related 
macular degeneration). 
 
 
3.13.2.2 Example 2 
Although three of the participants found the size 10 font in example 2 
relatively comfortable to read, the participant with ARMD found it too 
small and had to strain to read the text. The participant whose wife has 
ARMD agreed that some people with visual impairment would likely have 
difficulty reading the text. There was a general consensus that black print 
on a white background is best and that, for example, white on blue (which 
was used in the heading of the example) is difficult to read as it doesn't 
stand out. Illustrative comments are provided. 
 
"No, I have to strain a bit, I canʼt see what it says there." 
(Participant 4, 88 year old lady with ARMD) 
 
"The black on the white is the best." (Participant 2. 89 year old 
male with a refractive error who wears bifocals for general 
purposes and reading glasses) 
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3.13.2.3 Example 3 
Participants expressed a strong preference for example 3. All participants 
found the large, black and white size 25 font easy to read and felt that the 
diagrams were a helpful addition. Participants found the exercise 
instructions clear and easy to understand. Although one participant gave 
a slight preference for the landscape orientation of example 3, it was 
difficult to determine whether this was a reflection of the general 
preference for the design of this example. Illustrative comments are 
provided below. 
 
"Yeah, now that is good, black on the white background, you can 
see that." (participant 2. 89 year old male with a refractive error 
who wears bifocals for general purposes and reading glasses).  
 
"You can see everything no problem. Even with bad eyesight." 
(participant 3. 80 year old male with relatively good vision whose 
wife has age-related macular degeneration).  (in reply)  "As soon 
as you look at it. As soon as you look at it." (participant 2. 89 year 
old male with a refractive error who wears bifocals for general 
purposes and reading glasses). 
 
"I find them very good, theyʼre black and white, arenʼt they?" 
(participant 4. 88 year old lady with ARMD). 
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"Yeah, I think thatʼs alright, I think thatʼs a good illustration, the 
heels are raised." (participant 1. 97 year old lady with relatively 
good vision requiring only the occasional use of reading glasses). 
 
3.13.2.4 Example 4 
The participant with ARMD found the size 11.5 font a bit difficult to read, 
particularly when a different colour text was used. The text instructions 
were considered to be relatively clear. Participants found the photographs 
helpful but felt that the green background did not provide the right amount 
of contrast, which made it more difficult to understand the exercise. One 
participant commented that when there was more than one photograph 
used, it would be clearer if the photographs were numbered sequentially.  
Comments are provided below. 
 
"Can I read it though? Iʼm not sure...Itʼs a bit difficult." (participant 
4. 88 year old lady with ARMD). 
 
"I donʼt care for the green." (participant 4. 88 year old lady with 
ARMD). 
 
"Well it's easy to follow what theyʼre getting at (in the 
explanations), yes, itʼs alright." (participant 1. 97 year old lady with 
relatively good vision requiring only the occasional use of reading 
glasses). (in reply) "Yes, itʼs plain enough that is." (participant 3. 
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80 year old male with relatively good vision whose wife has age-
related macular degeneration). 
 
"Everybody can understand that by looking at (the photograph)." 
(participant 2. 89 year old male with a refractive error who wears 
bifocals for general purposes and reading glasses). 
 
"If they try and make them interesting by changing colours, thatʼs 
no good, you want to stick to something you can read and 
understand, black and white." (participant 2. 89 year old male with 
a refractive error who wears bifocals for general purposes and 
reading glasses). 
 
 
3.14 Discussion 
The needs of those who are visually impaired should always be 
considered when designing documents and providing information to frail 
older people. Our needs assessment exercise has identified that, when 
designing an exercise manual, frail older people prefer a minimum of size 
14 font and, if possible, should be provided with a text size in excess of 
this. Black text on a white background is preferred, and some 
combinations of text colours (for example white on blue, red on blue) can 
be more difficult to read. Visually impaired frail older people may have 
greater difficulty interpreting colour and emphasis should be placed on 
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ensuring adequate contrast between different colours. Exercise 
descriptions should be as plain and simple as possible. 
 
The results of our needs assessment exercise agree broadly with the 
RNIB Clear Print Guidelines, which advise that when designing 
documents for visually impaired people text size should be 12-14 point 
(preferably 14 point); text layout should be kept clear, simple and 
consistent; the contrast between the text and background should be as 
high as possible and that any information conveyed in colour or through 
images should also be described. The results of this needs assessment 
exercise will help improve the provision of information to frail older people 
in the HOPE manual. 
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3.15 Section 3.  Delphi consensus process 
 
3.16 Background 
Consensus methods are a means of assessing the level of agreement 
between experts or lay people about a specific issue (256). The Delphi 
process is a consensus method that involves expert participation and 
follows a series of ordered rounds (234). Two rounds of a Delphi process 
were used in the development of a home-based exercise intervention for 
frail older people in preparation for testing in a pilot randomised controlled 
trial.  
 
3.17 Methodology 
3.17.1 Round one 
Preliminary results from the modelling exercise (section 1) were analysed 
to identify emerging findings and key points to inform a questionnaire to 
assess the level of agreement with a series of key statements regarding 
the development of a home-based exercise intervention for frail older 
people (234). 
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3.17.2 Round two 
In round two, the experienced healthcare professionals who participated 
in the focus group meetings were contacted by email and asked to 
provide responses to the key statements in the questionnaire developed 
following round 1. Responses were assessed using a nine-point Likert 
scale (1 = strongly disagree, 9 = strongly agree). Free text responses to 
the ten key points were also sought. An example questionnaire is 
provided in appendix 2. 
 
Written, informed consent was taken from all participants. Full ethics 
approval was given by Bradford Research Ethics Committee (REC 
reference 09/H1302/55). 
 
3.18 Results 
Seven experienced healthcare professionals (one head of therapy 
services, one physiotherapy clinical coordinator for older people, three 
community physiotherapists and two community matrons) took part in the 
Delphi process. 
 
3.18.1 Round one 
The key themes of 'wanting to keep going' and 'managing to keep 
moving', along with the important constraints and motivational factors 
identified, were incorporated into the questionnaire. 
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3.18.2 Round two 
Responses from six participants were received in round two. The results 
are summarised in table 3.1. 
 
Statement 
number 
Statement Mean 
agreement,  
Likert score 
(standard 
deviation) 
1 There is a large amount of variation in the functional 
abilities of frail older people living at home 
8.2 (1.0) 
2 Thought needs to be given to this variation when designing 
an exercise programme to improve the functional abilities of 
frail older people living at home i.e. a 'one size fits all 
approach' is inappropriate 
8.0 (1.1) 
3a Older people are commonly limited by lower limb weakness 7.8 (1.2) 
3b Older people are commonly limited by poor postural 
flexibility/stability 
8.5 (0.6) 
4 These limitations are often expressed functionally by 
difficulty in standing from a chair and difficulty climbing 
stairs 
8.0 (0.9) 
5 Older people will require face-to-face contact on more than 
one occasion to help learn a structured exercise 
programme and improve compliance 
8.3 (0.8) 
6 The exercise programme needs to be simple 8.2 (1.0) 
7a It is important to include goal setting in the exercise 
programme 
7.5 (1.4) 
7b It is important to monitor success/benefit throughout the 
exercise programme 
8.0 (0.9) 
7c It is important to allow participants to advance during the 
exercise programme 
7.7 (1.0) 
8a Key perceived barriers to participation are likely to be 
respiratory problems 
7.0 (2.1) 
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8b Key perceived barriers to participation are likely to be joint 
stiffness/joint pain 
7.8 (1.0) 
8c Key perceived barriers to participation are likely to be low 
mood 
7.3 (1.6) 
9 Flares of chronic medical diseases may impact on 
participation in the exercise programme 
7.5 (1.6) 
10a Potential measures to improve involvement/ compliance 
include allowing adaptation to the exercise programme, i.e. 
if a participant is feeling unwell then they should complete 
the warm-up exercises only 
7.3 (1.6) 
10b Potential measures to improve involvement/ compliance 
include attempting to incorporate the programme into 
normal daily routine 
8.7 (0.5) 
10c Potential measures to improve involvement/ compliance 
include making the programme meaningful to the individual 
8.7 (0.5) 
10d Potential measures to improve involvement/ compliance 
include engaging with & involving family/carers 
8.3 (0.5) 
10e Potential measures to improve involvement/ compliance 
include using different levels of exercise (e.g. chair 
based/standing) depending on the ability of the individual 
8.3 (0.5) 
Table 3.1.  Agreement with a series of key statements in round two 
of a Delphi consensus process. 
 
Relatively strong agreement with all key points was recorded (median 8.0, 
range 7.0 - 8.7). Lowest mean agreement was recorded regarding 
statements 8a (A key perceived barrier to participation is likely to be 
respiratory problems), 8c (A key perceived barrier to participation is likely 
to be low mood), and 10a (Potential measures to improve 
involvement/compliance include allowing adaptation to the exercise 
programme). Highest mean agreement was recorded regarding 
statements 3b (Older people are commonly limited by poor postural 
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flexibility/stability), 10b (Potential measures to improve 
involvement/compliance include attempting to incorporate the programme 
into normal daily routine) and 10c (Potential measures to improve 
involvement/compliance include making the programme meaningful to the 
individual). As there was relatively strong agreement with all the key 
points identified, it was considered that a third round of the consensus 
process would unlikely be beneficial. 
 
3.19 Discussion 
Two rounds of a Dephi consensus process have identified relatively 
strong agreement with a series of key statements regarding development 
of the HOPE programme. The results of the consensus process provide 
greater insight into engaging frail older people in exercise by identifying 
the important motivational factors and common barriers to participation in 
exercise and will be incorporated into the design of the HOPE 
programme.
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3.20 Section 4.  Behaviour change techniques 
It is recognised that people can contribute to their overall health and well-
being by adopting or avoiding certain health behaviours. Choice of health 
behaviour is influenced by multiple factors, including personality, cognitive 
and socioeconomic factors. To facilitate health behaviour change, a 
series of theoretical frameworks have been developed that consider these 
important factors (235). These frameworks have been incorporated into a 
wide range of health interventions, including interventions to increase 
physical activity in adults (257). In addition to considering these 
frameworks when developing health interventions it has been proposed 
that the individual elements of interventions, training and supervision of 
intervention providers, treatment delivery and treatment adherence 
should be reported by researchers, to aid in the identification of 
successful behaviour change techniques. 
 
Importantly, behaviour change theories rarely specify techniques to 
change behaviour (258). Recent attempts have been made to develop a 
reliable, standardised taxonomy of behaviour change techniques (BCTs) 
used in interventions (259). This taxonomy both details behaviour change 
techniques and maps these onto existing theory. It is anticipated that this 
standardised and reliable taxonomy will facilitate identification of BCTs 
incorporated into successful interventions to aid in the application of 
evidence based behaviour change. 
 189 
 
A summary of this taxonomy is provided in table 3.2. The 26 BCTs 
identified reflect a range of theoretical frameworks, including the 
information-motivation-behavioral skills model (IMB); theory of reasoned 
action (TRA); theory of planned behavior (TPB); social-cognitive theory 
(SCogT); control theory (CT) and operant conditioning (OC). 
 
 
Behaviour change 
technique (theoretical 
framework) 
Definition 
1)  Provide information 
about behaviour-health 
link. (IMB) 
General information about behavioural risk, for example, susceptibility 
to poor health outcomes or mortality risk in relation to the behaviour 
2)  Provide information 
on consequences. (TRA, 
TPB, SCogT, IMB) 
Information about the benefits and costs of action or inaction, focusing 
on what will happen if the person does or does not perform the 
behaviour 
3)  Provide information 
about others approval. 
(TRA, TPB, IMB) 
Information about what others think about the personʼs behaviour and 
whether others will approve or disapprove of any proposed behaviour 
change 
4)  Prompt intention 
formation. (TRA, TPB, 
SCogT, IMB) 
Encouraging the person to decide to act or set a general goal, for 
example, to make a behavioural resolution such as “I will take more 
exercise next weekʻ 
5)  Prompt barrier 
identification. (SCogT) 
Identify barriers to performing the behaviour and plan ways of 
overcoming them 
6)  Provide general 
encouragement. 
(SCogT) 
Praising or rewarding the person for effort or performance without this 
being contingent on specified behaviours or standards of performance 
7)  Set graded tasks. 
(SCogT) 
Set easy tasks, and increase difficulty until target behaviour is 
performed 
8)  Provide instruction. 
(SCogT) 
Telling the person how to perform a behaviour and/or preparatory 
behaviours 
9)  Model or 
demonstrate the 
behaviour. (SCogT) 
An expert shows the person how to correctly perform a behaviour, for 
example, in class or on video 
10)  Prompt specific goal 
setting. (CT) 
Involves detailed planning of what the person will do, including a 
definition of the behaviour specifying frequency, intensity, or duration 
and specification of at least one context, that is, where, when, how, or 
with whom 
11)  Prompt review of 
behavioural goals. (CT) 
Review and/or reconsideration of previously set goals or intentions 
12)  Prompt self-
monitoring of behaviour. 
(CT) 
The person is asked to keep a record of specified behaviour(s) (e.g., 
in a diary) 
13)  Provide feedback 
on performance. (CT) 
Providing data about recorded behaviour or evaluating performance in 
relation to a set standard or othersʼ performance, i.e., the person 
received feedback on their behaviour 
14)  Provide contingent 
rewards. (OC) 
Praise, encouragement, or material rewards that are explicitly linked 
to the achievement of specified behaviours 
15)  Teach to use 
prompts or cues. (OC) 
Teach the person to identify environmental cues that can be used to 
remind them to perform a behaviour, including times of day or 
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elements of contexts 
16)  Agree on 
behavioural contract. 
(OC) 
Agreement (e.g., signing) of a contract specifying behaviour to be 
performed so that there is a written record of the personʼs resolution 
witnessed by another 
17)  Prompt practice. 
(OC) 
Prompt the person to rehearse and repeat the behavior or preparatory 
behaviours 
18)  Use follow-up 
prompts. 
Contacting the person again after the main part of the intervention is 
complete 
19)  Provide 
opportunities for social 
comparison. (SCompT) 
Facilitate observation of nonexpert othersʼ performance for example, 
in a group class or using video or case study 
20)  Plan social support 
or social change. (social 
support theories) 
Prompting consideration of how others could change their behaviour 
to offer the person help or (instrumental) social support, including 
“buddy”systems and/or providing social support 
21)  Prompt 
identification as a role 
model. 
Indicating how the person may be an example to others and influence 
their behaviour or provide an opportunity for the person to set a good 
example 
22)  Prompt self-talk. Encourage use of self-instruction and self-encouragement (aloud or 
silently) to support action 
23)  Relapse prevention. 
(relapse prevention 
therapy) 
Following initial change, help identify situations likely to result in 
readopting risk behaviours or failure to maintain new behaviours and 
help the person plan to avoid or manage these situations 
24)  Stress management 
(stress theories) 
May involve a variety of specific techniques (e.g., progressive 
relaxation) that do not target the behaviour but seek to reduce anxiety 
and stress 
25)  Motivational 
interviewing 
Prompting the person to provide self-motivating statements and 
evaluations of their own behaviour to minimize resistance to change 
26)  Time management Helping the person make time for the behaviour (e.g., to fit it into a 
daily schedule) 
Table 3.2. A summary of behaviour change techniques and 
illustrative theoretical frameworks. 
IMB, information-motivation-behavioral skills model; TRA, theory of 
reasoned action; TPB, theory of planned behavior; SCogT, social-
cognitive theory; CT, control theory; OC, operant conditioning (259). 
 
A brief description of each of the theoretical frameworks is provided 
below.   
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3.20.1 Information-motivation-behavioural skills 
model 
The IMB model was first described as a conceptualisation of AIDS 
preventive behaviour (260). The model asserts that risk behaviour 
change is a function of people's information about a health condition, 
motivation to reduce risk and their behavioural skills for performing the 
necessary tasks for risk reduction. 
 
3.20.2 Theory of planned behaviour/theory of 
reasoned action 
The TPB is derived from the earlier TRA and both are considered to be 
deliberative processing models implying that attitudes and behaviours are 
constructed following careful consideration of available information (261-
263). The TPB asserts that behaviour is determined by both the level of 
intention to engage in the behaviour and perception of control over 
performance (261). 
 
3.20.3 Social cognitive theory 
SCogT identifies that behavioural change is achieved through a personal 
sense of control; if people believe that they have the capability to 
address, for example, a health problem they become more willing to 
engage in behaviour change and develop a commitment to the decision 
(264).   
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3.20.4 Control theory 
CT is based on the concept of a behaviour feedback loop and asserts 
that behaviour change is most likely if feedback is provided alongside 
comparison with behavioural target(s) and by individualised action plans 
(258, 265). 
 
3.20.5 Operant conditioning 
OC is based on the principle that behaviour is modified due to the 
susceptibility of an individual to behavioural reinforcement by particular 
consequences, which can be positively or negatively reinforcing (266). 
 
3.21 Evidence for behaviour change techniques in 
the development of exercise interventions for 
frail older people 
There is currently no evidence-based guidance for the application of 
BCTs in the development of home-based exercise interventions for frail 
older people. There is, however, guidance for the use of BCTs derived 
from trials conducted in the general adult population. A 2005 UK Health 
Development Agency review of a series of systematic reviews and meta-
analyses identified that interventions based on BCTs and tailored to 
individual needs are associated with longer-term changes in behaviour 
(267). Furthermore, trials that incorporated regular contact with an 
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exercise specialist were associated with sustained changes in physical 
activity. Both home-based and group based sessions appeared to be 
equally effective. Use of telephone support and exercise log-books were 
also identified in successful interventions.   
 
Although evidence regarding the application of particular behaviour 
change theoretical frameworks in the development of home-based 
exercise interventions for frail older people is also lacking, the social 
cognitive model of behaviour change has previously been shown to 
successfully increase physical activity participation in adults (259, 268-
270). 
 
3.22 Discussion 
Although there is currently an absence of evidence-based guidance 
regarding the application of BCTs in the development of home-based 
exercise interventions for frail older people, certain BCTs have been more 
frequently found in effective community-based physical activity 
interventions in adults. This indirect evidence, in conjunction with the 
recently published taxonomy of behaviour change techniques outlined 
above, will help inform the incorporation of BCTs into the HOPE 
programme. 
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4 Chapter 4.  The HOPE programme 
 
The HOPE programme has been developed by synthesising information 
from the four key domains outlined at the start of Chapter 3; the 
systematic literature review; the process of intervention modelling work 
incorporating a series of multiperspective focus group meetings, an 
information provision needs assessment exercise and a Delphi 
consensus process; the review of behaviour change techniques and the 
review of international consensus guidelines on the development of 
exercise interventions for older people.   
 
4.1 How the information from the four key domains 
was synthesised together 
Emerging findings from the four key domains were presented by myself to 
the members of the HOPE study steering group at monthly meetings. The 
steering group members were; Professor John Young, Professor of 
Elderly Care Medicine, Academic Unit of Elderly Care & Rehabilitation,  
University of Leeds; Professor Anne Forster, Professor of Stroke 
Rehabilitation, Academic Unit of Elderly Care & Rehabilitation, University 
of Leeds; Dr Sally Barber, Senior Research Fellow & Exercise 
Physiologist, Academic Unit of Elderly Care & Rehabilitation, University of 
Leeds; Dr Louise Johnson, Senior Lecturer in Physiotherapy, School of 
Health Studies, University of Bradford and Dr Alison Pighills, 
 195 
Rehabilitation Projects Manager, NHS Bradford & Airedale. The emerging 
findings were discussed in detail and consensus was reached regarding 
the key aspects of the HOPE programme, including the key exercises to 
be included, the intensity (frequency & duration) of the intervention and 
the proposed physiotherapist timeline. Any disagreements were resolved 
by group consensus. 
 
A draft HOPE manual was then circulated to members of the HOPE study 
steering group by email. The draft HOPE manual was further refined 
through discussion at subsequent steering group meetings to improve the 
clarity of general instructions to participants and text descriptions of 
exercises. Expert validation was achieved at a further group meeting 
following email circulation of the draft HOPE manual and physiotherapy 
timeline to the Bradford Teaching Hospitals NHS Foundation Trust 
therapy directorate team who took part in the focus group meetings. The 
feasibility of delivery of the HOPE programme was confirmed through 
discussion with Jill Gregson, head of therapy services at Bradford 
Teaching Hospitals NHS Foundation Trust and Phil Wright, Physiotherapy 
Clinical Coordinator for Older People at Bradford Teaching Hospitals NHS 
Foundation Trust. 
 
A complete description of the HOPE programme, including behaviour 
change strategies that have been incorporated into the intervention, is 
provided below. 
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4.2 Description of the HOPE programme 
The HOPE programme is a 12 week progressive exercise intervention 
that is presented to participants in an exercise manual and delivered by 
trained community-based physiotherapists from Bradford Teaching 
Hospitals NHS Foundation Trust. The manual contains five sections; 1) 
information, 2) safety tips, 3) good posture, 4) exercises and 5) staying on 
track. The exercises have been selected to target the physical limitations 
and ADL difficulties identified during the modelling phase, supported by 
the UK national research questionnaire literature and Delphi consensus 
process. To account for the diversity of our participant group, the HOPE 
programme is graded into three levels. Participants are stratified to the 
appropriate level using the baseline timed-up and go test (TUGT) (246). 
Those who take 30 seconds or more to complete the TUGT are stratified 
into level 1; those who take between 20-29 seconds are stratified into 
level 2 and those who take less than 20 seconds are stratified into level 3. 
The complete manuals for each of the three levels of the HOPE 
programme are included in the supplementary material CD at the back of 
this thesis. 
 
All of the exercises are easy to learn, require no special equipment and 
can be performed without professional supervision. The exercises for 
each level of the programme (Level 1, 2 and 3), their purpose (to improve 
strength, mobility, balance or aerobic capacity) and their functional 
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relevance (e.g. to improve standing up from a chair) are provided in table 
4.1.  
 
Exercise Level Purpose Functional relevance 
Breathing 
warm up  
 
1, 2, 3 A preparatory exercise 
to increase lung 
capacity 
Reduce shortness of breath 
Sitting-up 
 
1, 2, 3 Trunk/abdominal 
strength  
Stair climbing, standing up 
from a chair, walking, 
balance 
Spine 
rotation 
 
1, 2, 3 Trunk mobility Washing and dressing, 
reaching for something on a 
shelf, stair climbing 
Armchair 
rise – arm 
strength 
 
1 Upper body strength Standing up from a chair, 
lifting/carrying household 
objects 
Leg kicks 
 
1 Lower body strength Standing up from a chair, 
walking * 
Toe-heel 
pointing 
 
1 Lower body strength Walking, stair climbing * 
Marching 
 
1P, 2 Lower body strength  Standing from a chair, stair 
climbing * 
Standing 
arm raises 
(for 30 
seconds)  
1P Upper body strength 
and mobility and 
balance 
Reaching for something on a 
shelf, lifting/carrying 
household objects, washing 
and dressing falls prevention 
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Armchair 
rise – arm 
and leg 
strength 
 
2 Upper and lower body 
strength 
Walking, stair climbing, 
standing up from a chair, 
lifting/carrying household 
objects 
Calf raises 
 
2 Lower body strength 
and balance  
Walking and stair climbing  
Leg swing 
back 
 
2P Lower body strength 
and hip mobility 
Standing up from a chair, 
dressing* 
Side 
stepping 
 
2P Balance Falls prevention 
Chair rise 
 
3 Lower body strength Walking, stair climbing, 
standing up from a chair 
Wall press-
up 
 
3 Upper body strength 
and mobility 
Lifting/carrying household 
objects, washing and 
dressing 
Single foot 
calf raise  
3 Lower body strength Walking and stair climbing 
Leg back 
swing and 
side raise 
 
3P Lower body strength 
and hip mobility 
Standing from a chair, 
dressing * 
Stand on 
one leg 
 
3P Balance Falls prevention 
Walking toe 
to heel  
3P Balance Falls prevention 
Aerobic 
exercises 
 
 
 
3P Aerobic Sustaining engagement in 
physical activities * 
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Table 4.1. Exercises included in the three levels of the HOPE 
programme. 
P, progression exercise;  * may also reduce arthritic pain at the 
mobilized joint.  Copyright © 2011. 
 
At the beginning of the intervention participants are requested to perform 
five repetitions of each exercise in the routine. This progresses to 10 and 
then 15 repetitions as performance improves. The exercise routine takes 
less than 15 minutes to complete, and participants are requested to 
complete the routine 3 times a day on 5 days of the week.  
 
A physiotherapist timeline for the HOPE programme is provided in 
appendix 5. Participants receive weekly support from physiotherapists 
through either a face-to-face home visit or telephone call. If participants 
are coping well with the exercises they are encouraged to progress within 
the programme. Progression is by increasing repetitions, introducing new 
exercises or advancing to the next level of the HOPE programme. Gentle 
aerobic exercise is incorporated as a progression exercise at Level 3 of 
the HOPE programme to introduce the concept of aerobic exercise to the 
more physically able participants. 
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4.2.1 Strategies to support behaviour change 
The HOPE programme is based predominantly on the social cognitive 
model of behaviour change as a theoretical framework, as this has 
previously been shown to successfully increase physical activity 
participation in adults (259, 268-270). Details of the behaviour change 
techniques and how they are incorporated into the HOPE programme are 
shown in Table 4.2. 
 
Behaviour change technique 
(theoretical framework) 
How the technique is in the 
intervention 
Provide information on consequences 
(SCogT) 
Information given about the value of 
exercise for health in older age 
Provide general encouragement (SCogT) Praise and encouragement given by 
physiotherapists weekly during either a 
home visit or telephone call 
Set graded tasks (SCogT) Opportunities to progress (increased 
repetitions, addition of progression 
exercises, advancing to the next level of 
the programme) are discussed between 
participant and physiotherapists and an 
individual progression plan is agreed upon  
Provide instruction (SCogT) Each participant receives a HOPE 
programme manual that gives instructions 
for the programme and describes in written 
and pictorial format how to perform each 
exercise.  Physiotherapists also provide 
instruction during home visits and 
telephone calls  
Model or demonstrate the behaviour 
(SCogT) 
Physiotherapists demonstrate how to 
correctly perform exercises during home 
visits 
Prompt specific goal setting (CT) The physiotherapists facilitates the 
participant to set specific functional 
improvement goals  
Prompt self-monitoring behaviour (CT) The participant is asked to keep a record 
of which days they do their exercises on 
and how many times they complete the 
routine that day 
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Prompt practice (OC) Participants are provided with a HOPE 
programme fridge magnet to prompt them 
to perform their exercise routine 
Relapse prevention Three “gentle exercises” are provided in 
the HOPE manual for participants to 
complete if they are “having a bad day” 
(this was identified in focus groups as a 
situation likely to result in failure to 
maintain the exercise programme) 
Table 4.2. Behaviour change techniques used in the HOPE 
programme. 
Techniques and theoretical frameworks were defined using (259).  
SCogT, social cognitive theory; CT, control theory; OC, operant 
conditioning. 
 
4.3 Discussion 
The HOPE programme has been developed using rigorous research 
methodology that has assimilated evidence from RCTs, international 
consensus guidelines and considerable input from frail older people and 
expert healthcare professionals. The evaluation of the HOPE programme 
in a pilot RCT (the HOPE trial) will be discussed in Chapter 5. 
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5 Chapter 5.  Evaluation of the Home-Based 
Older People's Exercise (HOPE) 
programme: the HOPE trial 
 
5.1 Background 
The MRC framework for developing and evaluating complex health 
interventions stresses the importance of piloting and feasibility work prior 
to testing an intervention in a definitive trial (233). This chapter describes 
the evaluation of the HOPE programme in a pilot RCT. 
 
5.2 Objectives 
To conduct a pilot RCT to: 
1)  explore methods to identify frail older people in community settings; 
2)  assess the acceptability of the HOPE programme to frail older people; 
3)  test for a preliminary estimate of effectiveness; 
4)  test the feasibility of recording data to identify the therapy  resources 
required to deliver the HOPE programme; 
5)  gather data to inform the design of a definitive clinical trial 
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5.3 Design 
The HOPE trial design and methodology is based on the MRC framework 
(233) and international consensus guidelines for the design of RCTs of 
interventions to prevent functional decline and disability in frail older 
people (232). The international consensus guidelines provide 
recommendations to address the major potential challenges that should 
be considered when designing RCTs of interventions for frail older people 
and are summarised in table 5.1. These potential challenges and 
recommendations have informed the development of the HOPE trial and 
have been incorporated into the trial design where possible. 
 
 
Challenges Recommendations 
Standard criteria for physical frailty are 
lacking 
Operationalise variables in the domains of 
mobility, nutrition, and body composition. 
Justify the specific criteria used in the trial 
Enrolling the most appropriate study 
population may be complex and expensive 
Use a multistage selection process: 1) 
Exclude the ʻʻrobust.ʼʼ 2) Identify those who 
are frail. 3) Identify subset according to 
specific domains of physical frailty. 
Excessive exclusions may reduce 
generalisability 
Design studies with the idea of enabling 
participation.  
The principal exclusion criteria should be 
factors that prevent participation. 
Avoid exclusions for comorbidity. 
Ascertain the level of cognitive impairment 
incompatible with participation in specific 
interventions. 
Inclusion and exclusion of frail older 
persons from trials raise ethical concerns 
Make explicit the procedures used for 
consenting participants. Provide multiple 
methods to explain the study to the 
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participants and involve a surrogate when 
needed. Discuss ethical issues when 
reporting results. 
Assessing disability through self-report 
may be problematic 
Limit self-report to primary outcomes that 
are ʻʻhardʼʼ measures of disability such as 
activity of daily living disability, mobility 
disability.  
Standardize disability questions and 
responses and provide continuing, 
intensive training to interviewers. 
Collect objective measures of physical 
function and proxy information in parallel. 
Make the outcome less sensitive to 
random fluctuations (e.g., defining 
disability as ʻʻlasting more than 3 monthsʼʼ 
or targeting ʻʻmultiple fallsʼʼ) Include 
mortality in the primary outcomes. 
The mechanism by which the intervention 
prevents disability may be unclear 
Use as secondary outcomes physiological 
or functional measures that are in the 
theoretical pathway between the 
intervention target and the disability 
outcome. 
Improvements in functional status may not 
translate into well-being and quality of life 
Use secondary outcome measures that 
assess perceived well-being and 
factors,such as somatic symptoms, that 
are important for quality of life in frail older 
persons. Consider global impression. 
Avoid attrition and competing morbidity The expected mortality and dropout rates 
should be incorporated into sample size 
calculations. 
Adherence rates can be improved by 
designing interventions feasible by most, 
allowing flexible time-frame for follow-up 
interviews, providing a comfortable 
environment, prioritizing safety, providing 
transportation, establishing a good 
relationship with family or caregivers, 
preplanning alternatives to full clinic visits 
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(e.g., shorter home visits, telephone calls). 
Table 5.1.  Major challenges and recommendations involving 
randomised controlled trials of disability prevention in frail older 
persons. 
Adapted from (232). 
 
The HOPE trial is a two arm, assessor blind pilot RCT to assess the 
effectiveness of an exercise intervention (the HOPE programme) 
designed to improve the mobility and functional abilities of frail older 
people living at home, compared with usual care. The 12 week HOPE 
programme is delivered to trial participants by community-based 
therapists from Bradford Teaching Hospitals NHS Foundation Trust.  
Follow-up is at 14 weeks post randomisation. 
 
5.4 Methodology 
5.4.1 Setting 
Bradford, UK; a post-industrial ethnically diverse northern city with a 
population of 350,000 people. 
 
5.4.2 Methods of recruitment & inclusion criteria 
Those eligible for inclusion were frail older people. A research question 
under investigation in this pilot trial was to identify the most efficient 
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recruitment method(s) for this hard to reach group of people. Multiple 
recruitment sources were therefore used to identify frail older people: 
 
1. Older people living at home and under the care of a case 
manager (CM) in Bradford, UK. CMs are experienced nurses 
specifically trained in the management of long term conditions and 
provide nurse-led case management working alongside primary 
care teams and social service staff. The case management service 
has been developed nationally with a specific policy objective of 
reducing acute hospital admissions for people with multiple long-
term conditions, who are more likely to be frail. There are a 
number of models of case management within the Bradford 
Primary Care Trust (PCT), including case management by 
Community Matrons and Advanced Nurse Practitioners. CMs were 
identified with the assistance of the NHS Bradford & Airedale 
General Services Management Team following a series of 
educational meetings. 
 
2. Older people who were housebound, defined as being unable to 
leave the house without the assistance of another person.  
Housebound older people were identified through Read code 
searching of general practitioner (GP) registers of National Institute 
for Health Research (NIHR) 'Research Ready' GP practices in 
Bradford, UK; social services sites providing day centre and 
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respite care in Bradford, UK and at discharge from intermediate 
care hospitals in Bradford, UK. 
 
The initial method of approach for those identified through GP registers of 
NIHR Research Ready practices was by letter from the GP practice. The 
initial method of approach for potential participants identified by case 
managers, social services sites providing day centre and respite care and 
intermediate care hospitals was by face-to-face or telephone contact from 
the healthcare professional or senior member of social services staff who 
was co-ordinating care. 
 
5.4.3 Exclusion criteria 
1. Unable to stand and walk independently 
2. Current participation in an alternative exercise programme (e.g. falls 
prevention programme, pulmonary rehabilitation) 
3. Registered blind 
4. Poorly controlled angina 
5. Another member of the household already in the HOPE trial 
6. Severe dementia 
7. Receiving palliative care  
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5.4.4 Sample size 
A successful pilot RCT provides important information regarding process, 
resource, management and scientific data (271). To provide useful 
process, resource, management and scientific data a recruitment target of 
100 participants (50 per group) was set. A formal sample size calculation 
was not done because the estimates of effect size and variance obtained 
from the pilot RCT will be used to inform the power calculation for a future 
definitive RCT. 
 
This pilot RCT was designed to explore: 
 1)  Process: test feasibility of the trial and intervention e.g. trial 
 recruitment rates, drop out rates, intervention compliance 
 2)  Resources: record resources required to identify and gain 
 consent from participants, time to complete study assessments, 
 resources required to deliver the intervention 
 3)  Management: gain insight into trial personnel and data 
 management issues 
 4)  Scientific: estimate intervention effect size and variance, test
 intervention safety 
 
5.4.5 Randomisation 
Participants underwent central, concealed randomised allocation to 
intervention or usual care. Participants were stratified by the baseline 
timed up and go test and underwent randomisation using restricted 
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blocks of random size with an allocation ratio of 1:1. Generation and 
storage of the HOPE trial randomisation sequence, and conduction of 
individual participant randomisation was conducted by the University of 
Leeds Clinical Trials Research Unit (CTRU), ensuring allocation 
concealment. 
 
5.4.6 Baseline assessment 
Baseline assessment was conducted by an elderly care researcher and 
included age, sex, cognitive assessment (Mini-Mental State Examination, 
MMSE), co-morbidity index (272) and the Edmonton Frail Scale (EFS), a 
validated and reliable measure of frailty (273). The EFS samples 10 
domains, including cognitive impairment, functional ability and mobility.  
The maximum score is 17, which represents the highest level of frailty.  
The EFS demonstrates good inter-rater reliability (estimated $ = 0.7) and 
internal consistency (Cronbach's " = 0.62). 
 
Involvement in previous formal exercise programmes and the dates of 
any previous involvement were also recorded. 
 
5.4.7 Primary outcome measure 
1. Timed Up and Go test (TUGT) (246), measured at baseline and 14 
weeks post-randomisation. The TUGT measures, in seconds, the time 
taken to stand up from a standard chair, walk a distance of 3 metres, turn, 
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walk back to the chair and sit down. A chair with armrests and a seating 
depth of 44-47cm is recommended. For the HOPE trial, if a chair with 
armrests and a recommended seating height was available in the 
participant's home this was used for the TUGT. If a chair with armrests 
and recommended seating height was not available, a standard chair with 
adjustable seating height was used (Prima modular shower stool with 
back and arms, available from Gordon Ellis & Co). A distance of 3m was 
measured out and, after one practice test, the participant was instructed 
to start the TUGT on the word 'go', at which point the stopwatch was 
started. The stopwatch was stopped when the participant had sat down in 
the chair again and the time was recorded. If the participant was unable 
to complete the TUGT, an a priori score of 300s was recorded, as this 
was the maximum time taken to complete the TUGT in the original 
validation study. 
 
Those who complete the test in less than 20 seconds tend to be 
independently mobile, able to get in and out of a chair without assistance 
and climb stairs. Those who complete the test in 30 seconds or more 
tend to require assistance with getting in and out of a chair, climbing 
stairs and leaving the house. Those who complete the test in 20-29 
seconds demonstrate greater variability in mobility, balance and 
functional ability (246). 
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The TUGT has been demonstrated to be a practical, reliable and valid 
measure of mobility in community dwelling older people (274). It is 
associated with high participation rates across this group and is therefore 
considered to be an appropriate measure of mobility for frail older people, 
including those who use a walking aid (274). The TUGT score 
demonstrates high inter-rater and intra-rater reliability (intraclass 
correlation coefficients (ICCs) 0.99 and 0.99 respectively) and correlates 
well with measures of gait speed, functional ability and balance. An 
improvement of 1.4 seconds on the TUGT (within-patient change score) 
has been identified as the minimum clinically important difference (MCID) 
(275). 
 
5.4.8 Secondary outcome measures 
1. Modified Barthel Index of activities of daily living (ADL) (194), 
measured at baseline and at 14 weeks post-randomisation. The Barthel 
Index assesses functional status on a 20 point scale by recording ability 
to complete ten activities of daily living; bathing, bladder function, bowel 
function, dressing, feeding, grooming, mobility, stairs, toilet use and 
transfers. Higher scores indicate greater independence. An MCID of 1.85 
points has been identified, but floor and ceiling effects can limit the utility 
of the Barthel Index (276, 277). For the HOPE trial, self-reported Barthel 
Index was recorded. Where self-reported information was not possible or 
considered unreliable, a proxy report was sought.  
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2. The EuroQol Group 5-Dimension Self-Report Questionnaire (EQ-5D) 
(222), measured at baseline and at 14 weeks post-randomisation. The 
EQ-5D is a standardised measure of health utility (quality of life) 
comprising five dimensions: mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression. Each dimension has three levels: 
no problems, some problems, severe problems. The scores for each of 
the five dimensions are combined in a five digit number representing 
health status that can be converted into a summary index (0 for dead, 1 
for perfect health and negative values for states worse than death) using 
the time trade-off method (278). 
 
3. Geriatric Depression Scale - Short Form 15 (GDS) (279), measured at 
baseline and at 14 weeks post-randomisation. The GDS is a screen for 
the presence and severity of depression in older people. It comprises 15 
individual questions; a score of 0-4 indicates no depression, 5-10 is 
suggestive of mild depression and 11+ is suggestive of severe 
depression. 
 
Recruitment rates; proportions and reasons for non-consent; protocol 
compliance by therapists; rates of adherence to the HOPE programme by 
patients; drop out rates; rates of completion of outcome measures; 
unscheduled admissions to hospital were also recorded, along with falls 
and documentation of muscle/joint pain. 
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It was anticipated that the main cost of the intervention would be the 
future therapy resources associated with delivery of the HOPE 
programme. To perform a formal cost-effectiveness analysis in the future 
definitive trial, the feasibility of collection of data to identify the therapy 
resources required for delivery was therefore tested. This data included 
time taken for each physiotherapist home visit, time for telephone 
consultations and travel time and was recorded by the physiotherapists 
who delivered the intervention. 
 
5.4.9 Analysis plan 
The exploratory nature of this pilot study requires mainly descriptive 
statistics and focuses on the estimation of effects sizes, 95% confidence 
intervals and variation estimation for planning of the future definitive trial.  
The baseline differences between the control and intervention groups in 
terms of the baseline assessment tests were compared and differences in 
any other potential confounding variables (age, sex, co-morbidity) were 
assessed. 
 
Histograms with normal curves were plotted to assess the distribution of 
data for each of the primary and secondary outcome measures. Skewed 
data were log transformed to yield lognormal distributions. 
 
All outcome measures were summarised and 95% confidence intervals 
constructed for the difference in outcomes between control and 
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intervention groups. Change scores were calculated by subtracting follow-
up values from baseline values. As analysing change does not control for 
baseline imbalances because of regression to the mean (280), analysis of 
covariance (ANCOVA) tests were used for continuous outcomes, with 
adjustment for baseline values. Both adjusted and unadjusted values 
were tested to detect which has the smaller variance for future planning. 
Risk ratios with 95% confidence intervals were used for binary outcomes. 
Missing data were addressed by listwise exclusion. 
 
The final intention-to-treat analysis included all randomised participants 
for whom the follow-up assessment of the primary outcome measure was 
available. The per-protocol analysis included all randomised participants 
who were deemed to have no protocol violations. 
 
5.4.10 Protocol violations 
Participants who were randomised to the HOPE programme (intervention) 
arm but did not undertake any of the HOPE programme were deemed to 
be protocol violations. 
 
5.4.11 Risks 
Safe exercise guidelines were followed and exercise intensity was 
increased gradually by therapists with experience in the delivery of 
exercise interventions to frail older people living at home. All potential 
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participants were informed of the potential risks in the participant 
information documents provided, so that informed consent was taken with 
full knowledge of potential risks. Potential risks included muscle pain, 
general fatigue and risk of falls. 
 
5.4.12 Adverse events 
An adverse event (AE) was any unfavourable and unintended sign, 
symptom, syndrome or illness that developed or worsened during the 
period of observation in the trial. This included: 
1.  Exacerbation of a pre-existing illness 
2.  Increase in frequency or intensity of a pre-existing episodic event or 
condition 
3.  Condition detected or diagnosed after the intervention even though it 
may have been present prior to the start of the trial 
4.  Continuous persistent disease or symptoms present at baseline that 
worsen following the start of the trial. 
 
A serious adverse event (SAE) was any AE occurring following trial 
mandated procedures that results in any of the following outcomes: 
1.  Death 
2.  A life-threatening adverse event 
3.  Inpatient hospitalisation 
4.  A disability/incapacity 
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All AEs were assessed for seriousness, causality and expectedness by 
the trial chief investigator (AC) and recorded and closely monitored. The 
chief investigator was to be informed immediately following any SAE to 
determine causality and expectedness. Any SAE that was deemed to be 
directly related to the trial intervention, or suspected to be related to the 
trial intervention, was to be reported immediately to the ethics committee. 
 
5.4.13 Informed consent 
Informed, written consent was obtained from all trial participants by an 
elderly care researcher during a visit to the participantʼs home. Consent 
was in full accordance with the Mental Capacity Act 2005 (281) and 
International Conference on Harmonisation-Good Clinical Practice (ICH-
GCP) (282). It was emphasised that participants were free to withdraw 
from the trial at any time and that this will not affect the future care that 
they received. 
 
5.4.14 Ethical and organisational review 
The Bradford Research Ethics Committee (application number 
09/H1302/55) granted ethical approval for the HOPE trial. NHS Bradford 
and Airedale and Bradford Teaching Hospitals NHS Foundation Trust 
granted NHS Research & Development (R&D) approval. 
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5.5 Results 
A change to case manager service provision in south Bradford meant that 
recruitment rates were lower than anticipated, and 60 participants were 
recruited to February 2011. The results presented are an interim analysis 
of data obtained from these 60 participants. Trial recruitment is ongoing 
and 84 participants have now been recruited (end November 2011).   
 
5.5.1 Trial recruitment 
Between July 2010 and February 2011 a total of 264 potential 
participants were assessed for eligibility. Information regarding those who 
were excluded and the overall flow of participants through the trial is 
summarised in the CONSORT diagram provided below (figure 5.1).  
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Figure 5.1.  CONSORT flow diagram. 
 
Of the 264 participants who were assessed for eligibility, 174 did not wish 
to participate in the trial and 30 were ineligible. A total of 60 participants 
(23% of those who were assessed) were successfully recruited and 
 219 
randomised. Eight participants withdrew from the trial (four from each 
arm), three were lost to follow-up (one in the intervention group, two in the 
control group) and three participants died (one in the intervention group, 
two in the control group). None of the deaths were directly related to the 
exercise intervention. Follow-up information is therefore available for 46 
participants (77% of those randomised). 
 
5.5.2 Reasons given by those who did not wish to 
participate 
A summary of reasons given by those who did not wish to participate is 
presented in table 5.2 and discussed below.   
 
Reason given by those who did not 
wish to participate Percentage, % 
Not interested 39 
Did not reply to letter 28 
Already exercise 10 
General ill health 8 
Unable to commit 4 
Felt ʻtoo oldʼ 3 
Too much pain 2 
Other 6 
 
Table 5.2.  Reasons why people did not wish to participate in the 
HOPE trial. 
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Common reasons for declining participation were lack of interest, already 
being engaged in regular self-directed exercise and general ill health.  
Less common reasons for declining participation include an inability to 
commit to a 12 week exercise programme, feeling ʻtoo oldʼ and having too 
much pain. 
 
5.5.3 Recruitment rates from different sources 
Information about the recruitment rates from different sources is provided 
in table 5.1. 
 
Method of 
identification 
Number 
approached 
Number 
recruited 
Recruitment 
rate 
Case manager 146 47 0.32 
Respite care 8 2 0.25 
Day centre 46 6 0.13 
Intermediate care 15 2 0.13 
GP practice 49 3 0.06 
Table 5.1.  Recruitment rates by method of participant identification. 
 
5.5.4 Baseline characteristics 
Mean age of participants was 78 years (standard deviation, SD, 9.8 
years). The majority (70%) of participants were female. Baseline 
characteristics were similar in the two groups, with no statistically 
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significant differences between the intervention and control groups (table 
4.2).   
 
The overall mean baseline Edmonton Frail Scale was 8.4 (SD 2.6), 
indicating that participants were relatively frail. The overall mean baseline 
TUGT for all participants was 48.1 seconds (SD 54.8 seconds). The 
mean baseline TUGT was 51.6 seconds in the intervention group and 
44.5 seconds in the control group. The majority of participants in both 
intervention (79%) and control groups (77%) were mobile either 
independently or with a walking stick. 
 
Intervention and control groups were well balanced in terms of 
stratification levels, with 15 participants stratified to level 1 in each group, 
six to level 2 in each group and nine to level 3 in each group. 
 
Characteristic Intervention Group 
(n = 30) 
Control Group 
(n = 30) 
Age - years, mean (SD) 78.8 (8.6)    77.4 (11.1) 
Sex, no. (%) 
female 
male 
 
23 (77%) 
7 (23%) 
 
19 (63%) 
11 (37%) 
Ethnicity, no. (%) 
Caucasian 
Asian 
 
24 (80%) 
6 (20%) 
 
24 (80%) 
6 (20%) 
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Characteristic Intervention Group 
(n = 30) 
Control Group 
(n = 30) 
Living circumstances, no. (%) 
living alone 
living with spouse/partner 
living with family 
 
14 (47%) 
11 (36%) 
5 (17%) 
 
13 (43%) 
8 (27%) 
9 (30%) 
Mobility aid used *, no. (%) 
independent 
walking stick(s) 
Zimmer frame 
3-wheeled walker 
 
11 (39%) 
11 (39%) 
5 (18%) 
1 (4%) 
 
16 (53%) 
7 (23%) 
4 (13%) 
3 (10%) 
Charlson comorbidity index, mean (SD) 2.6 (2.1) 3.0 (2.2) 
TUGT (seconds), mean (SD) 51.6 (56.8) 44.5 (53.4) 
Stratification level, no. (%) 
Level 1 (> 30 seconds on TUGT) 
Level 2 (20-29 seconds on TUGT) 
Level 3 (0-19 seconds on TUGT) 
 
15 (50%) 
6 (20%) 
9 (30%) 
 
15 (50%) 
6 (20%) 
9 (30%) 
Edmonton frail scale, mean (SD) 8.2 (2.3) 8.5 (2.9) 
Barthel index, mean (SD) 15.5 (3.7) 15.2 (4.0) 
Mini-mental state examination, mean (SD) 25.9 (4.5) 24.3 (4.5) 
Geriatric depression scale, mean (SD) 4.0 (2.7) 5.3 (3.1) 
 
Table 5.2. Baseline characteristics. 
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There were no statistically significant differences in any of these 
characteristics between the intervention and control groups.  Chi-
square tests were used for categorical variables, t-tests were used 
for continuous variables. 
* - numbers do not add up to totals due to missing data 
Key: SD, standard deviation; TUGT, timed-up-and-go test 
 
5.5.5 Time required for consent, baseline and follow-up 
assessments 
Data was only recorded for participants who were successfully recruited. 
A mean time of 84 minutes (SD 23 minutes) was required for the initial 
consent and baseline assessment; a mean time of 49 minutes (SD 20 
minutes) was required for the follow-up assessment. 
 
5.5.6 Intervention completion rates and participant 
compliance 
Twenty participants in the intervention group (66%) completed the 12 
week HOPE programme. Six participants requested to drop out from the 
intervention, three participants were considerd by the physiotherapist to 
have alternative rehabilitation needs that were not provided by the HOPE 
programme and one relative requested that a participant with moderate 
dementia drop out of the intervention, as they were non-compliant. 
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Complaince diaries were returned by 16 of the 20 participants (80%) who 
completed the 12 week intervention. Of the 16 compliance diaries that 
were returned, mean diary completion (defined as the percentage of the 
compliance diary that was completed) was 60% (SD 41%). Mean total 
compliance (defined as the percentage of days that the intervention was 
completed three times a day over the course of the 12 week intervention) 
was 45% (SD 40%). Mean partial compliance (defined as the percentage 
of days that the intervention was completed at least once a day over the 
course of the 12 week intervention) was 75% (SD 34%). 
 
5.5.7 Between group comparisons 
Unadjusted and adjusted between group differences in primary and 
secondary outcome measures are summarised in table 5.3. Adverse 
outcomes are summarised in table 5.4. 
 
5.5.7.1 Primary outcome 
Although mobility had deteriorated in both groups at follow-up 
(intervention group mean adjusted change in TUGT -20.0s (95%CI -54.4, 
14.5s), control group mean adjusted change in TUGT -36.7s (95% CI -
72.8, -0.6s) there was a non-significant trend towards a clinically 
meaningful improved outcome in the intervention group (mean adjusted 
between group difference in TUGT 16.7s, 95% CI -33.3, 66.6s). Wide 
confidence limits indicate considerable uncertainty in this result. Two 
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participants in the intervention group and four participants in the control 
group were unable to complete the TUGT at follow-up and were hence 
assigned an a priori score of 300s. To test the contribution of these 
participants to the overall results a sensitivity analysis was performed 
whereby the data analysis was re-run with the results from these 
participants removed. Following the sensitivity analysis, the non-
significant trend towards a clinically meaningful slower deterioration in 
mean TUGT in the intervention group was maintained, but diminished 
(mean adjusted between group difference 4.1s, 95% CI -11.9, 20.0s). 
 
5.5.7.2 Secondary outcomes 
There were no between group differences in activities of daily living, 
measured using the Barthel Index, quality of life, measured using the 
EQ5D or depression, measured using the geriatric depression scale. 
 
5.5.7.3 Adverse outcomes 
There were no differences in risk of falls (risk ratio 0.93, 95% CI 0.29, 
2.93) or hospitalisation (risk ratio 0.74, 95% CI 0.14, 3.95). There were no 
admissions to long-term care in either group. 
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Table 5.3.  Unadjusted and adjusted between-group differences in 
primary and secondary outcome measures. 
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To control for baseline imbalances, data were adjusted using 
analysis of covariance (ANCOVA) tests.  SD, standard deviation; CI, 
confidence interval; EQ5D, EuroQol 5-Dimension self-report 
questionnaire; GDS, geriatric depression scale. 
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Table 5.4.  Risk of falls and hospitalisation in intervention and 
control groups. 
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CI, confidence interval. 
 
5.5.7.4 Subgroup analyses 
Participants were classified into those who were frail and those who were 
non-frail, using a baseline EFS > 8 to identify frailty. For the primary 
outcome, there was a non-significant trend towards maintenance of 
mobility in those who were frail (mean adjusted between group TUGT 
difference 14.6s, 95% CI -60.3, 89.6s).  There was no difference for those 
who were non-frail (mean adjusted between group difference -0.5s, 95% 
CI -13.9, 12.8s). 
 
Subgroup analyses were also performed by stratification level. For the 
primary outcome, there was a non-significant trend towards maintenance 
of mobility in level 1 participants (mean adjusted between group TUGT 
difference 25.9s, 95% CI -47.8, 99.8s) and level 2 participants (35.2s, 
95% CI -182.7, 253.1s). The wide confidence limits imply considerable 
uncertainty. There was a small, non-significant between group difference 
for level 3 participants (mean adjusted between group difference -2.9s, 
95% CI -11.8, 17.5s). 
 
5.5.7.5 Protocol violations 
There was only one protocol violation and, as this participant withdrew 
from the trial so no follow-up data was available, a per-protocol analysis 
was not performed. 
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5.5.8 Therapy resources required 
Therapy records were returned for 15 participants (50%) who were 
randomised to the intervention group. Median time between 
randomisation and date of the first visit by the physiotherapist was 16 
days (range 7-44 days). Limitations of data obtained from therapy records 
did not permit estimates of therapy resources required for delivery of the 
intervention to be made. 
 
5.5.9 Rates of researcher unblinding 
Despite the use of multiple measures to maintain blinding, including clear 
information in the participant information leaflet, verbal information at 
baseline assessment and a verbal request by the research team prior to 
the follow-up visit, researchers were unblinded by participants during 59% 
of follow-up visits. Unblinding was more common when participants were 
in the intervention group (65%) as compared to the control group (52%). 
Unblinding was either by direct information from the participant or through 
indirect information, such as the HOPE programme manual being on 
display at the follow-up visit or the delivery of the HOPE programme 
being delayed due to unforeseen circumstances, necessitating 
rearrangement of the follow-up visit. 
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6 Chapter 6.  Discussion 
The HOPE programme has been evaluated in a methodologically 
rigorous pilot randomised controlled trial that has followed the MRC 
guidelines for the development and evaluation of complex interventions.   
The pilot trial has provided valuable process, resource, management and 
scientific data. 
 
6.1.1 Process data 
The HOPE trial has provided valuable process data to help inform the 
development of a future definitive RCT. As there is currently no simple 
method of identification of frail older people as part of routine care, 
recruitment of frail older people to the HOPE trial was particularly 
challenging. A number of methods to identify frail older people were 
adopted and, of those who were approached, approximately 1/4 were 
successfully recruited into the trial. Perhaps unsurprisingly, recruitment 
tended to be most successful when the initial approach was made face-
to-face by a healthcare professional or member of the social services 
team who was well known to the potential participant. 
 
Given that the trial recruited a population of frail older people at high risk 
of adverse outcomes, retention rates were relatively high, with only eight 
out of 60 participants (13%) withdrawing from the trial. Only three 
participants (5%) were lost to follow-up. 
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66% of participants completed the 12 week intervention and most 
participants returned the compliance diary, although of those that were 
returned, the completion rates were relatively low at 60%. Although mean 
partial intervention compliance was relatively high at 75%, total 
compliance was lower, with a mean of 45% suggesting that a home-
based exercise intervention intensity of three times per day on five days 
of the week may be too much for some frail older people. 
 
6.1.2 Resource data 
Participants required considerable time for completion of the consent 
process and both baseline and follow-up assessments, with 
approximately 2 1/2 hours of face-to-face contact required. Although 
limitations of data from therapy records prevented estimates of resources 
required for delivery of the intervention, modifications have been made to 
the therapy record and will help facilitate ongoing collection of data. 
 
6.1.3 Management data 
The principle challenge of trial management was maintenance of 
assessor blinding. Assessors were frequently unblinded, both directly and 
indirectly, at the follow-up assessment. Measures were incorporated to 
attempt to maintain blinding, including clear information in the participant 
information leaflet and a verbal reminder prior to the follow-up 
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assessment. However, the presence of cognitive impairment in the frail 
older population can make maintenance of assessor blinding particularly 
challenging as there is likely to be a greater potential for participants 
forgetting information that has been provided to them regarding the 
importance of maintaining blinding. The high rates of assessor unblinding 
highlight the need to consider including a sham intervention when 
designing RCTs of complex interventions for frail older people. 
 
The median time between randomisation and first physiotherapist visit 
was 16 days. A delay between randomisation and first physiotherapist 
visit necessitated a change to the date of participant follow-up, which had 
the potential to compromise assessor blinding in a small number of 
cases. NHS physiotherapists from Bradford Teaching Hospitals NHS 
Foundation Trust worked exceptionally hard to deliver the HOPE 
programme in addition to usual NHS commitments. To facilitate delivery 
of the initial physiotherapist visit and help maintain assessor blinding, 
consideration should be given to employment of a dedicated HOPE 
physiotherapist for a future definitve trial, particularly if a sham 
intervention is to be considered. 
 
6.1.4 Scientific data 
The pilot RCT has provided preliminary evidence that a home-based 
exercise intervention for frail older people is feasible, acceptable and 
safe. The results from the pilot RCT have demonstrated a trend towards a 
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clinically meaningful slower deterioration in mobility, measured using the 
TUGT, in the group who received the HOPE programme compared to the 
control group, who received usual care. Sensitivity analyses 
demonstrated that the trend was maintained, albeit diminished, when 
those who were unable to complete the TUGT at follow-up were excluded 
from the analysis. Subgroup analyses demonstrated that the trends were 
maintained in those who were frail, defined using a validated measure of 
frailty.   
 
6.2 Strengths of the trial 
The HOPE trial was methodologically rigorous and followed international 
guidelines for both the development and evaluation of complex 
interventions and design of randomised controlled trials for frail older 
people. A number of recruitment methods were used to identify frail older 
people for the HOPE trial. The mean age of 78 years and mean EFS 
score of 8.4 at baseline adds confidence that these recruitment methods 
were appropriate and did indeed identify older people who were frail. The 
earlier systematic review identified that there were no previous trials of 
home-based exercise interventions for frail older people that used a 
validated measure of frailty to select participants or stratify results. On the 
basis of current knowledge, the HOPE trial is the first RCT of a home-
based exercise intervention for frail older people that has reported 
baseline frailty and stratified results using a validated frailty model. 
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In keeping with a successful pilot RCT, the HOPE trial has provided 
valuable process, resources, management and scientific data. This 
valuable data will inform the design of a future definitive trial and help 
guide the design of future RCTs of exercise interventions for frail older 
people. 
 
6.3 Limitations of the trial 
As a result of the considerable challenges of identifying and recruiting frail 
older people to the HOPE trial, recruitment rates were lower than 
anticipated and 60 participants were recruited to February 2011. Trial 
recruitment is ongoing and accrual is steadily increasing. 
 
Although the secondary outcome measures were appropriate for a pilot 
RCT of a home-based exercise intervention for frail older people, it is 
plausible that these ordinal outcomes were not sufficiently sensitive to 
detect change for a trial that recorded outcomes over a 14 week period. 
Previous research has demonstrated that the EQ-5D may be less 
sensitive to change than alternative quality of life measures (283) and 
there is uncertainty regarding the sensitivity to change over time for the 
Barthel Index (284).   
 
A further potential limitation of the trial was the high rates of assessor 
unblinding. These data highlight the need to consider inclusion of a sham 
intervention when designing RCTs of complex interventions for frail older 
 236 
people, who are likely to have an increased risk of cognitive impairment, 
and who hence may not consistently remember the importance of 
maintaining assessor blinding, despite repeated reminders. 
 
Limitations in the data required to investigate therapy resources needed 
for delivery of the HOPE programme meant that estimates of cost were 
precluded. However, the pilot trial is ongoing and a number of simple 
changes have increased the utility of the therapy record, helping to 
capture the necessary data required for cost estimates to be made. 
 
6.4 Consideration of the results from the HOPE 
trial in the context of previous research 
 
6.4.1 Potential implications of the between-group TUGT 
difference recorded in the HOPE trial 
An adjusted between-group TUGT difference of 16.7s (95% CI -33.3, 
66.6s) was recorded in the HOPE trial. It is important to identify the 
potential implications of a between-group TUGT difference of this 
magnitude. Although the TUGT demonstrates good agreement with 
measures of functional ability and is considered sensitive to mobility 
changes (246, 285, 286) there is a paucity of data regarding the potential 
functional relevance of changes of different magnitude. Information to aid 
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interpretation of the clinical relevance of differences in outcome is 
provided by values for the minimal clinically important difference. 
 
6.4.1.1 The minimal clinically important difference 
The minimal clinically important difference (MCID) identifies the threshold 
that defines when an individual (or group) has begun to experience an 
important improvement (287). A 2001 review identified a taxonomy of 
nine different methods for evaluating MCID; patient comparison to a 
global rating; patient conversation; clinician consensus development; 
clinician-led patient scenario scoring; clinician-led patient scenario 
comparison; clinician-led prognostic rating scale; data-driven approach; 
discerning important improvement criteria and achieving treatment goals 
(288).   
 
A 2011 prospective cohort study compared three approaches to defining 
the MCID for four performance measures (including the TUGT) in 65 
patients (mean age 66.5 years, SD 9.4 years) with hip osteoarthritis 
receiving physiotherapy treatment (275). The three approaches were all 
based on patient comparison to a global rating score - the Global Rating 
of Change Score (GRCS) (289). GRCS measured at baseline and nine 
weeks was used as the anchor, and an a priori literature review identified 
that a difference of greater that five GRCS points was considered 
clinically important. The first approach was based on sensitivity/specificity 
and the ability of the performance measure to correctly classify patients 
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as improved or not improved. The second was based on the within-
patients performance measure score change that corresponded to 
patients who were defined as having shown major improvement in the 
GRCS. The third was based on the between-patients score change and 
was calculated as the difference in change score of patients showing 
major improvement in GRCS and those showing unimportant change.   
 
The three methods used in the study identified borderline statistically 
significant (p=0.06) MCIDs for the TUGT of 0.8s (approach 1), 1.4 s 
(approach 2) and 1.2s (approach 3). In the absence of similar data for 
community dwelling frail older people, it is reasonable to surmise that the 
results derived from this study of older people receiving a nine-week 
physiotherapy intervention for hip osteoarthritis have implications for frail 
older people, including those recruited to the HOPE trial. If confirmed in a 
future definitive trial, an adjusted between group difference of 16.7s is 
therefore likely to be of clinical importance in relation to future change in 
health status. Furthermore, the more conservative estimate of an 
adjusted between-group difference of 5.3s derived from the sensitivity 
analysis is also likely to be clinically important. 
 
 
Although not an a priori powered RCT, the sample size achieved in the 
HOPE trial is comparable to sample sizes achieved in two of the four high 
quality RCTs of home-based exercise interventions for frail older people 
identified in the systematic review (229, 230). To increase overall power, 
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it is possible to pool data from the HOPE trial with data from earlier trials 
of high methodological quality identified in the earlier systematic review 
for the outcomes of mobility and disability. 
 
6.4.2 Pooling data from the HOPE trial with previous RCT 
data 
 
6.4.2.1 Mobility 
It is possible to pool data from the HOPE trial with TUGT data from one  
trial of high methodological quality identified in the earlier systematic 
review (229). Data in this trial were reported in the form of median 
(range). For the purposes of meta analysis, the mean was estimated to 
be equivalent to the median and standard deviation was estimated as 
range/4 (290). Mean differences were pooled using random effect inverse 
variance methods. Pooling of overall data demonstrated a non-significant 
trend towards a clinically unimportant difference (mean difference 1.2s, 
95% CI -3.0, 5.5). The earlier trial was over a duration of six months, 
which may suggest that an early between group difference in TUGT at 
three months, as observed in the HOPE trial, may not be maintained over 
time.  Although data were pooled a total sample size of 107 was 
obtained.  Limitations of sample size are clearly still evident and the 
relationship between maintenance in TUGT and time requires further 
investigation. 
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6.4.2.2 Disability 
It is also possible to pool data from the HOPE trial with disability data 
from one earlier trial of high methodological quality identified in the earlier 
systematic review (230). As outcome measurement tools were different, 
standardised mean differences (SMDs) were pooled using inverse 
variance random effects methods. The SMD is the difference in mean 
effects divided by the pooled standard deviation and therefore depends 
on the effect size and the individual standard deviations (291). A 
reasonable rule of thumb is that a pooled SMD value of 0.2 represents a 
small effect size, a value of 0.5 represents a moderate effect size and a 
value of 0.8 a large effect. A pooled SMD of 0.13 was obtained (95% CI -
0.25, 0.51), indicating a probable small effect size.  
 
Both trials were over a short duration. Interestingly, although a statistically 
significant between-group difference in disability score at seven months 
was reported in one previous RCT of high methodological quality, there 
was no statistically significant between-group difference at three months 
in the trial (227). It is reasonable to anticipate that, unless a sudden 
deterioration is encountered, a clinically meaningful between-group 
difference in TUGT may eventually translate into a clinically important 
difference in ADL score. In light of these data and the potential concerns 
regarding sensitivity to change of ADL instruments outlined above, 
appropriate length of follow-up should therefore be incorporated into a 
future definitive RCT to test the relationship between improvement in 
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mobility score and ADL. The relationship between maintenance of 
mobility and future disability will be considered in greater detail below. 
 
6.4.3 The relationship between early maintenance of 
mobility and future disability 
Loss of the ability to complete ADL is accompanied by an increased need 
for help from family members, friends or carers and predicts increased 
risk of hospitalisation, admission to long-term care and death (292, 293).   
A large prospective cohort study to observe the development and 
progression of ADL disability in 5151 participants reported a distinct 
hierarchy of dependency onset (294). This study used the order of 
incident disability recorded over a six year period in a US national 
probability sample of older people (mean age 78 years). 
 
Total six year incidence rates for walking, bathing, transferring, dressing, 
toileting and feeding disabilities were 34%, 25%, 19%, 13%, 9% and 6% 
respectively, indicating that initial difficulties with walking (mobility) are 
likely to be followed, in order, by difficulties in bathing, transferring, 
dressing, toileting and feeding. The ordered median ages of disability 
onset were 84, 87, 90, 92, 93 and 100 respectively. Older women 
developed disability at earlier ages and experienced higher incidence 
rates of disability. 
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The authors of the study reported that the results differ from the Katz 
ordering of disability, which reports an initial onset of dependency in 
bathing followed by dependency in dressing, toileting, transferring, 
continence and feeding (295). However, the Katz hierarchy was 
developed in a cross-sectional study of 1001 younger and older people 
with a wide range of underlying diseases, including hip fracture, stroke, 
paraplegia, quadriplegia, cerebral palsy and motor neuron disease. As a 
hierarchical order must, by definition, be inferred from cross-sectional 
data a hierarchical order derived from longitudinal data is potentially more 
reliable (294). Of note, disability in transferring was recorded before 
disability in dressing and toileting in the longitudinal study when 
compared with the cross-sectional Katz study. As transferring requires 
strength in both upper and lower limbs, the ability to transfer is potentially 
more vulnerable to deterioration over time when compared to dressing, 
which requires only upper limb strength and dexterity. The results may 
indicate that lower extremity disability is likely to precede upper extremity 
disability in older age (294). 
 
If the hierarchy of disability progression does indeed begin with difficulties 
with mobility and progress in an ordered manner over time it is therefore 
plausible that early maintenance of mobility, as recorded in the HOPE 
trial, may be associated with future maintenance of other ADL disabilities.  
Results from earlier trials would potentially support this possibility (227).  
This hypothesis requires evaluation in a future definitive RCT. 
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6.4.4 Risk of falls in the HOPE trial and previous research 
literature 
There was no difference in risk of falls (risk ratio 0.93, 95% CI 0.29 - 
2.93). In a meta-analysis of data from three trials including 566 
participants a 2009 Cochrane review of home-based interventions for 
preventing falls in older people living in the community reported a pooled 
risk ratio of 0.77 (95% CI 0.61 - 0.97) (216). 
 
6.5 Consideration of whether home-based 
exercise interventions are likely to improve 
outcomes for those who are most frail 
A critical question is whether home-based exercise interventions are 
likely to improve outcomes for those who are most frail. The subgroup 
analysis identified that the overall between-group difference in TUGT was 
sustained in those who were considered to be most frail, as defined by 
the EFS. However, an earlier RCT of high methodological quality 
identified in the systematic review reported no improvement in disability 
score at three, seven or twelve months for those who were severely frail, 
defined using an operationalised measure of frailty (227).   
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Immunohistochemical and structural evidence of skeletal muscle 
remodelling in frail older people through exercise has previously been 
demonstrated (211). Critically, uncertainty remains regarding whether this 
biological improvement can eventually translate into clinically meaningful 
outcomes. Alternatively, as frail older people are at such high risk of 
sudden deterioration, it is possible that initial muscle remodelling and 
potential improvement in early mobility may not necessarily translate into 
an improvement in disability score when measured over a longer period 
of time. This critical question requires further investigation in a definitive 
RCT that incorporates both measurement of frailty in participants using a 
validated measure at baseline and an appropriate length of participant 
follow-up. 
 
6.6 Implications for future research 
The objectives of the HOPE trial were to 
1)  explore methods to identify frail older people in community settings; 
2)  assess the acceptability of the HOPE programme to frail older people; 
3)  test for a preliminary estimate of effectiveness; 
4)  test the feasibility of recording data to identify the therapy  resources 
required to deliver the HOPE programme; 
5)  gather data to inform the design of a definitive clinical trial 
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The implications for future research will be considered in light of the 
HOPE trial objectives 
 
6.6.1 Methods to identify frail older people in community 
settings 
There is currently no proven reliable method to identify frailty as part of 
routine healthcare, which has made identification and recruitment of frail 
older people to the HOPE trial particularly challenging. Future research to 
test methods of identifying frailty to health and social care providers as 
part of routine care would greatly facilitate frailty research and potentially 
improve service provision for this vulnerable group. 
 
At an early stage of trial recruitment, changes were made to the case 
manager service delivery model in south Bradford. Case managers, who 
had previously been based in the community, were moved at short notice 
into care homes, meaning that they were unable to identify additional 
participants for trial recruitment. This highlighted the importance of 
considering alternative methods of participant recruitment, particularly 
when a relatively new model of care that is subject to change is used to 
identify potential participants for clinical trials. 
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6.6.2 The acceptability of the HOPE programme to frail 
older people 
Approximately 1/4 of those approached were successfully recruited into 
the HOPE trial. Although recruitment rates were lower than the majority of 
previous RCTs identified in the earlier systematic review this may reflect 
different inclusion/exclusion criteria and methods of approach. Although 
beyond the scope of this study, future research to better understand the 
reasons why many frail older people decline to take part in trials of home-
based exercise interventions is of particular importance. Training of those 
who undertake trial recruitment in behaviour change methods may be one 
strategy to help facilitate recruitment of frail older people to future RCTs. 
 
Although partial intervention compliance was relatively high, total 
intervention compliance was lower, suggesting that a proportion of 
participants found the intervention intensity of three times a day on five 
days of the week too much. It is therefore likely that a period of further 
intervention modelling work will be required before the HOPE programme 
can be tested in a future definitive RCT, to gain additional insight into the 
optimal intensity of a home-based exercise intervention for frail older 
people. 
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6.6.3 A preliminary estimate of effectiveness 
The pilot HOPE trial has provided the necessary information required for 
a preliminary estimate of intervention effectiveness. By design, the pilot 
HOPE trial was not based on an a priori sample size calculation. This 
means that any result that achieves statistical significance would be an 
unexpected chance result and hypothesis testing by calculation of p 
values is therefore not indicated. Instead, a carefully considered narrative 
interpretation of estimates of effect size with confidence intervals is 
warranted. 
 
There was a non-significant trend towards a clinically meaningful 
improved outcome in the intervention group (mean adjusted between 
group difference in TUGT 16.7s, 95% CI -33.3, 66.6s) that was robust to 
sensitivity analysis. There were no differences in any of the secondary 
outcomes and no differences in adverse outcomes, which may reflect 
concerns regarding the sensitivity to change of the secondary outcome 
measures over a 14 week period. The preliminary estimates of 
effectiveness and variance provides the necessary information that is 
required for the sample size calculation for a future definitive trial. 
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6.6.4 The feasibility of recording data to identify the 
therapy resources required for delivery of the HOPE 
programme 
Although the physiotherapists delivering the HOPE programme were 
requested to include the time taken to deliver the HOPE programme at 
each home visit, the time taken for travel to and from the home of the 
participant and the time taken for each telephone call this important data 
was not initially recorded. The simple addition of dedicated boxes for the 
recording of this information on the therapy record, along with written 
instructions to therapists, has helped facilitate collection of this 
information for the more recent trial participants. 
 
6.6.5 Data to inform the design of a definitive clinical trial 
The pilot HOPE trial has provided the necessary data to help design a 
future definitive randomised controlled trial of a home-based exercise 
intervention for frail older people. Assuming a two-sided " level of 0.05, a 
future trial with 351 participants would have 80% power to detect a 
difference of 18.0s in the TUGT. On the basis of the more conservative 
estimates from the sensitivity analysis, assuming a two-sided " level of 
0.05, a future trial with 463 participants would have 80% power to detect 
a difference of 5.3s in the TUGT. Assuming withdrawal rates of 13%, the 
sample sizes would require inflation to 397 and 523 respectively. 
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As discussed previously, future RCTs of complex interventions for frail 
older people should consider the importance of including a sham 
intervention where possible, to help maintain assessor blinding. Future 
RCTs that measure change scores should consider whether outcome 
measures are suitably sensitive to change, and consider incorporation of 
long-term follow-up to investigate important outcome measures including 
disability, quality of life, hospitalisation and admission to long-term care. 
 
6.7 Implications for clinicians and commissioners 
The HOPE trial has identified that home-based exercise interventions are 
acceptable to frail older people and feasible to deliver. The trial provides 
evidence of the potential benefit of exercise in frailty, but this provisional 
evidence requires confirmation in a future definitive trial. 
 
There is robust evidence for the effectiveness of falls prevention 
interventions for older people living in the community, including home-
based falls prevention interventions for older people (216, 223).  
However, on the basis of the evidence from the HOPE trial, 
commissioning of home-based exercise interventions for frail older people 
cannot be recommended until they have been demonstrated to be both 
clinically and cost-effective. 
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6.8 Conclusion 
The HOPE trial has identified that a home-based exercise intervention for 
frail older people is feasible, acceptable and safe. The trial has provided 
preliminary evidence that the deterioration in mobility experienced by frail 
older people can potentially be diminished through exercise. This 
preliminary evidence requires confirmation in a future definitive, 
adequately powered RCT that incorporates long-term follow-up of 
important outcomes including disability, quality of life and admission to 
hospital and long-term care. The HOPE trial has provided valuable 
process, resource, management and scientific data to guide the 
development of a future definitive RCT and has provided important 
information to help inform future research involving frail older people. 
 251 
7 References 
 
1. Walston J, Hadley EC, Ferrucci L, Guralnik JM, Newman AB, 
Studenski SA, Ershler WB, Harris T, Fried LP. Research agenda for frailty 
in older adults: toward a better understanding of physiology and etiology: 
summary from the American Geriatrics Society/National Institute on Aging 
Research Conference on Frailty in Older Adults. J Am Geriatr Soc. 
2006;54(6):991-1001. 
2. Strandberg TE, Pitkala KH. Frailty in elderly people. Lancet. 
2007;369(9570):1328-9. 
3. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, 
Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA. 
Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci 
Med Sci. 2001;56(3):M146-56. 
4. Syddall H, Roberts HC, Evandrou M, Cooper C, Bergman H, Aihie 
Sayer A. Prevalence and correlates of frailty among community-dwelling 
older men and women. Age Ageing. 2010;39(2):197-203. 
5. Andrew MK, Mitnitski AB, Rockwood K. Social vulnerability, frailty 
and mortality in elderly people. PLoS One. 2008;3(5):e2232. 
6. Berkman LF, Glass T, Brissette I, Seeman TE. From social 
integration to health: Durkheim in the new millennium. Soc Sci Med. 
2000;51(6):843-57. 
7. Woodhouse KW, Wynne H, Baillie S, James OF, Rawlins MD. 
Who are the frail elderly? Q J Med. 1988;68(255):505-6. 
 252 
8. Bell J. Redefining Disease.  The Harveian Oration 2010.: Royal 
College of Physicians.; 2010. p. 1-37. 
9. de Vries NM, Staal JB, van Ravensberg CD, Hobbelen JS, Olde 
Rikkert MG, Nijhuis-van der Sanden MW. Outcome instruments to 
measure frailty: a systematic review. Ageing Res Rev. 2011;10(1):104-
14. 
10. Martin FC, Brighton P. Frailty: different tools for different 
purposes? Age Ageing. 2008;37(2):129-31. 
11. Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, 
McDowell I, Mitnitski A. A global clinical measure of fitness and frailty in 
elderly people. CMAJ. 2005;173(5):489-95. 
12. Cawthon PM, Marshall LM, Michael Y, Dam TT, Ensrud KE, 
Barrett-Connor E, Orwoll ES. Frailty in older men: prevalence, 
progression, and relationship with mortality. J Am Geriatr Soc. 
2007;55(8):1216-23. 
13. Ensrud KE, Ewing SK, Taylor BC, Fink HA, Stone KL, Cauley JA, 
Tracy JK, Hochberg MC, Rodondi N, Cawthon PM. Frailty and risk of 
falls, fracture, and mortality in older women: the study of osteoporotic 
fractures. J Gerontol A Biol Sci Med Sci. 2007;62(7):744-51. 
14. Mendes de Leon CF, Glass TA, Berkman LF. Social engagement 
and disability in a community population of older adults: the New Haven 
EPESE. Am J Epidemiol. 2003;157(7):633-42. 
 253 
15. Grundy E, Sloggett A. Health inequalities in the older population: 
the role of personal capital, social resources and socio-economic 
circumstances. Soc Sci Med. 2003;56(5):935-47. 
16. Holt-Lunstad J, Smith TB, Layton JB. Social relationships and 
mortality risk: a meta-analytic review. PLoS Med. 2010;7(7):e1000316. 
17. Rockwood K, Mitnitski A. Frailty in relation to the accumulation of 
deficits. J Gerontol A Biol Sci Med Sci. 2007;62(7):722-7. 
18. Jones DM, Song X, Rockwood K. Operationalizing a frailty index 
from a standardized comprehensive geriatric assessment. J Am Geriatr 
Soc. 2004;52(11):1929-33. 
19. Rockwood K, Andrew M, Mitnitski A. A comparison of two 
approaches to measuring frailty in elderly people. J Gerontol A Biol Sci 
Med Sci. 2007;62(7):738-43. 
20. Kirkwood TB. Understanding the odd science of aging. Cell. 
2005;120(4):437-47. 
21. Kirkwood TB. Evolution of ageing. Nature. 1977;270(5635):301-4. 
22. Sahin E, Depinho RA. Linking functional decline of telomeres, 
mitochondria and stem cells during ageing. Nature. 2010;464(7288):520-
8. 
23. Lombard DB, Chua KF, Mostoslavsky R, Franco S, Gostissa M, Alt 
FW. DNA repair, genome stability, and aging. Cell. 2005;120(4):497-512. 
24. Karanjawala ZE, Lieber MR. DNA damage and aging. Mech 
Ageing Dev. 2004;125(6):405-16. 
 254 
25. Wallace DC. Mitochondrial diseases in man and mouse. Science. 
1999;283(5407):1482-8. 
26. Yaffe MP. The machinery of mitochondrial inheritance and 
behavior. Science. 1999;283(5407):1493-7. 
27. Harman D. Aging: a theory based on free radical and radiation 
chemistry. J Gerontol. 1956;11(3):298-300. 
28. Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and 
aging. Cell. 2005;120(4):483-95. 
29. Lambeth JD. NOX enzymes and the biology of reactive oxygen. 
Nat Rev Immunol. 2004;4(3):181-9. 
30. Saraste M. Oxidative phosphorylation at the fin de siecle. Science. 
1999;283(5407):1488-93. 
31. Babior BM, Lambeth JD, Nauseef W. The neutrophil NADPH 
oxidase. Arch Biochem Biophys. 2002;397(2):342-4. 
32. Sohal RS, Weindruch R. Oxidative stress, caloric restriction, and 
aging. Science. 1996;273(5271):59-63. 
33. Arnheim N, Cortopassi G. Deleterious mitochondrial DNA 
mutations accumulate in aging human tissues. Mutat Res. 1992;275(3-
6):157-67. 
34. Wu IC, Shiesh SC, Kuo PH, Lin XZ. High oxidative stress is 
correlated with frailty in elderly chinese. J Am Geriatr Soc. 
2009;57(9):1666-71. 
35. Moore AZ, Biggs ML, Matteini A, O'Connor A, McGuire S, Beamer 
BA, Fallin MD, Fried LP, Walston J, Chakravarti A, Arking DE. 
 255 
Polymorphisms in the mitochondrial DNA control region and frailty in older 
adults. PLoS One. 2010;5(6):e11069. 
36. Muiras ML, Muller M, Schachter F, Burkle A. Increased poly(ADP-
ribose) polymerase activity in lymphoblastoid cell lines from centenarians. 
J Mol Med. 1998;76(5):346-54. 
37. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson J. 
Molecular Biology of the Cell. Garland Publishing; 1994. 
38. Verdun RE, Karlseder J. Replication and protection of telomeres. 
Nature. 2007;447(7147):924-31. 
39. Hayflick L, Moorhead PS. The serial cultivation of human diploid 
cell strains. Exp Cell Res. 1961;25:585-621. 
40. Hayflick L. The illusion of cell immortality. Br J Cancer. 
2000;83(7):841-6. 
41. von Zglinicki T, Saretzki G, Docke W, Lotze C. Mild hyperoxia 
shortens telomeres and inhibits proliferation of fibroblasts: a model for 
senescence? Exp Cell Res. 1995;220(1):186-93. 
42. Kirkwood TB. A systematic look at an old problem. Nature. 
2008;451(7179):644-7. 
43. Njajou OT, Hsueh WC, Blackburn EH, Newman AB, Wu SH, Li R, 
Simonsick EM, Harris TM, Cummings SR, Cawthon RM. Association 
between telomere length, specific causes of death, and years of healthy 
life in health, aging, and body composition, a population-based cohort 
study. J Gerontol A Biol Sci Med Sci. 2009;64(8):860-4. 
 256 
44. Cawthon RM, Smith KR, O'Brien E, Sivatchenko A, Kerber RA. 
Association between telomere length in blood and mortality in people 
aged 60 years or older. Lancet. 2003;361(9355):393-5. 
45. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, 
Harley CB, Shay JW, Lichtsteiner S, Wright WE. Extension of life-span by 
introduction of telomerase into normal human cells. Science. 
1998;279(5349):349-52. 
46. Vulliamy T, Marrone A, Goldman F, Dearlove A, Bessler M, Mason 
PJ, Dokal I. The RNA component of telomerase is mutated in autosomal 
dominant dyskeratosis congenita. Nature. 2001;413(6854):432-5. 
47. Woo J, Tang NL, Suen E, Leung JC, Leung PC. Telomeres and 
frailty. Mech Ageing Dev. 2008;129(11):642-8. 
48. Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The role 
of the ubiquitin-proteasome pathway. N Engl J Med. 1996;335(25):1897-
905. 
49. Hershko A, Ciechanover A. The ubiquitin system for protein 
degradation. Annu Rev Biochem. 1992;61:761-807. 
50. Attaix D, Mosoni L, Dardevet D, Combaret L, Mirand PP, Grizard J. 
Altered responses in skeletal muscle protein turnover during aging in 
anabolic and catabolic periods. Int J Biochem Cell Biol. 
2005;37(10):1962-73. 
51. Obin M, Shang F, Gong X, Handelman G, Blumberg J, Taylor A. 
Redox regulation of ubiquitin-conjugating enzymes: mechanistic insights 
using the thiol-specific oxidant diamide. FASEB J. 1998;12(7):561-9. 
 257 
52. Campisi J. Aging, tumor suppression and cancer: high wire-act! 
Mech Ageing Dev. 2005;126(1):51-8. 
53. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad 
things happen to good cells. Nat Rev Mol Cell Biol. 2007;8(9):729-40. 
54. Krtolica A, Campisi J. Cancer and aging: a model for the cancer 
promoting effects of the aging stroma. Int J Biochem Cell Biol. 
2002;34(11):1401-14. 
55. Serrano M. Cancer: a lower bar for senescence. Nature. 
2010;464(7287):363-4. 
56. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor 
gene. Nature. 1991;351(6326):453-6. 
57. Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N, 
Igelmann H, Lu X, Soron G, Cooper B, Brayton C, Hee Park S, Thompson 
T, Karsenty G, Bradley A, Donehower LA. p53 mutant mice that display 
early ageing-associated phenotypes. Nature. 2002;415(6867):45-53. 
58. Beausejour CM, Krtolica A, Galimi F, Narita M, Lowe SW, Yaswen 
P, Campisi J. Reversal of human cellular senescence: roles of the p53 
and p16 pathways. EMBO J. 2003;22(16):4212-22. 
59. Campisi J. Senescent cells, tumor suppression, and organismal 
aging: good citizens, bad neighbors. Cell. 2005;120(4):513-22. 
60. Jackson DA. Spatial epigenetics: linking nuclear structure and 
function in higher eukaryotes. Essays Biochem. 2010;48(1):25-43. 
 258 
61. McGowan PO, Szyf M. Environmental epigenomics: understanding 
the effects of parental care on the epigenome. Essays Biochem. 
2010;48(1):275-87. 
62. Kahn A, Fraga MF. Epigenetics and aging: status, challenges, and 
needs for the future. J Gerontol A Biol Sci Med Sci. 2009;64(2):195-8. 
63. Calvanese V, Lara E, Kahn A, Fraga MF. The role of epigenetics in 
aging and age-related diseases. Ageing Res Rev. 2009;8(4):268-76. 
64. Roth TL, Roth ED, Sweatt JD. Epigenetic regulation of genes in 
learning and memory. Essays Biochem. 2010;48(1):263-74. 
65. Graff J, Mansuy IM. Epigenetic dysregulation in cognitive 
disorders. Eur J Neurosci. 2009;30(1):1-8. 
66. Trougakos IP, Saridaki A, Panayotou G, Gonos ES. Identification 
of differentially expressed proteins in senescent human embryonic 
fibroblasts. Mech Ageing Dev. 2006;127(1):88-92. 
67. Kipling D, Davis T, Ostler EL, Faragher RG. What can progeroid 
syndromes tell us about human aging? Science. 2004;305(5689):1426-
31. 
68. Bishop NA, Lu T, Yankner BA. Neural mechanisms of ageing and 
cognitive decline. Nature. 2010;464(7288):529-35. 
69. Yankner BA, Lu T, Loerch P. The aging brain. Annu Rev Pathol. 
2008;3:41-66. 
70. Andrews-Hanna JR, Snyder AZ, Vincent JL, Lustig C, Head D, 
Raichle ME, Buckner RL. Disruption of large-scale brain systems in 
advanced aging. Neuron. 2007;56(5):924-35. 
 259 
71. West MJ, Coleman PD, Flood DG, Troncoso JC. Differences in the 
pattern of hippocampal neuronal loss in normal ageing and Alzheimer's 
disease. Lancet. 1994;344(8925):769-72. 
72. Herrup K, Yang Y. Cell cycle regulation in the postmitotic neuron: 
oxymoron or new biology? Nat Rev Neurosci. 2007;8(5):368-78. 
73. Luo XG, Ding JQ, Chen SD. Microglia in the aging brain: relevance 
to neurodegeneration. Mol Neurodegener. 2010;5:12. 
74. Klionsky DJ. Neurodegeneration: good riddance to bad rubbish. 
Nature. 2006;441(7095):819-20. 
75. Lu T, Pan Y, Kao SY, Li C, Kohane I, Chan J, Yankner BA. Gene 
regulation and DNA damage in the ageing human brain. Nature. 
2004;429(6994):883-91. 
76. Loerch PM, Lu T, Dakin KA, Vann JM, Isaacs A, Geula C, Wang J, 
Pan Y, Gabuzda DH, Li C, Prolla TA, Yankner BA. Evolution of the aging 
brain transcriptome and synaptic regulation. PLoS One. 
2008;3(10):e3329. 
77. Panegyres PK. The contribution of the study of neurodegenerative 
disorders to the understanding of human memory. QJM. 2004;97(9):555-
67. 
78. Miller DB, O'Callaghan JP. Aging, stress and the hippocampus. 
Ageing Res Rev. 2005;4(2):123-40. 
79. Rea SL, Ventura N, Johnson TE. Relationship between 
mitochondrial electron transport chain dysfunction, development, and life 
extension in Caenorhabditis elegans. PLoS Biol. 2007;5(10):e259. 
 260 
80. Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, Ueno 
T, Koike M, Uchiyama Y, Kominami E, Tanaka K. Loss of autophagy in 
the central nervous system causes neurodegeneration in mice. Nature. 
2006;441(7095):880-4. 
81. Schieke SM, Finkel T. Mitochondrial signaling, TOR, and life span. 
Biol Chem. 2006;387(10-11):1357-61. 
82. Garden GA, Moller T. Microglia biology in health and disease. J 
Neuroimmune Pharmacol. 2006;1(2):127-37. 
83. Rock RB, Peterson PK. Microglia as a pharmacological target in 
infectious and inflammatory diseases of the brain. J Neuroimmune 
Pharmacol. 2006;1(2):117-26. 
84. Cunningham C, Wilcockson DC, Campion S, Lunnon K, Perry VH. 
Central and systemic endotoxin challenges exacerbate the local 
inflammatory response and increase neuronal death during chronic 
neurodegeneration. J Neurosci. 2005;25(40):9275-84. 
85. Streit WJ. Microglial senescence: does the brain's immune system 
have an expiration date? Trends Neurosci. 2006;29(9):506-10. 
86. van Gool WA, van de Beek D, Eikelenboom P. Systemic infection 
and delirium: when cytokines and acetylcholine collide. Lancet. 
2010;375(9716):773-5. 
87. Yang F, Sun X, Beech W, Teter B, Wu S, Sigel J, Vinters HV, 
Frautschy SA, Cole GM. Antibody to caspase-cleaved actin detects 
apoptosis in differentiated neuroblastoma and plaque-associated neurons 
and microglia in Alzheimer's disease. Am J Pathol. 1998;152(2):379-89. 
 261 
88. Flanary BE, Sammons NW, Nguyen C, Walker D, Streit WJ. 
Evidence that aging and amyloid promote microglial cell senescence. 
Rejuvenation Res. 2007;10(1):61-74. 
89. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: 
uncovering the molecular mechanisms. Nat Rev Neurosci. 2007;8(1):57-
69. 
90. National Institute for Health and Clinical Excellence Delirium 
Guidelines 2010.  Delirium:  diagnosis, prevention and management (CG 
103).  2010; Available from: http://guidance.nice.org.uk/CG103. 
91. Eeles EM, Hubbard RE, White SV, O'Mahony MS, Savva GM, 
Bayer AJ. Hospital use, institutionalisation and mortality associated with 
delirium. Age Ageing. 2010;39(4):470-5. 
92. Jones RN, Yang FM, Zhang Y, Kiely DK, Marcantonio ER, Inouye 
SK. Does educational attainment contribute to risk for delirium? A 
potential role for cognitive reserve. J Gerontol A Biol Sci Med Sci. 
2006;61(12):1307-11. 
93. Fricchione GL, Nejad SH, Esses JA, Cummings TJ, Jr., Querques 
J, Cassem NH, Murray GB. Postoperative delirium. Am J Psychiatry. 
2008;165(7):803-12. 
94. Boyle PA, Buchman AS, Wilson RS, Leurgans SE, Bennett DA. 
Physical frailty is associated with incident mild cognitive impairment in 
community-based older persons. J Am Geriatr Soc. 2010;58(2):248-55. 
 262 
95. Buchman AS, Boyle PA, Wilson RS, Tang Y, Bennett DA. Frailty is 
associated with incident Alzheimer's disease and cognitive decline in the 
elderly. Psychosom Med. 2007;69(5):483-9. 
96. Jankord R, Herman JP. Limbic regulation of hypothalamo-pituitary-
adrenocortical function during acute and chronic stress. Ann N Y Acad 
Sci. 2008;1148:64-73. 
97. Turnbull AV, Rivier CL. Regulation of the hypothalamic-pituitary-
adrenal axis by cytokines: actions and mechanisms of action. Physiol 
Rev. 1999;79(1):1-71. 
98. Conrad CD. Chronic stress-induced hippocampal vulnerability: the 
glucocorticoid vulnerability hypothesis. Rev Neurosci. 2008;19(6):395-
411. 
99. Varadhan R, Walston J, Cappola AR, Carlson MC, Wand GS, 
Fried LP. Higher levels and blunted diurnal variation of cortisol in frail 
older women. J Gerontol A Biol Sci Med Sci. 2008;63(2):190-5. 
100. Florini JR, Ewton DZ, Magri KA. Hormones, growth factors, and 
myogenic differentiation. Annu Rev Physiol. 1991;53:201-16. 
101. Hameed M, Harridge SD, Goldspink G. Sarcopenia and 
hypertrophy: a role for insulin-like growth factor-1 in aged muscle? Exerc 
Sport Sci Rev. 2002;30(1):15-9. 
102. Kenyon CJ. The genetics of ageing. Nature. 2010;464(7288):504-
12. 
 263 
103. Amrit FR, Boehnisch CM, May RC. Phenotypic covariance of 
longevity, immunity and stress resistance in the caenorhabditis 
nematodes. PLoS One. 2010;5(4):e9978. 
104. Pawlikowska L, Hu D, Huntsman S, Sung A, Chu C, Chen J, 
Joyner AH, Schork NJ, Hsueh WC, Reiner AP, Psaty BM, Atzmon G, 
Barzilai N, Cummings SR, Browner WS, Kwok PY, Ziv E. Association of 
common genetic variation in the insulin/IGF1 signaling pathway with 
human longevity. Aging Cell. 2009;8(4):460-72. 
105. Leng SX, Cappola AR, Andersen RE, Blackman MR, Koenig K, 
Blair M, Walston JD. Serum levels of insulin-like growth factor-I (IGF-I) 
and dehydroepiandrosterone sulfate (DHEA-S), and their relationships 
with serum interleukin-6, in the geriatric syndrome of frailty. Aging Clin 
Exp Res. 2004;16(2):153-7. 
106. Leng SX, Hung W, Cappola AR, Yu Q, Xue QL, Fried LP. White 
blood cell counts, insulin-like growth factor-1 levels, and frailty in 
community-dwelling older women. J Gerontol A Biol Sci Med Sci. 
2009;64(4):499-502. 
107. Suh Y, Atzmon G, Cho MO, Hwang D, Liu B, Leahy DJ, Barzilai N, 
Cohen P. Functionally significant insulin-like growth factor I receptor 
mutations in centenarians. Proc Natl Acad Sci U S A. 2008;105(9):3438-
42. 
108. Musaro A, McCullagh KJ, Naya FJ, Olson EN, Rosenthal N. IGF-1 
induces skeletal myocyte hypertrophy through calcineurin in association 
with GATA-2 and NF-ATc1. Nature. 1999;400(6744):581-5. 
 264 
109. Miller RA. The aging immune system: primer and prospectus. 
Science. 1996;273(5271):70-4. 
110. Medzhitov R. Origin and physiological roles of inflammation. 
Nature. 2008;454(7203):428-35. 
111. Kumar V, Abbas A, Fausto N, Aster J. Robbins and Cottran.  
Pathological Basis of Disease: Saunders Elselvier; 2010. 
112. Eltzschig H, Carmeliet P. Hypoxia and inflammation. NEJM. 
2011;364:656-65. 
113. Jancso N, Jancso-Gabor A, Szolcsanyi J. Direct evidence for 
neurogenic inflammation and its prevention by denervation and by 
pretreatment with capsaicin. Br J Pharmacol Chemother. 1967;31(1):138-
51. 
114. Brain SD. New feelings about the role of sensory nerves in 
inflammation. Nat Med. 2000;6(2):134-5. 
115. Pober JS, Sessa WC. Evolving functions of endothelial cells in 
inflammation. Nat Rev Immunol. 2007;7(10):803-15. 
116. Tracey KJ. The inflammatory reflex. Nature. 2002;420(6917):853-
9. 
117. Nathan C. Points of control in inflammation. Nature. 
2002;420(6917):846-52. 
118. Zhang M, Borovikova LV, Wang H, Metz C, Tracey KJ. Spermine 
inhibition of monocyte activation and inflammation. Mol Med. 
1999;5(9):595-605. 
 265 
119. Tsunawaki S, Sporn M, Ding A, Nathan C. Deactivation of 
macrophages by transforming growth factor-beta. Nature. 
1988;334(6179):260-2. 
120. Bertini R, Bianchi M, Ghezzi P. Adrenalectomy sensitizes mice to 
the lethal effects of interleukin 1 and tumor necrosis factor. J Exp Med. 
1988;167(5):1708-12. 
121. Davidson NJ, Leach MW, Fort MM, Thompson-Snipes L, Kuhn R, 
Muller W, Berg DJ, Rennick DM. T helper cell 1-type CD4+ T cells, but 
not B cells, mediate colitis in interleukin 10-deficient mice. J Exp Med. 
1996;184(1):241-51. 
122. Fagiolo U, Cossarizza A, Scala E, Fanales-Belasio E, Ortolani C, 
Cozzi E, Monti D, Franceschi C, Paganelli R. Increased cytokine 
production in mononuclear cells of healthy elderly people. Eur J Immunol. 
1993;23(9):2375-8. 
123. Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, 
Ottaviani E, De Benedictis G. Inflamm-aging. An evolutionary perspective 
on immunosenescence. Ann N Y Acad Sci. 2000;908:244-54. 
124. Ferrucci L, Corsi A, Lauretani F, Bandinelli S, Bartali B, Taub DD, 
Guralnik JM, Longo DL. The origins of age-related proinflammatory state. 
Blood. 2005;105(6):2294-9. 
125. Gurven M, Kaplan H, Winking J, Finch C, Crimmins EM. Aging and 
inflammation in two epidemiological worlds. J Gerontol A Biol Sci Med 
Sci. 2008;63(2):196-9. 
 266 
126. Mundy GR. Osteoporosis and inflammation. Nutr Rev. 2007;65(12 
Pt 2):S147-51. 
127. Hansson GK. Inflammation, atherosclerosis, and coronary artery 
disease. N Engl J Med. 2005;352(16):1685-95. 
128. Payette H, Roubenoff R, Jacques PF, Dinarello CA, Wilson PW, 
Abad LW, Harris T. Insulin-like growth factor-1 and interleukin 6 predict 
sarcopenia in very old community-living men and women: the 
Framingham Heart Study. J Am Geriatr Soc. 2003;51(9):1237-43. 
129. Schaap LA, Pluijm SM, Deeg DJ, Visser M. Inflammatory markers 
and loss of muscle mass (sarcopenia) and strength. Am J Med. 
2006;119(6):526 e9-17. 
130. Barzilay JI, Blaum C, Moore T, Xue QL, Hirsch CH, Walston JD, 
Fried LP. Insulin resistance and inflammation as precursors of frailty: the 
Cardiovascular Health Study. Arch Intern Med. 2007;167(7):635-41. 
131. Hubbard RE, O'Mahony MS, Savva GM, Calver BL, Woodhouse 
KW. Inflammation and frailty measures in older people. J Cell Mol Med. 
2009;13(9B):3103-9. 
132. Leng SX, Xue QL, Tian J, Walston JD, Fried LP. Inflammation and 
frailty in older women. J Am Geriatr Soc. 2007;55(6):864-71. 
133. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger 
WH, Jr., Heimovitz H, Cohen HJ, Wallace R. Associations of elevated 
interleukin-6 and C-reactive protein levels with mortality in the elderly. Am 
J Med. 1999;106(5):506-12. 
 267 
134. Cohen HJ, Pieper CF, Harris T, Rao KM, Currie MS. The 
association of plasma IL-6 levels with functional disability in community-
dwelling elderly. J Gerontol A Biol Sci Med Sci. 1997;52(4):M201-8. 
135. Neville LF, Mathiak G, Bagasra O. The immunobiology of 
interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic 
member of the C-X-C chemokine superfamily. Cytokine Growth Factor 
Rev. 1997;8(3):207-19. 
136. Qu T, Yang H, Walston JD, Fedarko NS, Leng SX. Upregulated 
monocytic expression of CXC chemokine ligand 10 (CXCL-10) and its 
relationship with serum interleukin-6 levels in the syndrome of frailty. 
Cytokine. 2009;46(3):319-24. 
137. Qu T, Walston JD, Yang H, Fedarko NS, Xue QL, Beamer BA, 
Ferrucci L, Rose NR, Leng SX. Upregulated ex vivo expression of stress-
responsive inflammatory pathway genes by LPS-challenged CD14(+) 
monocytes in frail older adults. Mech Ageing Dev. 2009;130(3):161-6. 
138. Beishuizen A, Thijs LG. Endotoxin and the hypothalamo-pituitary-
adrenal (HPA) axis. J Endotoxin Res. 2003;9(1):3-24. 
139. Woiciechowsky C, Asadullah K, Nestler D, Eberhardt B, Platzer C, 
Schoning B, Glockner F, Lanksch WR, Volk HD, Docke WD. Sympathetic 
activation triggers systemic interleukin-10 release in immunodepression 
induced by brain injury. Nat Med. 1998;4(7):808-13. 
140. Molina PE. Noradrenergic inhibition of TNF upregulation in 
hemorrhagic shock. Neuroimmunomodulation. 2001;9(3):125-33. 
 268 
141. Sapolsky RM, Romero LM, Munck AU. How do glucocorticoids 
influence stress responses? Integrating permissive, suppressive, 
stimulatory, and preparative actions. Endocr Rev. 2000;21(1):55-89. 
142. Otte C, Hart S, Neylan TC, Marmar CR, Yaffe K, Mohr DC. A 
meta-analysis of cortisol response to challenge in human aging: 
importance of gender. Psychoneuroendocrinology. 2005;30(1):80-91. 
143. Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. 
Prevalence of anemia in persons 65 years and older in the United States: 
evidence for a high rate of unexplained anemia. Blood. 2004;104(8):2263-
8. 
144. Izaks GJ, Westendorp RG, Knook DL. The definition of anemia in 
older persons. JAMA. 1999;281(18):1714-7. 
145. Chaves PH, Semba RD, Leng SX, Woodman RC, Ferrucci L, 
Guralnik JM, Fried LP. Impact of anemia and cardiovascular disease on 
frailty status of community-dwelling older women: the Women's Health 
and Aging Studies I and II. J Gerontol A Biol Sci Med Sci. 
2005;60(6):729-35. 
146. Howard C, Ferrucci L, Sun K, Fried LP, Walston J, Varadhan R, 
Guralnik JM, Semba RD. Oxidative protein damage is associated with 
poor grip strength among older women living in the community. J Appl 
Physiol. 2007;103(1):17-20. 
147. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, 
Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinkova E, 
Vandewoude M, Zamboni M. Sarcopenia: European consensus on 
 269 
definition and diagnosis: Report of the European Working Group on 
Sarcopenia in Older People. Age Ageing. 2010;39(4):412-23. 
148. Isaacs B. Clinical and laboratory studies of falls in old people. 
Prospects for prevention. Clin Geriatr Med. 1985;1(3):513-24. 
149. Clark DJ, Patten C, Reid KF, Carabello RJ, Phillips EM, Fielding 
RA. Impaired voluntary neuromuscular activation limits muscle power in 
mobility-limited older adults. J Gerontol A Biol Sci Med Sci. 
2010;65(5):495-502. 
150. Doherty TJ. Invited review: Aging and sarcopenia. J Appl Physiol. 
2003;95(4):1717-27. 
151. Gopinath SD, Rando TA. Stem cell review series: aging of the 
skeletal muscle stem cell niche. Aging Cell. 2008;7(4):590-8. 
152. Borisov AB, Dedkov EI, Carlson BM. Interrelations of myogenic 
response, progressive atrophy of muscle fibers, and cell death in 
denervated skeletal muscle. Anat Rec. 2001;264(2):203-18. 
153. Conboy IM, Conboy MJ, Smythe GM, Rando TA. Notch-mediated 
restoration of regenerative potential to aged muscle. Science. 
2003;302(5650):1575-7. 
154. Jejurikar SS, Henkelman EA, Cederna PS, Marcelo CL, Urbanchek 
MG, Kuzon WM, Jr. Aging increases the susceptibility of skeletal muscle 
derived satellite cells to apoptosis. Exp Gerontol. 2006;41(9):828-36. 
155. Jejurikar SS, Kuzon WM, Jr. Satellite cell depletion in degenerative 
skeletal muscle. Apoptosis. 2003;8(6):573-8. 
 270 
156. Gianni P, Jan KJ, Douglas MJ, Stuart PM, Tarnopolsky MA. 
Oxidative stress and the mitochondrial theory of aging in human skeletal 
muscle. Exp Gerontol. 2004;39(9):1391-400. 
157. Brierley EJ, Johnson MA, Lightowlers RN, James OF, Turnbull 
DM. Role of mitochondrial DNA mutations in human aging: implications 
for the central nervous system and muscle. Ann Neurol. 1998;43(2):217-
23. 
158. Hiona A, Sanz A, Kujoth GC, Pamplona R, Seo AY, Hofer T, 
Someya S, Miyakawa T, Nakayama C, Samhan-Arias AK, Servais S, 
Barger JL, Portero-Otin M, Tanokura M, Prolla TA, Leeuwenburgh C. 
Mitochondrial DNA mutations induce mitochondrial dysfunction, apoptosis 
and sarcopenia in skeletal muscle of mitochondrial DNA mutator mice. 
PLoS One. 2010;5(7):e11468. 
159. Wing SS, Haas AL, Goldberg AL. Increase in ubiquitin-protein 
conjugates concomitant with the increase in proteolysis in rat skeletal 
muscle during starvation and atrophy denervation. Biochem J. 1995;307 ( 
Pt 3):639-45. 
160. Combaret L, Dardevet D, Bechet D, Taillandier D, Mosoni L, Attaix 
D. Skeletal muscle proteolysis in aging. Curr Opin Clin Nutr Metab Care. 
2009;12(1):37-41. 
161. Gaczynska M, Rock KL, Spies T, Goldberg AL. Peptidase activities 
of proteasomes are differentially regulated by the major histocompatibility 
complex-encoded genes for LMP2 and LMP7. Proc Natl Acad Sci U S A. 
1994;91(20):9213-7. 
 271 
162. Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN, 
Yancopoulos GD, Glass DJ. Mediation of IGF-1-induced skeletal myotube 
hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat 
Cell Biol. 2001;3(11):1009-13. 
163. Glass DJ. Signalling pathways that mediate skeletal muscle 
hypertrophy and atrophy. Nat Cell Biol. 2003;5(2):87-90. 
164. Wing SS, Goldberg AL. Glucocorticoids activate the ATP-ubiquitin-
dependent proteolytic system in skeletal muscle during fasting. Am J 
Physiol. 1993;264(4 Pt 1):E668-76. 
165. Sinha-Hikim I, Cornford M, Gaytan H, Lee ML, Bhasin S. Effects of 
testosterone supplementation on skeletal muscle fiber hypertrophy and 
satellite cells in community-dwelling older men. J Clin Endocrinol Metab. 
2006;91(8):3024-33. 
166. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, 
Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman 
KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, 
Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, 
LeBrasseur N, Fiore LD, Bhasin S. Adverse events associated with 
testosterone administration. N Engl J Med. 2010;363(2):109-22. 
167. Eisen A, Entezari-Taher M, Stewart H. Cortical projections to 
spinal motoneurons: changes with aging and amyotrophic lateral 
sclerosis. Neurology. 1996;46(5):1396-404. 
 272 
168. Peinemann A, Lehner C, Conrad B, Siebner HR. Age-related 
decrease in paired-pulse intracortical inhibition in the human primary 
motor cortex. Neurosci Lett. 2001;313(1-2):33-6. 
169. Oliviero A, Profice P, Tonali PA, Pilato F, Saturno E, Dileone M, 
Ranieri F, Di Lazzaro V. Effects of aging on motor cortex excitability. 
Neurosci Res. 2006;55(1):74-7. 
170. Sullivan DH, Patch GA, Walls RC, Lipschitz DA. Impact of nutrition 
status on morbidity and mortality in a select population of geriatric 
rehabilitation patients. Am J Clin Nutr. 1990;51(5):749-58. 
171. Payette H, Coulombe C, Boutier V, Gray-Donald K. Nutrition risk 
factors for institutionalization in a free-living functionally dependent elderly 
population. J Clin Epidemiol. 2000;53(6):579-87. 
172. Newman AB, Yanez D, Harris T, Duxbury A, Enright PL, Fried LP. 
Weight change in old age and its association with mortality. J Am Geriatr 
Soc. 2001;49(10):1309-18. 
173. Oldenburg HS, Rogy MA, Lazarus DD, Van Zee KJ, Keeler BP, 
Chizzonite RA, Lowry SF, Moldawer LL. Cachexia and the acute-phase 
protein response in inflammation are regulated by interleukin-6. Eur J 
Immunol. 1993;23(8):1889-94. 
174. Hubbard RE, O'Mahony MS, Calver BL, Woodhouse KW. Nutrition, 
inflammation, and leptin levels in aging and frailty. J Am Geriatr Soc. 
2008;56(2):279-84. 
175. Fong Y, Moldawer LL, Marano M, Wei H, Barber A, Manogue K, 
Tracey KJ, Kuo G, Fischman DA, Cerami A, et al. Cachectin/TNF or IL-1 
 273 
alpha induces cachexia with redistribution of body proteins. Am J Physiol. 
1989;256(3 Pt 2):R659-65. 
176. Gautron L, Laye S. Neurobiology of inflammation-associated 
anorexia. Front Neurosci. 2009;3:59. 
177. Kelesidis T, Kelesidis I, Chou S, Mantzoros CS. Narrative review: 
the role of leptin in human physiology: emerging clinical applications. Ann 
Intern Med. 2010;152(2):93-100. 
178. Elmquist JK, Elias CF, Saper CB. From lesions to leptin: 
hypothalamic control of food intake and body weight. Neuron. 
1999;22(2):221-32. 
179. Fiatarone MA, O'Neill EF, Ryan ND, Clements KM, Solares GR, 
Nelson ME, Roberts SB, Kehayias JJ, Lipsitz LA, Evans WJ. Exercise 
training and nutritional supplementation for physical frailty in very elderly 
people. N Engl J Med. 1994;330(25):1769-75. 
180. Langer G, Schloemer G, Knerr A, Kuss O, Behrens J. Nutritional 
interventions for preventing and treating pressure ulcers. Cochrane 
Database Syst Rev. 2003(4):CD003216. 
181. Tsuchiya T, Higami Y, Komatsu T, Tanaka K, Honda S, Yamaza 
H, Chiba T, Ayabe H, Shimokawa I. Acute stress response in calorie-
restricted rats to lipopolysaccharide-induced inflammation. Mech Ageing 
Dev. 2005;126(5):568-79. 
182. Lang IA, Llewellyn DJ, Langa KM, Wallace RB, Huppert FA, 
Melzer D. Neighborhood deprivation, individual socioeconomic status, 
 274 
and cognitive function in older people: analyses from the English 
Longitudinal Study of Ageing. J Am Geriatr Soc. 2008;56(2):191-8. 
183. Davey Smith G, Hart C, Hole D, MacKinnon P, Gillis C, Watt G, 
Blane D, Hawthorne V. Education and occupational social class: which is 
the more important indicator of mortality risk? J Epidemiol Community 
Health. 1998;52(3):153-60. 
184. Campbell SE, Seymour DG, Primrose WR, Lynch JE, Dunstan E, 
Espallargues M, Lamura G, Lawson P, Philp I, Mestheneos E, Politynska 
B, Raiha I. A multi-centre European study of factors affecting the 
discharge destination of older people admitted to hospital: analysis of in-
hospital data from the ACMEplus project. Age Ageing. 2005;34(5):467-
75. 
185. Lang IA, Hubbard RE, Andrew MK, Llewellyn DJ, Melzer D, 
Rockwood K. Neighborhood deprivation, individual socioeconomic status, 
and frailty in older adults. J Am Geriatr Soc. 2009;57(10):1776-80. 
186. Financial circumstances, health and well-being of the older 
population in England.  The 2008 English Longitudinal Study of Ageing 
(Wave 4). London: Insitute for Fiscal Studies; 2008. 
187. Chrousos GP, Gold PW. The concepts of stress and stress system 
disorders. Overview of physical and behavioral homeostasis. JAMA. 
1992;267(9):1244-52. 
188. McEwen BS. Protective and damaging effects of stress mediators. 
N Engl J Med. 1998;338(3):171-9. 
 275 
189. Epel ES, Blackburn EH, Lin J, Dhabhar FS, Adler NE, Morrow JD, 
Cawthon RM. Accelerated telomere shortening in response to life stress. 
Proc Natl Acad Sci U S A. 2004;101(49):17312-5. 
190. Simon NM, Smoller JW, McNamara KL, Maser RS, Zalta AK, 
Pollack MH, Nierenberg AA, Fava M, Wong KK. Telomere shortening and 
mood disorders: preliminary support for a chronic stress model of 
accelerated aging. Biol Psychiatry. 2006;60(5):432-5. 
191. Isaacs B. The challenge of geriatric medicine. Oxford: Oxford 
University Press; 1992. 
192. Miles TP, Palmer RF, Espino DV, Mouton CP, Lichtenstein MJ, 
Markides KS. New-onset incontinence and markers of frailty: data from 
the Hispanic Established Populations for Epidemiologic Studies of the 
Elderly. J Gerontol A Biol Sci Med Sci. 2001;56(1):M19-24. 
193. Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. 
Untangling the concepts of disability, frailty, and comorbidity: implications 
for improved targeting and care. J Gerontol A Biol Sci Med Sci. 
2004;59(3):255-63. 
194. Collin C, Wade DT, Davies S, Horne V. The Barthel ADL Index: a 
reliability study. Int Disabil Stud. 1988;10(2):61-3. 
195. Ferrucci L, Guralnik JM, Simonsick E, Salive ME, Corti C, Langlois 
J. Progressive versus catastrophic disability: a longitudinal view of the 
disablement process. J Gerontol A Biol Sci Med Sci. 1996;51(3):M123-30. 
196. Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing 
populations: the challenges ahead. Lancet. 2009;374(9696):1196-208. 
 276 
197. Report: Health Expectancies in the UK, 2002. London, UK: Health 
Statistics Quarterly; 2006. p. 59-62. 
198. Breakwell C, Bajekal M. Review of sources and methods to 
monitor Healthy Life Expectancy. Health Statistics Quarterly. 2005;26:17-
22. 
199. Leonardi M, Bickenbach J, Ustun TB, Kostanjsek N, Chatterji S. 
The definition of disability: what is in a name? Lancet. 
2006;368(9543):1219-21. 
200. Robine JM, Ritchie K. Healthy life expectancy: evaluation of global 
indicator of change in population health. BMJ. 1991;302(6774):457-60. 
201. Jitapunkul S, Kunanusont C, Phoolcharoen W, Suriyawongpaisal 
P, Ebrahim S. Disability-free life expectancy of elderly people in a 
population undergoing demographic and epidemiologic transition. Age 
Ageing. 2003;32(4):401-5. 
202. Healthy Life Expectancy.  Parliamentary Office of Science and 
Technology. 2006. p. 1-4. 
203. Heath Expectancy.  Living longer, more years in poor health.  
Office for National Statistics.  October 2008; Available from: 
www.statistics.gov.uk/cci/nugget.asp?id=934. 
204. EHEMU Technical Report 2.  Are we living longer, healthier lives in 
the EU?  Disability-Free Life Expectancy (DFLE) in EU Countries from 
1991 to 2003 based on the European Community Household Panel 
(ECHP).  July 2005 [24th November 2009]; Available from: 
 277 
ec.europa.eu/health/ph_projects/2003/action1/docs/2003_1_08_rep2_en.
pdf. 
205. Evert J, Lawler E, Bogan H, Perls T. Morbidity profiles of 
centenarians: survivors, delayers, and escapers. J Gerontol A Biol Sci 
Med Sci. 2003;58(3):232-7. 
206. Poole T. Funding adult social care in England. The Kings Fund; 
March 2009. p. 1-11. 
207. Koltai E, Szabo Z, Atalay M, Boldogh I, Naito H, Goto S, Nyakas C, 
Radak Z. Exercise alters SIRT1, SIRT6, NAD and NAMPT levels in 
skeletal muscle of aged rats. Mech Ageing Dev. 2010;131(1):21-8. 
208. van Praag H. Exercise and the brain: something to chew on. 
Trends Neurosci. 2009;32(5):283-90. 
209. Delbono O. Neural control of aging skeletal muscle. Aging Cell. 
2003;2(1):21-9. 
210. DeVol DL, Rotwein P, Sadow JL, Novakofski J, Bechtel PJ. 
Activation of insulin-like growth factor gene expression during work-
induced skeletal muscle growth. Am J Physiol. 1990;259(1 Pt 1):E89-95. 
211. Singh MA, Ding W, Manfredi TJ, Solares GS, O'Neill EF, Clements 
KM, Ryan ND, Kehayias JJ, Fielding RA, Evans WJ. Insulin-like growth 
factor I in skeletal muscle after weight-lifting exercise in frail elders. Am J 
Physiol. 1999;277(1 Pt 1):E135-43. 
212. Handschin C, Spiegelman BM. The role of exercise and 
PGC1alpha in inflammation and chronic disease. Nature. 
2008;454(7203):463-9. 
 278 
213. Gleeson M, McFarlin B, Flynn M. Exercise and Toll-like receptors. 
Exerc Immunol Rev. 2006;12:34-53. 
214. Puterman E, Lin J, Blackburn E, O'Donovan A, Adler N, Epel E. 
The power of exercise: buffering the effect of chronic stress on telomere 
length. PLoS One. 2010;5(5):e10837. 
215. Craft L. Exercise and clinical depression: examining two 
psychological mechanisms. Psych Sport Exer. 2005;6(2):151-71. 
216. Gillespie LD, Robertson MC, Gillespie WJ, Lamb SE, Gates S, 
Cumming RG, Rowe BH. Interventions for preventing falls in older people 
living in the community. Cochrane Database Syst Rev. 
2009(2):CD007146. 
217. Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary 
rehabilitation for chronic obstructive pulmonary disease. Cochrane 
Database Syst Rev. 2006(4):CD003793. 
218. Forster A, Lambley R, Young JB. Is physical rehabilitation for older 
people in long-term care effective? Findings from a systematic review. 
Age Ageing. 2010;39(2):169-75. 
219. Ashworth NL, Chad KE, Harrison EL, Reeder BA, Marshall SC. 
Home versus center based physical activity programs in older adults. 
Cochrane Database Syst Rev. 2005(1):CD004017. 
220. Our health, our care, our say: a new direction for community 
services. Department of Health, London. 2006. 
 279 
221. Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic 
functional mobility for frail elderly persons. Journal of the American 
Geriatrics Society. 1991;39(2):142-8. 
222. The EuroQol Group.  EuroQol-a new facility for the measurement 
of health-related quality of life. Health Policy. 1990;16(3):199-208. 
223. Thomas S, Mackintosh S, Halbert J. Does the 'Otago exercise 
programme' reduce mortality and falls in older adults?: a systematic 
review and meta-analysis. Age Ageing. 2010;39(6):681-7. 
224. Higgins J, Altman D. Chapter 8: Assessing risk of bias in included 
studies.  In Higgins JPT, Green S (editors). Cochrane Handbook for 
Systematic Reviews of Interventions.  2009; Available from: 
http://www.cochrane-handbook.org/. 
225. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting 
items for systematic reviews and meta-analyses: the PRISMA statement. 
BMJ. 2009;339:b2535. 
226. Chandler JM, Duncan PW, Kochersberger G, Studenski S. Is lower 
extremity strength gain associated with improvement in physical 
performance and disability in frail, community-dwelling elders? Archives 
of Physical Medicine and Rehabilitation. 1998;79(1):24-30. 
227. Gill TM, Baker DI, Gottschalk M, Peduzzi PN, Allore H, Byers A. A 
program to prevent functional decline in physically frail, elderly persons 
who live at home. The New England Journal of Medicine. 
2002;347(14):1068-74\. 
 280 
228. Luukinen H, Lehtola S, Jokelainen J, Vaananen-Sainio R, 
Lotvonen S, Koistinen P. Prevention of disability by exercise among the 
elderly: a population-based, randomized, controlled trial. Scand J Prim 
Health Care. 2006;24(4):199-205. 
229. McMurdo ME, Johnstone R. A randomized controlled trial of a 
home exercise programme for elderly people with poor mobility. Age and 
Ageing. 1995;24(5):425-8\. 
230. Rosie J, Taylor D. Sit-to-stand as home exercise for mobility-
limited adults over 80 years of age - GrandStand SystemTM may keep 
you standing? Age and Ageing. 2007;36(5):555-62. 
231. Vestergaard S, Kronborg C, Puggaard L. Home-based video 
exercise intervention for community-dwelling frail older women: a 
randomized controlled trial. Aging Clin Exp Res. 2008;20(5):479-86. 
232. Ferrucci L, Guralnik JM, Studenski S, Fried LP, Cutler GB, Jr., 
Walston JD. Designing randomized, controlled trials aimed at preventing 
or delaying functional decline and disability in frail, older persons: a 
consensus report. J Am Geriatr Soc. 2004;52(4):625-34. 
233. Medical Research Council. Developing and evaluating complex 
interventions: new guidance. London: MRC; 2008. 
234. Linstone H, Turoff M. The Delphi method: techniques and 
applications. Reading, MA: Adison-Wesley; 1975. 
235. Conner M, Norman P. Predicting health behaviour: a social 
cognition approach. In: Conner M, Norman P, editors. Predicting health 
 281 
behaviour: research and practice with social cognition models. 
Maidenhead: Open University Press; 2005. p. 1-27. 
236. Nelson ME, Rejeski WJ, Blair SN, Duncan PW, Judge JO, King 
AC, Macera CA, Castaneda-Sceppa C. Physical activity and public health 
in older adults: recommendation from the American College of Sports 
Medicine and the American Heart Association. Med Sci Sports Exerc. 
2007;39(8):1435-45. 
237. Kitzinger J. Qualitative research. Introducing focus groups. BMJ. 
1995;311(7000):299-302. 
238. Kendall M, Murray SA, Carduff E, Worth A, Harris F, Lloyd A, 
Cavers D, Grant L, Boyd K, Sheikh A. Use of multiperspective qualitative 
interviews to understand patients' and carers' beliefs, experiences, and 
needs. BMJ. 2009;339:b4122. 
239. National Service Framework for Older People.  Supporting 
Implementation.  Intermediate Care: Moving Forward.  Department of 
Health June 2002.  London. 
240. Glaser B, Strauss A. The discovery of grounded theory; strategies 
for qualitative research. Chicago, IL: Aldine Publishing Co; 1967. 
241. Pope C, Ziebland S, Mays N. Qualitative research in health care. 
Analysing qualitative data. BMJ. 2000;320(7227):114-6. 
242. Abercrombie N, Hill S, BS. T. Dictionary of sociology. 
Harmondsworth, UK: Penguin; 1984. 
243. Flyvbjerg B. Five misunderstandings about case-study research. 
Qualitative inquiry. 2006;12(2):219-45. 
 282 
244. Swanborn P. Case study research. London: SAGE Publications 
Ltd; 2010. 
245. Jagger C, Matthews R, King D, Comas-Herrera A, Grundy E, 
Stuchbury R, Morciano M, Hancock R. Calibrating disability measures 
across British national surveys. In: Pensions DoWa, editor. London: 
Department of Work and Pensions; 2009. 
246. Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic 
functional mobility for frail elderly persons. J Am Geriatr Soc. 
1991;39(2):142-8. 
247. Hanson J, Percival J. The housing and support needs of visually 
impaired adults living in England today. Br J Visual Imp. 2005;23:102-7. 
248. Evans JR, Fletcher AE, Wormald RP, Ng ES, Stirling S, Smeeth L, 
Breeze E, Bulpitt CJ, Nunes M, Jones D, Tulloch A. Prevalence of visual 
impairment in people aged 75 years and older in Britain: results from the 
MRC trial of assessment and management of older people in the 
community. Br J Ophthalmol. 2002;86(7):795-800. 
249. Charles N. Estimates of the number of older people with a visual 
impairment in the UK. Br J Visual Imp. 2007;25(3):199-215. 
250. Klein BE, Klein R, Knudtson MD, Lee KE. Relationship of 
measures of frailty to visual function: the Beaver Dam Eye Study. Trans 
Am Ophthalmol Soc. 2003;101:191-6; discussion 6-9. 
251. Clear Print Guidelines.  Royal National Institute of Blind People 
2011.; Available from: 
 283 
http://www.rnib.org.uk/professionals/accessibleinformation/text/Pages/cle
ar_print.aspx. 
252. Patient handout: improve your balance in 10 minutes a day.  The 
American Geriatrics Foundation for Health in Aging. Available from: 
http://www.healthinaging.org/public_education/tools/12_improve_your_bal
ance.pdf. 
253. Patient handout: balance and fall prevention.  Advance for 
Directors in Rehabilitation. Available from: 
http://www.horizonmedtech.com/PDFs/BalanceFallPrevention.pdf. 
254. Preventing falls: strength and balance exercises for healthy 
ageing.  AgeUK. Available from: www.ageuk.org.uk/documents/en-
gb/id8950%20strength%20and%20balance%20book.pdf?dtrak=true. 
255. Exercise and physical activity.  US Department of Health and 
Human Services.  National Institute of Health.  National Institute on Aging.  
2010; Available from: www.nia.nih.gov/NR/rdonlyres/E2A819E3-8BAA-
46AA-89E8-321B527D8A2B/0/ExerciseGuide_FINAL_Aug2010.pdf. 
256. Jones J, Hunter D. Consensus methods for medical and health 
services research. BMJ. 1995;311(7001):376-80. 
257. Marcus BH, Dubbert PM, Forsyth LH, McKenzie TL, Stone EJ, 
Dunn AL, Blair SN. Physical activity behavior change: issues in adoption 
and maintenance. Health Psychol. 2000;19(1 Suppl):32-41. 
258. Gardner B, Whittington C, McAteer J, Eccles MP, Michie S. Using 
theory to synthesise evidence from behaviour change interventions: the 
example of audit and feedback. Soc Sci Med. 2010;70(10):1618-25. 
 284 
259. Abraham C, Michie S. A taxonomy of behavior change techniques 
used in interventions. Health Psychol. 2008;27(3):379-87. 
260. Fisher JD, Fisher WA. Changing AIDS-risk behavior. Psychol Bull. 
1992;111(3):455-74. 
261. Conner M, Sparks P. Theory of planned behaviour and health 
behaviour. In: Conner M, Norman P, editors. Predicting health behaviour. 
Maidenhead: Open University Press; 2005. p. 170-222. 
262. Fishbein M, Ajzen I. Belief, attitude, intention and behavior: an 
introduction to theory and research. Reading, MA.: Addison-Wesley; 
1975. 
263. Ajzen I. Attitudes, personality and behavior. Milton Keynes: Open 
University Press; 1988. 
264. Luszczynska A, Schwarzer R. Social cognitive theory. 2 ed. 
Maidenhead: Open University Press; 2005. p. 127-69. 
265. Carver CS, Scheier MF. Control theory: a useful conceptual 
framework for personality-social, clinical, and health psychology. Psychol 
Bull. 1982;92(1):111-35. 
266. Skinner BF. Selection by consequences. Science. 
1981;213(4507):501-4. 
267. Hillsdon M, Foster CE, Cavill N, Crombie H, Naidoo B. The 
effectiveness of public health interventions for increasing physical activity 
among adults: a review of reviews. 2nd edition ed. London: Health 
Development Agency; 2005. 
 285 
268. Baker G, Gray SR, Wright A, Fitzsimons C, Nimmo M, Lowry R, 
Mutrie N. The effect of a pedometer-based community walking 
intervention "Walking for Wellbeing in the West" on physical activity levels 
and health outcomes: a 12-week randomized controlled trial. Int J Behav 
Nutr Phys Act. 2008;5:44. 
269. Hughes AR, Gillies F, Kirk AF, Mutrie N, Hillis WS, MacIntyre PD. 
Exercise consultation improves short-term adherence to exercise during 
phase IV cardiac rehabilitation: a randomized, controlled trial. J 
Cardiopulm Rehabil. 2002;22(6):421-5. 
270. Kirk A, Mutrie N, MacIntyre P, Fisher M. Effects of a 12-month 
physical activity counselling intervention on glycaemic control and on the 
status of cardiovascular risk factors in people with Type 2 diabetes. 
Diabetologia. 2004;47(5):821-32. 
271. Thabane L, Ma J, Chu R, Cheng J, Ismaila A, Rios LP, Robson R, 
Thabane M, Giangregorio L, Goldsmith CH. A tutorial on pilot studies: the 
what, why and how. BMC Med Res Methodol. 2010;10:1. 
272. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a 
combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245-51. 
273. Rolfson DB, Majumdar SR, Tsuyuki RT, Tahir A, Rockwood K. 
Validity and reliability of the Edmonton Frail Scale. Age Ageing. 
2006;35(5):526-9. 
274. Lin MR, Hwang HF, Hu MH, Wu HD, Wang YW, Huang FC. 
Psychometric comparisons of the timed up and go, one-leg stand, 
 286 
functional reach, and Tinetti balance measures in community-dwelling 
older people. J Am Geriatr Soc. 2004;52(8):1343-8. 
275. Wright AA, Cook CE, Baxter GD, Dockerty JD, Abbott JH. A 
comparison of 3 methodological approaches to defining major clinically 
important improvement of 4 performance measures in patients with hip 
osteoarthritis. J Orthop Sports Phys Ther. 2011;41(5):319-27. 
276. Hsieh YW, Wang CH, Wu SC, Chen PC, Sheu CF, Hsieh CL. 
Establishing the minimal clinically important difference of the Barthel 
Index in stroke patients. Neurorehabil Neural Repair. 2007;21(3):233-8. 
277. Wellwood I, Dennis MS, Warlow CP. A comparison of the Barthel 
Index and the OPCS disability instrument used to measure outcome after 
acute stroke. Age Ageing. 1995;24(1):54-7. 
278. Dolan P. Modeling valuations for EuroQol health states. Med Care. 
1997;35(11):1095-108. 
279. Sheikh JI, Yesavage JA, Brooks JO, 3rd, Friedman L, Gratzinger 
P, Hill RD, Zadeik A, Crook T. Proposed factor structure of the Geriatric 
Depression Scale. Int Psychogeriatr. 1991;3(1):23-8. 
280. Vickers AJ, Altman DG. Statistics notes: Analysing controlled trials 
with baseline and follow up measurements. BMJ. 2001;323(7321):1123-
4. 
281. Department for Constitutional Affairs.  Mental Capacity Act 2005 
Code of Practice.  TSO (The Stationery Office), London. 2007. 
 287 
282. International Committee on Harmonisation Good Clinical Practice 
(ICH-GCP) Guidelines.  2005; Available from: 
http://www.ich.org/products/guidelines.html. 
283. Eurich DT, Johnson JA, Reid KJ, Spertus JA. Assessing 
responsiveness of generic and specific health related quality of life 
measures in heart failure. Health Qual Life Outcomes. 2006;4:89. 
284. Hocking C, Williams M, Broad J, Baskett J. Sensitivity of Shah, 
Vanclay and Cooper's modified Barthel Index. Clin Rehabil. 
1999;13(2):141-7. 
285. van Iersel MB, Munneke M, Esselink RA, Benraad CE, Olde 
Rikkert MG. Gait velocity and the Timed-Up-and-Go test were sensitive to 
changes in mobility in frail elderly patients. J Clin Epidemiol. 
2008;61(2):186-91. 
286. Lin JH, Hsu MJ, Sheu CF, Wu TS, Lin RT, Chen CH, Hsieh CL. 
Psychometric comparisons of 4 measures for assessing upper-extremity 
function in people with stroke. Phys Ther. 2009;89(8):840-50. 
287. Beaton DE, Boers M, Wells GA. Many faces of the minimal 
clinically important difference (MCID): a literature review and directions 
for future research. Curr Opin Rheumatol. 2002;14(2):109-14. 
288. Wells G, Beaton D, Shea B, Boers M, Simon L, Strand V, Brooks 
P, Tugwell P. Minimal clinically important differences: review of methods. 
J Rheumatol. 2001;28(2):406-12. 
 288 
289. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. 
Ascertaining the minimal clinically important difference. Control Clin 
Trials. 1989;10(4):407-15. 
290. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and 
variance from the median, range, and the size of a sample. BMC Med 
Res Methodol. 2005;5:13. 
291. Schunemann HJ, Oxman A, Vist G, Higgins J, Deeks J, Glasziou 
P, Guyatt G. Chapter 12: Interpreting results and drawing conclusions.  In 
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic 
Reviews of Interventions. 2009. 
292. Branch LG, Jette AM. A prospective study of long-term care 
institutionalization among the aged. Am J Public Health. 
1982;72(12):1373-9. 
293. Mor V, Wilcox V, Rakowski W, Hiris J. Functional transitions 
among the elderly: patterns, predictors, and related hospital use. Am J 
Public Health. 1994;84(8):1274-80. 
294. Dunlop DD, Hughes SL, Manheim LM. Disability in activities of 
daily living: patterns of change and a hierarchy of disability. Am J Public 
Health. 1997;87(3):378-83. 
295. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies 
of Illness in the Aged. The Index of Adl: A Standardized Measure of 
Biological and Psychosocial Function. JAMA. 1963;185:914-9. 
 
 
 289 
8 Appendices 
Appendix 1.  Full systematic review search strategy. 
 
Trials were identified by searching Medline 1950-Jan week 3 2010, 
AMED 1985-Jan 2010, CINAHL 1981 to Jan2010, Cochrane Library Issue 
1 2010,EMBASE 1947-Feb 2010, PSYCINFO 1806-Jan week 4 2010 and 
PedRO to Jan2010. We did not confine our search to English language 
publications. The Cochrane Highly Sensitive Search Strategy for 
identifying randomised trials in Medline (Higgins, 2008 
http://www.cochrane-handbook.org/) was combined with the following 
search terms to identify RCTs  in Medline. The Medline search strategy 
was adapted for use in the other databases searched. 
 
MEDLINE strategy: 
1. early ambulation/ or exercise therapy/ or muscle stretching exercises/ 
or resistance training/ or occupational therapy/ 
2. physical therapy modalities/ or musculoskeletal manipulations/ 
3. "Physical Therapy (Specialty)"/ 
4. Exercise Movement Techniques/ 
5. Exercise/ 
6. "Physical Education and Training"/ 
7. Physical Fitness/ 
8. "Recovery of Function"/ 
9. Physical Stimulation/ 
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10. Health Promotion/ 
11. rehabilitation/ 
12. walking/ 
13. locomotion/ 
14. (rehabilitat$ or exercise$ or physiotherap$ or keep fit).tw. 
15. (physical adj3 (therap$ or education or train$ or stimulat$ or fitness or 
activit$ or function)).tw. 
16. ((exercise or movement or occupational) adj3 (therap$ or train$ or 
treatment or program$)).tw. 
17. ((strength$ or aerobic or resistance) adj3 activit$).tw. 
18. (improve$ adj3 (function or mobil$ or recover$)).tw. 
19. ((fitness or health) adj3 promotion).tw. 
20. ((endurance or balance or strength or flexibility or resistance) adj3 
training).tw. 
21. walk$.tw. 
22. or/1-21 
23. exp Aged/ 
24. (elder$ or older or oldest or old age or senior$ or geriatr$ or gerontol$ 
or aging or ageing or late life).tw. 
25. Geriatric assessment/ 
26. or/23-25 
27. (community adj3 (live or living or dwell$ or based)).tw. 
28. (independen$ adj3 (live or living or dwell$ or based)).tw. 
29. (sheltered adj (hous$ or accomm$ or home$ or living)).tw. 
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30. ((home or communit$) adj5 (caring or care$)).tw. 
31. (community adj (nurs$ or matron$)).tw. 
32. (housebound or house-bound or home-bound or homebound or 
home-based or homebased).tw. 
33. Homebound Persons/ 
34. "Home Care Services"/ 
35. independent living/ 
36. activities of daily living/ 
37. or/27-36 
38. randomized controlled trial.pt. 
39. controlled clinical trial.pt. 
40. randomized.ab. 
41. placebo.ab. 
42. drug therapy.fs. 
43. randomly.ab. 
44. trial.ab. 
45. groups.ab. 
46. 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 
47. humans.sh. 
48. 46 and 47 
49. 26 and 37 
50. 22 and 49 
51. 48 and 50 
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Appendix 2.  Key research questions that informed the semi-
structured interview schedules. 
Focus Groups 1 & 2 
What factors contribute to daily functional limitations in frail older people 
living at home? 
How is the concept of exercise in old age understood by frail older 
people? 
What are frail older peopleʼs perceived barriers to involvement in a 
targeted exercise programme? 
What should the intensity be of an exercise programme designed to 
improve the functional status of frail older people living at home? 
What would motivate frail older people living at home to complete a 
targeted exercise programme lasting 12 weeks? 
 
Focus Group 3 
1) What limitations in functional ability do you see in your patient group of 
frail older people? 
2) What types of exercises are likely to be effective at improving 
functional abilities of frail older people living at home? 
3) What do you think would motivate/aid frail older people to adhere to a 
home-based exercise training programme? 
4) What do you think are potential barriers to exercising in the home for 
frail older people? 
5) What should be the design (intensity/frequency/duration) of an exercise 
programme aimed at improving the functional status of frail older people 
living at home? 
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Appendix 3.  Sample questionnaire used in Delphi round two. 
 
 
Strongly disagree          Neutral   Strongly agree 
  
 1 2 3 4 5 6 7 8 9 
 
1)  There is a large amount of variation in the functional abilities of frail 
older people living at home. 
 
2)  Thought needs to be given to this variation when designing an 
exercise programme to improve the functional abilities of frail older people 
living at home i.e. a 'one size fits all  
approach' is inappropriate. 
 
3)  Older people are commonly limited by  
 a)  lower limb weakness 
 b)  poor postural flexibility/stability. 
 
4)  These limitations are often expressed functionally by difficulty in 
standing from a chair and difficulty climbing stairs. 
 
5)  Older people will require face-to-face contact on more than one 
occasion to help learn a  
structured exercise programme and improve compliance. 
 
6)  The exercise programme needs to be simple. 
 
7)  It is important to  
 a)  include goal setting in the exercise programme 
 b)  monitor success/benefit throughout the exercise programme 
 c)  allow participants to advance during the exercise programme. 
 
8)  Key perceived barriers to participation are likely to be  
 a) respiratory problems 
 b) joint stiffness/joint pain 
 c) low mood. 
 
9)  Flares of chronic medical diseases may impact on participation in the 
exercise programme. 
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10)  Potential measures to improve involvement/compliance include 
 
a)  Allowing adaptation to the exercise programme, i.e. if a participant is 
feeling unwell then they should complete the warm-up exercises only 
b)  Attempting to incorporate the programme into normal daily routine 
c)  Making the programme meaningful to the individual 
d)  Engaging with & involving family/carers 
e) Using different levels of exercise (e.g. chair based/standing) 
 depending on the ability of the individual 
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Appendix 4.  Example pages used in information provision needs 
assessment exercise. 
 
Example 1. Patient handout: improve your balance in 10 minutes a day.  The 
American Geriatrics Foundation for Health in Aging. 
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Example 2. Patient handout: balance and fall prevention.  Advance for 
Directors in Rehabilitation.
 297 
 
Example 3.  Preventing falls: strength and balance exercises for healthy ageing.  AgeUK.
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Example 4.  Exercise and physical activity.  US Department of Health and Human Services.  National Institute of Health.  National 
Institute on Aging.
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Appendix 5.  HOPE programme physiotherapist timeline. 
